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Abstract 
Acute myeloid leukaemia (AML) is a cancer of the blood forming cells of the bone marrow 
(BM) and has a high mortality rate in the elderly population. New, tolerable therapeutic 
strategies are necessary for reducing the mortality rate associated with AML in this fragile, 
less fit population. The tumour microenvironment is an evolving target in the search for 
lower chemotherapy-induced toxicity and strategies that can encompass a larger sector of 
the population including the elderly. Adipocytes in the BM were long considered to be mere 
occupants however, emerging research has identified these cells to be more than such and 
have an active role in metabolism regulation and an endocrine organ in its own right. In the 
context of cancers, adipocytes now pose an attractive target for novel cancer treatments due 
to their ability to confer chemoresistance in the tumour microenvironment. Here, I show the 
active participation of adipocytes that enhance the survival and proliferation of the AMLs 
within the BM microenvironment (BMM) though the support of several cellular functions 
in the AMLs. I also show that adipocytes support metabolism of AML by providing them 
with energy substrates in the form of fatty acid which are then used to support the 
proliferation of the AMLs. Additionally, I provide preliminary results implicating genes that 
may be responsible for the homing and free fatty acquisition in the BMM. These findings 
therefore provide important pre-clinical evidence for targeting factors in the BMM that 
support the tumour survival which may be less toxic than current therapies that do not 
encompass the wider AML population. 
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and untreated groups using Wilcoxon signed rank test.  Data are represented as mean 
± standard deviation. 
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Preface 
In the UK, just over a quarter of a million new cases of cancer were diagnosed in 2014. This 
amounts to 980 daily diagnosed cases with one diagnosed every two minutes. Half of all 
cancer cases in the UK are diagnosed in people aged 70 and over (within the 2012 – 2014 
bracket). Projected calculations by Cancer Research United Kingdom (CRUK) show a third 
of those diagnosed will die of the disease or associated complications and only about half of 
the diagnosed population will survive for 10 years or more. Acute myeloid leukaemia (AML) 
is a disease of the blood-forming cells of the bone marrow (BM) and is considerably rare in 
the UK: with around 3,072 new cases diagnosed in 2014 and accounts for under 1% of all 
cancer cases in the country. Although rare, the term, “acute” justifies the description of the 
disease as fast and aggressive with around 2,500 deaths in 2014. Approximately half the 
deaths from AML were in the ages of 75 years and over population, with the peak mortality 
age in 85-89 range. Despite advancements in cancer therapies, the hostile features of AML 
make it a therapeutic challenge in the older population affected by the disease. Frailty and 
comorbidities of the elderly make this particularly difficult, leading to the inevitable 
increased mortality of this population. Current curative therapies, including bone marrow 
transplants are considered adequate for the fitter and younger AML populations, leaving the 
elderly population with therapeutic strategies that are low intensity for symptom and disease 
management. Therefore, treatment options remain inadequate for the older AML population, 
with only a small proportion of them undergoing stem cell transplantation (SCT). 
The adult BM comprises of approximately 70% adipose tissue by volume and is an 
incremental change from the younger BM. As one ages, the content of the BM begins to 
change from a more haematopoietically active red marrow to a more adipocytic yellow 
marrow. This conversion begins in the peripherally and extend towards the central axial 
skeleton until the haematopoietically active component remains at the proximal end of the 
bone. As the marrow ages, the regenerative potential decreases in turn increasing the 
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potential of bone dysfunctions. Links between increased adiposity, cancer incidences and 
response to chemotherapy have been well established on a cellular and epidemiological 
basis. Obesity has been attributed to an estimated 15-20% of all cancer deaths. 
Hyperinsulinemia has been proposed to contribute to the link between cancer and obesity 
via the insulin-like growth factor signaling cascade leading to an increase in cell proliferation 
and a decrease in cell apoptosis. Adipocytes increase oestrogen levels which have been 
shown to be both pro-mitotic and pro-mutagenic and contribute to DNA damage.  
Under normal physiological conditions, adipocytes release “adipokines” that regulate 
numerous processes including but not limited to glucose regulation, insulin sensitivity, blood 
pressure maintenance and inflammatory responses. In conditions of obesity, excess adiposity 
dysregulates adipokine profiles, metabolic processes and promotes altered adipose-related 
metabolic and non-metabolic processes. In addition to epidemiological studies identifying 
specific adipokine links with increased cancer risks or poor prognosis, obesity-associated 
dysregulation leads to low-grade, chronic inflammation due to lipid accumulation. An 
increase in certain adipokine secretion can be a direct consequence of increased adiposity, 
which subsequently leads to a dysregulation of secretion of immune cytokines. This disrupts 
the physiological norm and increases adipose-associated factors that have been implicated 
in the progression, proliferation and metastasis of several tumor types.  
Taken together, it is not unreasonable to link the change in bone marrow composition (from 
red to an increased state of yellow marrow) with the increased incidence of AML. The link 
between age and the incidence of AML is a well-established notion and therefore, 
considering epidemiological and molecular studies, I hypothesised that adipocytes in the BM 
are active participants in their environment and are not simply spectators. I therefore 
investigated their role in the leukaemic microenvironment of the BM and the contributions 
made by them in the AML-orchestrated leukaemic compartment.  
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CHAPTER 1 – Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
21 
  
1.1 – The human bone marrow 
1.1.1 Background  
At birth, the bone marrow consists almost completely of red marrow i.e., hematopoietic 
marrow. With age, red marrow decreases and is gradually replaced by yellow or “fatty” 
marrow. Subsequently, there is a decrease in marrow haematopoietic tissue cellularity; 
indeed, by the second decade of life haematopoiesis no longer occurs in the shafts of long 
bones, which limits haematopoiesis to the axial skeleton and proximal regions of the bone. 
There is evidence suggesting this change in bone marrow cellularity in adults is linked to 
various age - related diseases of the bone such as osteoporosis, anaemia and malignancies 
[1, 2]. 
Acute myeloid leukaemia (AML) is one of the most aggressive and rapidly progressing 
forms of leukaemia. It is characterised by an increased growth of abnormal white blood cells 
in the bone marrow, which hinders the production of normal blood cells. The cause of AML 
is multifactorial with specific gene mutations and chromosomal translocations being the 
primary drivers of the disease. Furthermore, the microenvironment of the bone marrow is 
also a key player in the pathogenesis of AML as well as other haematological malignancies 
[3-5]. The ability of AML cells to divide at a significantly faster rate than normal cells is one 
of their characteristic features. This rapid turnover rate requires a high-energy supply, and 
to accommodate for this requirement, the cells and their environment undergo metabolic 
modifications. Glucose acquired from glycolysis provides some of this energy. In addition, 
some cancer cells use lipids, the synthesis of which has been found to be coupled to glucose 
metabolism[6]. Fatty acid (FA) synthesis has been shown to be a key pathway that cancer 
cells exploit for energy[7]. The use of FAs as an energy source has been reported to support 
the survival and proliferation of cancer cells. In this study, I propose that bone marrow 
adipocytes provide energy to the AML blasts in the form of fatty acids to support their rapid 
growth.  
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1.1.2 The normal bone marrow 
One of the largest organs in the human system is the blood and its contiguous bone 
marrow[8]. Although often regarded separately, together they function as a single unit. In 
axial and long bones, the bone marrow is located in the central cavity and contains 
haematopoietic and adipose tissue that are surrounded by vascular sinuses interposed with 
the sponge-like network of the trabecular bone. The bone marrow is the major 
haematopoietic organ, which is also the primary production site of lymphoid tissue in 
mammals which give rise to cells of various lineages each of which play an interdependent 
role in regulating the homeostasis of the bone marrow environment[9]. The inner surface of 
the bone cavity and the outer surface of the trabecular bone needles within the cavity are 
lined by a mono-layer of flat “bone-lining cells” reinforced by a layer of reticular connective 
tissue together constituting the endosteal lining. The blood supply of the bone and its 
marrow, are connected by venous sinuses in the marrow which receives arterial blood from 
the nutrient arteries of the bone and from the periosteal capillary network, which is connected 
to the sinuses thorough the Harversian canals[1]. The blood circulation therefore is circular 
from the center of the marrow to the periphery and then back to the center of the marrow 
(Figure 1.1).  
The bone is innervated by myelinated and non-myelinated nerves that pass along through 
the nutrient canals with some innervation occurring though the epiphyseal and metaphyseal 
foramina. Haematopoietic tissue within the marrow appears to be the termination point of 
nerve bundles that run though the arterioles that also innervate smooth muscles of the vessels 
that supply nutrient rich blood.  
The bone marrow consists of haematopoietic tissue that comprises a variety of cell types, 
which include blood cells and their precursors, adipocytes, macrophages and advential cells 
that exhibit an organised pattern of arrangement [10]. The microenvironment within the 
haematopoietic tissue of the bone marrow supports haematopoiesis by retaining stem cells 
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and providing essential factors necessary for the proliferation and differentiation of the 
haematopoietic stem cells (HSC) along committed lineages. Haematopoiesis is a continuous 
process that involves pluripotent stem cells in the bone marrow that are defined by two 
properties: maintaining their population by the process of self-renewal and their ability to 
differentiate and give rise to daughter cells.  
Our understanding of the haematopoietic process has been acquired from irradiated 
syngeneic mice models where haematopoietic cells from donor mice were introduced into 
the model, resulting in a stem cell pool formation within the spleen. These pools or nodules 
were visibly counted and further experiments revealed that these nodules were colonies of  
Figure 1.1. Cross-section of the human bone. Adapted from[9].  
 
stem cells arising from a single pluripotent cell with the ability to self-renew and differentiate 
into the major haematopoietic lineages [11-13]. These colonies were called colony forming 
unit-spleen (CFU-S). Following these ground-breaking findings in regenerative blood cells, 
the concept of stem cells was put forward and was defined as cells that fulfil the following 
two criteria: 1) self-renewal and 2) multi-potency[14]. Within the haematopoietic system, 
only a small population of cells possess both the ability to give rise to an identical cell 
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without differentiation (self-renewal) and the ability to differentiate into any blood cell. They 
are therefore, an exclusive population of the haematopoietic system on which the basis of 
several regenerative haematopoietic studies have been based.  
1.1.3 Haematopoiesis and HSC lineages 
Haematopoiesis is mostly described in a hierarchical structure with progenitors arising from 
HSCs which then give rise to precursors that vary with pathway commitments (single or 
multiple pathway). 
 
  
 
 
 
 
 
 
Figure 1.2. Schematic view of haematopoiesis. Adapted from[15].  
 
This representation, in Figure 1.2 is oversimplified but can allow for a clear distinction of 
properties between intermediary states of cells. A more detailed hierarchy of HSCs has been 
shown in Figure 1.3.  HSCs have also been characterised based on developmental capacity 
in transplantations or by in vitro methods identifying the common myeloid progenitors 
(CMP) and the common lymphoid progenitors (CLP). CLP and CMP isolation have led to 
the discovery of CLP and CMP capability of giving rise to lymphoid and myeloid-cell types, 
respectively. The CLP and CMP pathways function independently of each other leading to 
the production of lymphoid and myeloid type cells. In murine models, the multipotent active 
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subpopulation of haematopoietic cells were identified as a small percentage of cells that have 
high expression of a murine stem cell antigen, Sca-1 and stem cell factor receptor c-Kit (also 
known as CD117) but are lineage negative. These cell types, LSK (Lineage negative, Sca-
1, c-Kit), are defined as cells that are lineage-negative (lin-) devoid of lineage markers 
signifying their immaturity; Sca-1+ and c-Kit+ [16, 17]. It is this LSK fraction of cells that 
has been used for the application of several criteria for primitive HSC isolation. Further 
studies on murine HSC characterised three multipotent subpopulations of HSC namely long-
term-HSC (LT-HSC), short-term-HSC (ST-HSC and multipotent progenitor (MPP). LT-
HSC and ST-HSC are subtypes classified based on their repopulating ability within a 24-
week period following a clonal transplantation into primary recipient and eventually into a 
secondary recipient following a 20-week period [18, 19]. MPPs on the other hand, are a 
heterogeneous population of HSCs that have lost their capacity to self-renew but maintain 
their differentiation capacity [20, 21]. These cells therefore, differentiate into the common 
myeloid[22, 23] and lymphoid progenitors[24] which subsequently produce the effector 
cells of the haematopoietic system[25]. Figure 1.3 illustrates this hierarchy of HSC lineages 
showing the complexity of the haematopoietic system and their derivatives.  
The discovery of the ligand for L-selectin, CD34, is fundamental in the isolation and 
enrichment of HSCs from blood cells[26]. This ligand is expressed in 0.5-5% of blood cells 
in the adult BM, cord blood and liver[14], and these cells are  multipotent and heterogeneous. 
These cells also exhibited expression of CD90 and were Lin- generating progeny in vivo and 
in vitro of myeloid and lymphoid lineages[27]. Further studies that identified approximately 
90-99% of CD34+ cells differentially co-expressed CD38+ where the CD34+ CD38low-to-
CD38- cells were capable of producing progenies of the myeloid and the lymphoid lineage 
and were enriched in LT-HSCs [28-30].  
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Figure 1.3. Hierarchy of HSC lineages 
 
1.1.4 The stem cell niche 
The initial concept that a microenvironment or ‘niche’ is required for HSC maintenance and 
regulation was identified before the characterisation of HSCs. This was recognised during 
the investigations of two mice strains that lacked mast cells; the SI strain and the W strain. 
Briefly, these two phenotypically similar strains had normal BM transplantation but only the 
W strain had a restored haematopoietic profile[14, 31]. Following transplantation of the W 
strain BM into the SI strain, no restoration of the haematopoietic system was observed 
however, when the BM from the SI strain was transplanted into the W strain, restoration of 
the haematopoietic system in the W stain was observed. These observations suggested that 
non-haematopoietic cells contributed to the creation of a microenvironment or ‘niche’ 
system wherein the presence of this niche was necessary for the differentiation and self-
renewal properties of HSCs. Consequently, the difference between these two strains, W and 
SI, were due to their location on two different chromosomes 5 and 10 respectively. The W 
27 
  
locus was found to encode for c-Kit and SI locus for stem cell factor (SCF) thereby 
strengthening the future findings described above. Murine studies have, to an extent, 
characterised the non-haematopoietic cells and identified populations of these cells to be 
supportive of haematopoiesis. For example; bone marrow stromal cells (BMSC) have shown 
to provide support and maintenance of HSC differentiation or renewal [32]. HSC rich 
populations in the bone marrow have been found to localise in proximity of the endostea 
which is rich in blood supply. This bone and HSC rich environment can be developed in 
vitro by using osteochondral progenitor cells in combination with osteochondral stem cells, 
but not with the progenitor cells on their own[14].  These findings prove that the interaction 
between the HSC and their surrounding niche system is crucial for HSC maintenance.  
1.1.5 Niches of the bone marrow 
Under normal conditions, the haematopoietic system is sustained by a small number of 
HSCs, which reside in a specialised microenvironment of the BM wherein the fate of HSCs 
– differentiation or self-renewal – is determined. The concept of a HSC niche, the 
constituents of which regulate cell fate, was first proposed by Schofield in 1978 with further 
studies highlighting the role of HSC niches in physically anchoring stem cells, interacting 
molecules and the extracellular matrix[33]. Recent studies have now ascertained the specific 
regulators of HSCs and their progenitors in the BM, and have uncovered how a perturbation 
to one cell type can lead to an effect in another cell type without direct physical interaction 
between the two[34]. The heterogeneous nature of HSCs has prompted the notion of there 
being specialised niches for types of HSCs and their progeny, with each class of niche 
comprising different cell types that contribute to the niche in their own specialised way[35]. 
The biology of the two main types of niche that have been implicated in AML 
tumourigenesis – the osteoblastic and vascular niches – are described below. 
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1.1.5.1. Osteoblastic niche 
Following transplantation, one study established that HSCs relocate to the endosteal areas 
of the bone, i.e. regions adjacent to the trabecular or cortical regions. By contrast, mature 
differentiated cells were distributed away from these regions[36]. This observation 
combined with imaging studies that demonstrated a concentration of HSCs in endosteal 
regions provided evidence for the existence of an HSC-selective endosteal niche[37, 38]. 
The cellular population of the endosteum mainly comprises osteoblasts, which synthesise 
bone, and osteoclasts, which degrade bone. The ability of an osteoblast/HSC co-culture to 
recreate this environment in vitro has led to this niche being termed the “osteoblastic 
niche”[39]. The dependence of HSCs on osteoblasts for their maintenance was suggested by 
genetically altered mice that overproduce osteoblasts; in turn, an elevation in HSC numbers 
was observed[40]. Osteoclast activity and the associated rise in calcium levels has also been 
shown to stimulate the production of HSCs and their localisation to the endosteum[41]. The 
mechanics of HSC maintenance in the osteoblastic niche were uncovered by Taichman and 
Emerson who demonstrated that progenitor cells that were positive for CD34 and thus 
identifiable as HSCs, could be stimulated to proliferate by human osteoblasts via the 
production of Granulocyte Colony Stimulating Factor (G-CSF)[42]. Further studies have 
found that in vitro culture of CD34+ cells and osteoblasts supports the expansion of long term 
culture-initiating cells (LT-CIC), as well as channeling HSCs down the mono/macrophage 
lineage at the expense of the erythromegakaryocytic lineage[43, 44]. Taken together, it is 
clear that the endosteum is enriched with osteoblasts that support LT-HSC and investigations 
into the players involved have revealed that most HSCs reside in this niche[45] 
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1.1.5.2 Vascular niche 
Despite evidence for the importance of osteoblastic niches in haematopoiesis, the ability of 
HSCs to survive and proliferate in tissues that do not contain bone such as the spleen and 
liver, and the presence of stromal cells outside these regions spurred the search for alternative 
niches. The refinement of HSC markers into antibodies against CD150+CD48−CD41− cells, 
which provide a high purity means of identifying HSCs led to the discovery of HSCs at 
sinusoids, which are specialised vessels that can be found, among other places, on the surface 
of bone[46]. As well as HSCs, this vascular niche is populated by BMSCs. Studies into the 
interplay between HSCs and BMSCs found that the latter were able to drive the renewal and 
differentiation of HSCs[47]. More recent work has specifically linked the role of the 
osteoblastic niche with that of the vascular niche. Migration of quiescent HSC-derived 
progenitors from the osteoblastic niche into the vascular niche with subsequent direct contact 
of the endothelial cells therein has been found to promote the differentiation of these cells 
down blood cell lineages. This supports the hypothesis that the osteoblastic niche serves as 
the quiescent microenvironment with the vascular niche acting as the region for proliferation 
and further differentiation[48, 49]. 
1.1.6 Bone marrow stromal cells 
The bone marrow contains cells that contribute indirectly towards haematopoiesis. Although 
they are not directly involved, they play imperative roles in the bone marrow 
microenvironment that support the development and maintenance of the haematopoietic 
cells within[50, 51]. A lot is known about the cells of the bone marrow and as with most 
theories there is come controversy. The nature of stem cells within the bone marrow is a 
topic of debate among scientists. The most widely noted cell population within the marrow 
environment is the mesenchymal stem cell (MSC). This concept of MSC was first 
popularised by Caplan in 1991 where he showed that transplantation of the bone marrow to 
other anatomical sites resulted in the repopulation of these sites with bone and marrow 
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cells[52]. This landmark study supported many previously conducted studies that showed 
the potential of these cells to differentiate into osteogenic cells from bone-free bone marrow 
specimens[53]. However, the exact identity of these osteogenic progenitor cells could not be 
identified due to the heterogeneous population of cells used for transplantation. It was 
following these studies that Friedenstein et al., could identify a small subpopulation of BM 
cells from the heterogeneous population of transplanted cells by the ability of these cells to 
quickly adhere to the culture plastic and by their fibroblast-like appearance. This was the 
origin of the stromal cell compartment concept of the bone marrow.  
The stromal cells also produced colony-forming units of fibroblasts (CFU-F) when cultured 
in suspension[54]. The clonal identity of these CFU-Fs depended on the initial seeding 
density of the explants and were identified by time-lapse photography and Poisson 
distribution statistics [54-57]. This very important discovery lead to the concept that a 
number of skeletal tissue types could be produced in vivo from a single bone marrow stromal 
cell progeny. These cells were subsequently called osteogenic cells or stromal stem cells. 
With the discovery of embryonic stem cells, the term ‘mesenchymal stem cells’ proposed 
by Caplan began to take on a broader meaning as it became associated with attributes such 
as a type of postnatal human stem cells with a differentiation potential that may be broader 
than embryonic stem cells themselves. This finding brought about the concept of 
‘transgermal plasticity’ of these postnatal stem cells [58-60]. This concept, while interesting, 
also created a lot of confusion and remains a topic of controversy within the field [61]. 
Clarification of the definition of MSCs became more than just a semantics and was vital for 
the interpretation of the concept and the biological function. To illustrate this confusion, 
MSC are currently defined as fibroblast-like cells that adhere to culture plastic that can be 
obtained from any tissue site[62] but was initially considered as cultures of bone marrow 
stromal cells[52, 63].  
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A popular view on MSCs is that they are universally present in connective tissue, such as 
the bone marrow, and share phenotypical similarities with skeletal progenitor cells and 
pericytes. Recently, Bianco et al have pioneered a study to clearly define MSCs and have 
stratified them based on their in vivo differentiation potential as skeletal stem cells (SSC) 
which are found on the surface of sinusoids of the bone marrow[64, 65]. This study also 
further proved that MSCs from different sites have different transcriptomes and are classified 
as CD146+, CD34- and CD45- cells[66, 67]. Despite the current revisions of bone marrow 
stromal cell terminology, it does not detract from the contribution these cells provide in the 
maintenance of HSC pools within the bone marrow. 
1.1.6.1 Bone marrow endothelial cells  
Endothelial cells are found in the sinusoids of the bone marrow and play a critical role in the 
regulation of movement of cells between the bone marrow and the circulatory system[68]. 
Their role in the bone marrow microenvironment have been closely studied and they have 
been shown to support haematopoiesis amplification of soluble cytokines. These cells have 
been shown to increase expansion of haematopoietic progenitor cells that are cultured in the 
presence of bone marrow endothelial cells. Furthermore, they are mostly of the myeloid 
lineage expressing CD15 and CD14. Endothelial cells constitutively secrete interleukin-6, 
Kit ligand, granulocytes colony-stimulating factor (G-CSF) and granulocyte macrophage 
colony-stimulating factor (GM-CSF)[69]. This secretory profile is necessary for the 
differentiation of CD34+ haematopoietic cells. Bone marrow stromal cells are known to 
support myelopoiesis but endothelial cells provide the added benefit of not only supporting 
myelopoiesis but also megakaryocytopoiesis[69]. Endothelial cells are known to be major 
component of the bone marrow as they are required for the homing of HSC due to their 
secretory profile and ability to support of other multilineage haematopoietic cells[69]. 
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1.1.6.2 Bone marrow fibroblasts 
Bone marrow fibroblasts were originally identified when the stromal cell compartment of 
the bone marrow was discovered and characterised as colony forming units of fibroblasts. 
Much like endothelial cells from the same origin, they have been shown to directly regulate 
haematopoiesis but do so by interacting directly with haematopoietic progenitors[70]. The 
stromal cell component, which includes endothelial cells, fibroblasts and adipocytes, are 
anchored in the bone marrow and provided an array of cytokine profiles that regulate 
haematopoiesis either in a positive or negative manner. Development of long-term cultures 
of bone marrow has allowed researches to study, in detail, the various origins of the 
fibroblast (lung, marrow, skin etc.) and enabled the development of cell lines. The bone 
marrow stromal cell compartment consists of 50-70% fibroblasts whose surface expression 
differs from fibroblasts of other anatomical sites. Stromal cells lack the haematopoietic 
profile of CD14, CD34 and CD45 but do express the hyaluronate receptor CD44 and alpha-
smooth muscle actin stress fibers. It is important to note however, that progenitor cells of 
fibroblasts are of haematopoietic origin and are CD34+. When commitment towards lineage 
is made, cells begin to lose the expression of immature haematopoiesis and gain markers of 
the lineage in question. Morphologically, fibroblasts may be of two types based on long-
term cultures; bipolar spindle-cell morphology and a more widely spread polygonal form, 
both of which have a similar immunophenotype[50, 70].  
1.1.6.3 Adipocytes 
For years, researchers dismissed the presence of adipocytes in the stromal cell compartment 
as space filler or ‘hypocellular’ when describing an adipose rich marrow biopsy[71]. More 
recently, the role of the adipocytes in the bone marrow has been confirmed as no longer a 
space-filler or simply an observer in the bone marrow but as an active component within the 
microenvironment. Adipocytes, local and systemic, play an important role in health and 
disease. Therefore, identifying and understanding the mechanisms that regulate bone 
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marrow adipose formation is an important lead in novel therapeutic interventions. Many 
transcriptional factors that regulate adipocyte formation have been identified but the most 
characterised transcriptional factors are the CCAAT-enhanced-binding protein (C/EBP) α, 
β and δ and the perioxisome proliferator-activator receptors (PPAR) α, γ and δ, each of which 
is expressed in the bone marrow stromal cell compartment and is induced during adipocyte 
formation[72]. Adipogenesis changes stromal cells surface expression by reducing the 
adhesion proteins such as CD44, integrins and Vascular cell-adhesion proteins(V-CAM) 
while increasing the expression of fatty acid transporter proteins such as CD36[71]. 
This thesis focuses on the role of bone marrow adipocytes in the progression of leukaemia 
and therefore supports the hypothesis that adipocytes progress and support this 
haematological malignancy.  
1.1.7 Pathological diseases of the bone marrow 
Blood cancers constitute several different malignancies, which include cancer of the blood, 
bone marrow and lymphatic system. The lymphatic system constitutes the lymph nodes, 
lymphatic vessels and lymphoid tissues such as the spleen, tonsils and thymus. Lymphoma 
as the name suggests, initiates in the lymphatic system whereas leukaemia and multiple 
myeloma (MM) initiate in the bone marrow. Both leukaemia and MM interfere with normal 
production of blood forming cells, including white blood cells and red blood cells.  
1.1.7.1 Multiple myeloma (MM) 
MM is a disease characterised by the proliferation of plasma cells in the bone marrow, 
typically complemented by a secretion of immunoglobulins that are detectable in the serum 
and urine that cause tissue impairment. Studies have shown that these events are anticipated 
after monoclonal gammopathy of undetermined significance (MGUS). MUGS is the 
secretion of an abnormal paraprotein (protein secreted by B cells) and once detected in the 
blood or urine, MM is more than likely to follow. Once MM develops, the clonal plasma 
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cells become highly dependent on the bone marrow microenvironment and differ from 
healthy plasma cells in that they are able to reenter to a lower proliferative state[73].  
Initially, MM arises due to genetic changes that develop during the terminal differentiation 
of B lymphocytes to plasma cells. This makes MM unique because it is at this terminal stage 
that the disease initially manifests – as opposed to disease like myeloid leukaemias where 
that initiation of the disease can occur during early stages of myelopoiesis. Extensive 
genomic studies which shed some insight onto the clonal evolution of MM and revealed that 
contrary to the accepted hypothesis, MM does not arise from one single type of tumour cell 
but from a diverse subset of these tumour cells retaining a multitude of genetic diversities. 
These genomic studies therefore support the clinical incidence of bi-clonal disease[73].  
There is no intervention for MGUS and early asymptomatic myeloma however, in the last 
decade, significant leaps in clinical research and interventions have been made in the 
treatment of early asymptomatic myeloma. Proteasome inhibitors and immunomodulatory 
drugs such as Bortezomib and thalidomide or lenalidomide are now the conventional front 
line therapies for the management of this disease[74]. Because these interventions are non-
curative, relapse is unpreventable. Therefore, current research on the interaction between 
MM cells and the bone marrow environment on which they are dependent on is the highlight 
of MM research. 
1.1.7.2 Acute Myeloid Leukaemia 
As a heterogeneous disease, acute myeloid leukaemia (AML) is characterised by its clonal 
expression of its progenitors (myeloid blasts) and is one of the most studied blood 
malignancy[75]. The peak age of death from AML is between 85-89 years of age. 
Approximately 35-40% of those younger than 60 years old are cured by conventional front-
line therapies and stem cell transplantation however, the prognosis for those above 60 years 
of age remains poor. Recent studies have identified a series of recurrent genetic alterations 
that amass with age that have been categorised using deep sequencing as ‘founding clones’ 
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and ‘novel subclones’[76]. The morphology of AML blasts varies with sizes as large as 
monocytes or as small as lymphocytes, i.e. 10-30μm. Multiple antigens are expressed on 
AML blasts that are also on expressed on normal immature myeloid cells such as CD33, 
CD34 and CD13. Depending on the morphological subtype of AML, other expression 
antigens are also expressed based on the stage of differentiation such as CD45, CD11b for 
monocytic lineages and CD36 for erythroid lineages. AML blasts can also express antigens 
that are specific to T and B cells such as CD19. Occasionally, AML blasts can express both 
lymphoid and myeloid surface antigens that makes then harder to classify and are usually an 
indication of poor overall survival and have recently been classified as mixed phenotypic 
leukaemia[77]. 
AML has been characterised based on aetiology, genetics, morphology and 
immunophenotype. AML is most popularly classified according to the French-American-
British (FAB) classification which uses both the morphology and the immunophenotype to 
classify the disease into eight subtypes (M0 to M7)[78]. More recently, AML has now been 
classified by the World Health Organisation (WHO) in what has now replaced the FAB 
classification in the most part and stratifies AML as seven subtypes: 
1. AML with recurrent genetic abnormalities (includes mutation such as 
t(8;21)(q22;q22)-RUNX1-RUNX1T1 and 11q23-MLL mutations 
2. Myeloid neoplasms from therapy 
3. AML with myelodysplasia-related changes 
4. AML not otherwise specified 
5. Myeloid sarcoma 
6. Myeloid proliferations related to Down syndrome and 
7. Blastic plasmocytoid dendritic cell neoplasm 
AML is also classified in terms of aetiology into (1) Secondary AML (s-AML), (2) Therapy-
related AML (t-AML) and (3) de novo AML[79]. More recently, work carried out by 
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Papaemmanuil et al., 2016 has shown that the genomic classifications of AML extend well 
beyond the WHO or FAB classification. This landmark study investigated over one hundred 
genes known to cause the disease and found that patients could be classified into at least 
eleven main groups. These groups were identified based on constellations of mutations and 
characteristic clinical profiles. Despite identifying and characterizing patients according to 
these mutations, each patient presents a unique set of driver mutations that which sheds light 
on the differences in patient responses to therapies. The identification of this landscape is 
set to inform the classification and stratification of the disease enabling the prediction of 
responses to therapy and designing new trials for targeted treatment[80]. 
To attain complete remission, patients eligible for treatment undertake induction therapy 
however, minimal residual disease frequently occurs and subsequently relapse in inevitable 
should treatment be discontinued. Consequently, consolidation therapy is then followed in 
order to eliminate any residual disease. Induction therapy is usually a regime of 7 days of 
continuous cytarabine infusion followed by 3 days of anthracycline offered to patients with 
a favourable prognosis and low risk of treatment-related mortality. Anthracyclines are 
usually inducted at 60 – 90 mg/m2 (daunarubicin) however, for AML present with DNMTA 
and KMT2A mutations that represent poor prognosis benefit from higher doses of 
anthracycline[81]. Consolidation therapy usually involves several cycles of Cytarabine in 
high doses administered over a five day period and/or stem cell transplantation. These 
therapies limit the inclusion of the elderly population of AML patients as these harsh 
therapies are likely to cause treatment-related mortality and usually present with a high 
cytogenetic-risk profile[82]. For this reason, it is imperative to identify novel therapies that 
are suitable not only for the younger population of patients with AML but also for the older, 
more frail population. Identifying a target that does not directly affect the normal functioning 
of the haematopoietic system but one that exclusively targets mechanisms associated with 
the malignancy. 
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Like MM, AML is highly dependent on their microenvironment and required cell-cell 
interactions and secreted factors from the bone marrow associated cells to maintain AML 
survival and support their proliferation. Current research into the environment that interacts 
with these diseases is now at the forefront of cancer research. Indeed, targeting the 
environment poses as a favourable option as it may circumvent the use of high doses of 
cytotoxic drugs and widen the therapeutic window for older age groups. The following 
sections will discuss adipose tissue in the bone marrow microenvironment and the role it 
plays in the metabolism of cancer cells. 
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1.2 – Adipose tissue and Cancer metabolism 
1.2.1 Marrow adipose tissue 
Adipocytes of the bone marrow accumulate due to a variety of pathological conditions 
however, they remain relatively poorly understood in comparison to other cell types within 
the bone marrow system. Functionally, marrow adipose tissue (MAT) is a distinctive depot 
compartmentalised within the bone marrow. It has been shown to have the potential of 
playing a role in local and systemic metabolism and can be functionally activated by 
therapeutic interventions including chemotherapy and hormonal therapy[83, 84]. However, 
despite this, its regulation remains largely unknown. Recently, MAT regulation was 
characterised based on differences in regional distribution in rodents, which revealed 
regional based properties thereby categorizing MAT as regulatory or constitutive[85]. 
Mature adipocytes located in the distal regions of long bone lack haematopoietic activity and 
morphologically resemble white adipose tissue. They were therefore termed; “constitutive 
MAT” (cMAT). In contrast, MAT forming at haematopoietically active sites is typically 
distributed in the form of single adipocytes scattered within these haematopoietically active 
regions and accumulates or is lost in response to external stimuli; such sites were called 
“regulated” MAT (rMAT).  
Interestingly, Scheller et al., showed a change in adipocyte content of regulated MAT in 
mice subjected to a drop in temperature. This change was observed in both young and old 
mice, with a significant drop in rMAT by 76 and 56% in tibial epyphysis in 12 and 56-week-
old mice, respectively. The percentage of cMAT did not change suggesting that at a very 
basic level, these two types of MAT differed not only based on their morphology and 
location but also on the basis of their functionality and development. That is, cMAT develops 
soon after birth, consists predominantly of unsaturated lipids and is enriched for adipogenic 
transcriptional signatures (CEBP/A and CEBP/B) whereas, rMAT develops over the adult 
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lifetime, contains predominantly saturated lipids and has lower levels of these adipogenic 
transcription profiles which is similar to the white adipose tissue profile (WAT)[85-87]. 
MAT has also been suggested to have characteristics of beige or brown adipose tissue (BAT) 
as they have similar characteristics that may be affected by age or disease[88]. BAT is the 
main site for thermogenesis and has high expression of uncoupling protein-1 (UCP-1), which 
is present in mitochondria with which the brown adipose tissue is packed. UCP-1 expression 
can also be detected in WAT in response to specific stimuli and therefore this WAT is called 
beige adipose tissue[89, 90]. BAT morphology is different to WAT as BAT contain 
multilocular lipid droplets whilst those in WAT are unilocular. Although MAT is 
histologically different from BAT, a recent study conducted in young mice showed 
adipocytes from the lumbar vertebrae of young mice to be UCP-1+ and with BAT-like 
structure, suggesting a population of adipose tissue distinct from regular MAT found in the 
bone marrow[91]. These findings support the concept of a presence of beige-like MAT with 
potential functional properties that have yet to be delineated. 
1.2.1.1 Formation of MAT 
Bone marrow biopsies were used to first identify the displacement of red marrow to yellow 
marrow. Several methods of MAT quantification including non-invasive methods such as 
magnetic resonance imaging (MRI) showing the lipid distribution in BM sites. Saturated and 
unsaturated fatty acid content of adipocytes can also be monitored by proton magnetic 
resonance spectrometry which then combined with X-rays, can help identify bone mineral 
density and enable long-term follow up on BM adipocyte formation and development. 
Progenitors of adipocytes differentiate to produce MAT-like WAT. Progenitors of 
adipocytes generally have a fibroblast-like structure that amass lipids that eventually merge 
into a single locular lipid that causes a displacement of the nucleus and cytoplasm. Unlike 
BAT and WAT, MAT has reduced mitochondrial content and low levels of rough-
endoplasmic reticulum[92]. Studies have therefore suggested that progenitors of MAT are 
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separate from progenitors of BAT or WAT[93]. MAT is predominantly located near the 
endothelial sinuses where CXCL-12-abundant reticular (CAR) cells are located. MAT and 
CAR cells share similar perivascular cell characteristics although it is still unclear whether 
MAT from this location functions in a distinct manner from the MAT located in the endosteal 
surface. 
BMSC are defined by their ability to differentiate into osteocytes, chondrocytes and 
adipocytes[94]. The differentiation into adipocytes is controlled by the key transcription 
factors PPARγ and C/EBPα. MSCs are located in the marrow cavity, the endosteal surface 
and the perivascular component. The ability of these MSCs to differentiate into either of the 
three lineages means that within the bone marrow, there is a competitive process for the 
balance of adipocytes production and a shift towards any lineage depends on intricate 
interplay of local and systemic intermediaries[95]. 
1.2.1.2 Adipokines 
Historically, the main functions of adipocytes include thermoregulation, storage and release 
of triglycerides, protection of organs and an endocrine organ. However, it is now known that 
adipocytes also secrete factors also called adipokines that are active peptides and are mainly 
secreted proteins. Although other accessory cells are known to secret adipokines, true 
adipokines are primarily secreted by adipocytes only[96]. Adipokines are known to regulate 
physiological functions such as appetite regulation, fat distribution, secretion of insulin and 
haemostasis[97]. They have also been shown to regulate adipogenesis, metabolism and 
migration of immune cells. Biological processes that stimulate secretion of various 
adipokines have also been shown to regulate the processes. Some important processes 
include lipid metabolism, cell adhesion, fatty acid transportation, insulin sensitivity, 
inflammation, immune responsees and appetite regulation [98].  Alterations in secretion 
profiles of these activities are linked to an impairment in these biological processes. An 
adipokine profile is determined by the function and location of the adipose tissue. The two 
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main adipokines secreted from mature MAT are adiponectin and leptin. Adiponectin 
stimulates insulin sensitivity and fat oxidation, and is also a known biomarker for insulin 
resistance and heart disease. In obese states, levels of plasma adiponectin are reduced but in 
an apparent paradox, MAT and adiponectin levels increase in caloric restrictive states. 
Studies conducted have also shown that inhibition of MAT formation in mice also inhibited 
circulating adiponectin levels, indicating potential systemic effects of MAT[84].  This may 
suggest that adiponectin has conflicting roles depending on the organ in which this adipokine 
is released.  
Another important adipokine, leptin, is directly correlated to adipocyte mass and an 
inactivating mutation in leptin or its receptor results in obesity[99]. Leptin regulates immune 
responses and in the event of leptin deficiency, the potential of pro-inflammatory cytokine 
toxicity[96]. Adipocytes also possess a lipogenesis and lipolysis signature and maintain a 
delicate balance between these processes. An aim of this thesis was to also understand the 
adipokines involved in lipogenesis and lipolysis in the context of acute myeloid leukaemia. 
1.2.2 Cellular respiration 
In order for cells to grow, divide, move and perform cell type-specific functions, they need 
energy. The nucleotide, adenosine triphosphate (ATP), is the primary storage unit of 
intracellular energy. The chemical reaction that results in one of ATP’s phosphate-oxygen 
groups being removed to leave adenosine diphosphate (ADP) generates free energy. A series 
of biochemical reactions called ‘respiration’ takes place, in which nutrients, either with 
(aerobic respiration) or without oxygen (anaerobic respiration), are converted to ATP, 
carbon dioxide, and either lactic acid (if no oxygen is involved) or water (if oxygen is 
involved). 
There are four stages of aerobic respiration. The first stage is glycolysis in which glucose, 
the sugar molecule that is ultimately fed into respiration, is broken down into two pyruvate, 
two ATP and two nicotinamide adenine dinucleotide (NADH) molecules along with some 
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waste products. Glycolysis does not require oxygen and is common to both aerobic and 
anaerobic respiration. The second stage is acetyl coenzyme A formation. The way in which 
acetyl coenzyme A is generated depends on whether glucose availability is high, in which 
case pyruvate from glycolysis is used, or whether glucose availability is low, in which case 
fatty acids are used. In the glycolysis-dependent, high-glucose pathway, acetyl coenzyme A 
is produced both inside mitochondria by (1) importing and oxidisation of pyruvate to 2-
carbon acetyl, which binds to coenzyme A outside the mitochondria, and (2) outside 
mitochondria by break down of citrate produced by the tricarboxylic acid (TCA) cycle.  In 
the intra-mitochondrial low-glucose pathway, fatty acids undergo ß-oxidation.  
1.2.3 ß-oxidation 
ß-oxidation occurs in the mitochondria and the peroxisomes. This process generates energy 
in steps that constitute four phases of the process. First, free fatty acids (FFA) are imported 
into cells and ultimately inside the mitochondrial matrix via membrane transport proteins. 
For this to occur, they must be activated by CoA coupling which then allows the transfer of 
the acyl group via carnitine palmitoyltransferase 1 (CPT1) after which is it transported into 
the inner membrane of the mitochondria by CPT2. Next, the B-carbon of the fatty acids is 
oxidised to produce a carbonyl group in an acyl CoA molecule. Acyl CoA is then degraded 
to an acyl with two fewer carbons along with acetyl CoA. The third stage is the TCA cycle, 
also known as the Kreb’s or citric acid cycle, in which acetyl coenzyme A binds to 
oxaloacetate to generate citric acid. Two iterations of the cycle are needed to convert the 
input acetyl coenzyme A into two guanosine triphosphate (GTP) molecules, which are 
readily converted to ATP, six further NADH, and two flavin adenine dinucleotide (FADH2) 
molecules. The final stage is the electron transport chain in which NADH and FADH2 
molecules donate electrons, i.e. are oxidised, to produce ATP with oxygen as the acceptor 
of those electrons. As a result of oxidising one glucose molecule, an estimated 30 to 38 ATP 
molecules are generated[100]. 
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Figure 1.4. Mechanisms of cellular respiration 
 
Anaerobic respiration, by contrast, encompasses two principal stages: glycolysis, which 
proceeds as described above, and homolactic fermentation. In this latter stage, the NADH 
molecule donates a hydrogen to the pyruvate molecule generated by glycolysis to yield 
lactate. This reaction is catalysed by lactate dehydrogenase.  
1.2.4 Respiration of cancer cells 
To fuel the high growth and division rates that are typical of cancer cells, cellular metabolic 
processes, including respiration, are often subverted. These metabolic alterations have been 
extensively characterised. In 1956, Otto Warburg described one of the most studied 
phenomena in cancer cell metabolism, now known as the Warburg effect. He showed that 
contrary to normal cell metabolism, which relies mainly on mitochondrial oxidative 
phosphorylation for energy production, cancer cells circumvent this pathway and prioritise 
the aerobic glycolysis pathway. This alteration in glucose metabolism is energetically 
wasteful as cancer cells use glucose–derived carbon as building blocks for molecules instead 
of complete oxidation of glucose–derived carbon to carbon dioxide. Under normal 
circumstances, aerobic respiration through the glycolytic cycle and subsequently the TCA 
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and ETC produces approximately 30 to 38 ATP molecules. In the presence of limited 
oxygen, fermentation of pyruvate to lactate occurs in the cytoplasm producing 2 ATP 
molecules due to anaerobic glycolysis. This use of fermentation, even in the presence of 
oxygen, is what Otto Warburg described as an irreversible injury of respiration in cancer 
cells by which there is an uncoupling of respiration and the production of ATP as cancer 
cells can respire with diminished oxygen consumption.  
Another well characterised metabolic alteration in cancer cells is glutamine metabolism. In 
cancer cells, the importance of glutamine as a nutrient is highlighted by its ability to donate 
nitrogen and carbon to a number of growth-promoting pathways[101]. Under periods of 
stress or rapid proliferation, the demand for glutamine is higher than its production and thus 
becomes provisionally essential in creating an oncogene-dependent addiction within the 
cells[102].  
1.2.5 Fatty acid synthesis and cancer 
One of the primary roles of FA synthesis is for fatty acids (FA) to act as building blocks for 
synthesised membrane phospholipids[7]. FA are long-chained hydrocarbons with a 
carboxylate terminal group.  FA synthesis initiates with the conversion of acetyl-CoA into 
malonyl-CoA which is the substrate for fatty acid synthase to produce palmitate though 
various steps and is an example of metabolic channelling i.e., both CoA derivatives and FAs 
with more than four carbons can partake in palmitate synthesis directly but must be 
catabolised into acetyl-CoA before being reintroduced into the FA. An extra mitochondrial 
system is present in several sites such as liver, kidney and adipose tissue. Fatty acid synthase 
is almost exclusively located in the cytosol and therefore, acetyl-CoA is shuttled out of the 
mitochondria. In order to do so, it is first converted to citrate and transported out of the 
mitochondria membrane through the citrate transporter channel and then is converted back 
to acetyl-CoA in the cytoplasm. Acetyl-CoA is produced from pyruvate from glycolysis, 
amino acids and by fatty acid oxidation and is a precursor for the citric acid cycle (TCA). 
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FAs synthesised by cancer cells are less prone to lipid peroxidation compared to 
polyunsaturated FAs synthesised by non-malignant mammalian cells and therefore provide 
the cancer cells with more resistance to oxidative-stress induced apoptosis[6, 103]. These 
densely packed saturated lipids also limit the admittance of drugs, providing the cancer cells 
with further resistance to therapy due to the alteration of membrane dynamics[104]. 
Lipolysis occurs in concert with FA synthesis within the tumour environment. Certain cancer 
types exhibit a great deal of energy dependency on β – oxidation of FAs in a manner that 
involves low rates of glucose utilisation as well as upregulation of β – oxidation – associated 
enzymes[105, 106]. It must be noted, however, that although FA synthesis or lipogenesis is 
a characteristic feature of cancer cells, the end-product of this pathway is a toxic acid, 
palmitate, which can inhibit endogenous FA synthesis[107, 108]. For this reason, a balance 
between lipogenesis, lipolysis and lipid uptake is required within the cancer environment. 
This balance has been observed in the tumour microenvironment and is regulated in part by 
lipolysis associated enzymes[7]. Moreover, rapid lipolysis of adipose tissue in cancer 
patients has been posited to be the cause of cachexia[109, 110]. Studies have shown that in 
some cancers, tumour cells stimulate extracellular lipolysis and deplete adipose stores within 
the tumour environment[111]. A recent study has also shown cancer cells homing to adipose- 
rich tissue causing release of FAs from adipose tissue in ovarian cancer where the secondary 
site of metastasis is the adipose rich greater omentum[112]. Furthermore, a study on prostate 
cancer showed that the adiposity of the secondary site of metastasis, the bone marrow, 
promotes the survival of cancer cells[113]. Therefore, it is not unreasonable to suggest that 
bone marrow adipocytes play an important role in the protection and metabolism of several 
metastatic solid tumours.  
 
 
 
46 
  
1.2.6 Fatty acid trafficking 
Long chain FAs have been recognised for their function as metabolic substrates of complex 
lipids. In addition to serving as an energy source, FAs signal for metabolic regulation 
through enzymatic and transcriptional complexes that regulate gene expression and several 
other pathways, including survival growth, and metabolic responses[114-116]. Long-chain 
FAs are present in intracellular compartments and throughout circulation as triacylglycerols 
and cholesterol esters[117]. They are also found non-covalently bound to FA binding 
proteins (FABP), which function to increase the solubility of the FAs.  
The trafficking of FA in cells is a complicated dynamic process that influences many facets 
of cellular function[115]. In adipocytes, long-chain FA have been shown to transcriptionally 
activate genes that encode proteins involved in adipocyte metabolism, such as adipocyte 
lipid-binding protein (also known as FA binding protein 4 (FABP4)). This intracellular lipid 
chaperone is a member of the FA binding protein family and is one of the nine members of 
the FABP family, each initially categorised in terms of their occurrence in various tissue 
types; however, more recently it was found that the different isoforms of FABPs were not 
exclusive to their tissue of expression[118]  (Table 1). Moreover, FABPs have been 
proposed to be not only involved in the transport and storage of FAs but also in the 
metabolism of phospholipid and cholesterol and the recruitment and distribution of ligands 
that regulate signalling. Generally, FABPs are proteins that chaperone lipids and decide their 
biological functions[116, 119]. 
1.2.7 FABP4 expression and functionality 
FABP expression has been observed to increase in the presence of fatty acids (FA) or 
substrates for lipogenesis, storage or breakdown[120, 121]. Additionally, mass influx of 
lipids in cells subsequently increases the expression of this protein family, suggesting a 
continuous adaptive system that counters lipid presence and maintains its status with in the 
cell[120]. Under certain conditions, FABPs enter the nucleus and may target FAs to 
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transcription factors. Liver-FABP (FABP1), Heart-FABP (FABP3), Adipocyte-FABP 
(FABP4) and Epidermal-FABP (FABP5), whose ligands are FAs or other similar 
hydrophobic antagonists, are regulated by these transcription factors[122, 123]. FABP4 
physically interacts with PPAR-γ and therefore has been thought to be a co-activator in 
PPAR-mediated gene regulation. Similarly, FABP1 interacts with PPAR-α and FABP5 with 
PPAR-δ[124]. A study by Ayers et al. describes the transcriptional activation of PPAR-γ by 
FABP4 due to a continuous cytoplasmic shuttling. However, a negative feedback loop in 
which FABP4 terminates PPAR-γ activity has also been described by another study 
suggesting this feedback may be responsible for enhanced nuclear hormone receptor activity 
in macrophages[125, 126]. 
FABP4 accounts for 1 to 3 percent of total cytosolic protein in adipocytes and is a well-
recognised gene marker of mature adipocytes with a 50-fold upregulation when compared 
to more immature pre-adipocytes[127]. FABP4 is also expressed in monocytes and 
macrophages Lipolysis in adipocytes has been reported to be affected by this protein in in 
vitro and in vivo studies through a mechanism whereby FABP4 interacts with hormone 
sensitive lipase (HSL) and regulates its activity and the integrated signalling pathways 
responsible for inflammatory responses and lipid production[128, 129]. FAPB4 is becoming 
increasingly recognised for its presence in the serum and as a potential target for the 
treatment of type 2 diabetes mellitus and cardiovascular diseases. A higher concentration of 
FABP4 in the serum of obese patients compared to lean patients has also been reported. The 
presence of secreted FABP4 in the serum has yet to be addressed in the context of cancers 
but doing so may lead to a better understanding of lipid – mediated processes and their 
associated metabolic responses[130, 131]. 
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Table 1. Members of the fatty acid binding protein family. 
Gene Common name Tissue expression Amino 
acids 
References 
FABP1 Liver FABP Liver, kidney, lung, 
stomach, pancreas 
127 [132] 
FABP2 Intestinal FABP Intestine, liver 132 [133] 
FABP3 Heart FABP Cardiac and skeletal 
muscle, brain, kidney, 
lung, stomach, testis, 
adrenal gland, 
mammary gland, 
placenta, ovary, 
brown adipose tissue 
133 [134] 
FABP4 Adipocyte 
FABP/aP2 
Adipocytes, 
macrophages, 
dendritic cells, 
skeletal muscle fibers 
132 [135-137] 
FABP5 Epidermal FABP Skin, tongue, 
adipocyte, 
macrophage, 
dendritic cells, 
mammary gland, 
brain, stomach, 
kidney, liver, lung, 
heart, skeletal 
muscle, testis, lens, 
retina, spleen, 
placenta 
135 [118, 135] 
FABP6 Ileal FABP Ileum, ovary, adrenal 
gland, stomach 
128 [138] 
FABP7 Brain FABP Brain, central nervous 
system, glial cell, 
retina, mammary 
gland 
132 [139, 140] 
FABP8 Myelin FABP Peripheral nervous 
system, Schwann 
cells 
132 [141] 
FABP9 Testis FABP Testis, salivary gland, 
mammary gland 
132 [142, 143] 
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1.2.8 CD36  
CD36 (cluster of differentiation 36) is also known as fatty acid translocase (FAT), scavenger 
receptor class B, membrane 3 (SCARB3), thrombospondin receptor, glycoprotein IIb and is 
an integral membrane protein found in abundance on the surface of platelets and many other 
cells. It is a multifunctional membrane–associated protein that has been reported to play a 
role in lipid sensing and is found in tissue exposed to lipid fluxes such as adipose tissue, 
muscles of the skeleton and the heart, the mammary organ or small intestine[144]. Known 
members of the CD36 gene family include high-density lipoprotein receptor SR-B1, 
lysosomal integral membrane protein II (LIMP II) and its homologues LmpA, LmpB and 
LmpC all of which have been shown to share a common hairpin topology. This hairpin 
consists of two transmembrane domains one of which is a hydrophobic signal anchor 
adjacent to the NH2 terminus, and another that is a hydrophobic sequence adjacent to the 
COOH terminus. Both of these terminate in the cytosol[145]. The extracellular domain is 
heavily glycosylated and includes three disulphide bridges in the COOH-terminal half. 
Glycosylation can increase the protein mass from an unglycosylated 53 kDa to a molecular 
weight between 78 and 88 kDa depending on tissue[146].  
This membrane glycoprotein has also been reported on the surface of haematological cells 
such as erythroid precursors, megakaryocytes, platelets and monocytes. Subject to cellular 
settings, CD36’s primary role maybe that of a fatty acid uptake mediator, cellular adhesion 
or a class B scavenger receptor[147]. With its high affinity to long-chain FA binding, it is 
known to be a main facilitator of FA uptake. It is also a receptor for thrombospondin-1 (TSP-
1), an extracellular matrix protein involved in platelet aggregation and cell-cell 
interactions[148]. Due to its multifaceted functionality, a great deal about this protein has 
been researched showing its contributions in functions such as lipid metabolism, 
artherogenesis, thrombosis, inflammation, angiogenesis and pathogenesis of malaria.  
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In the context of cancer, this protein has been implicated in several cancer types for its role 
in the progression of the disease[149-152]. In leukaemia specifically, Ye and colleges 
identified within the bone morrow a subpopulation of leukaemic blasts with an altered 
metabolic profile that are enriched in the fat depots of the marrow. This subpopulation was 
CD36+ and are de-sensitised to chemotherapy[150]. In another study, CD36 and other 
adipogenic genes, including FABP4, were associated with prevention of apoptosis[151]. 
These studies signify the importance of CD36 in cancer progression. 
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1.3 – MAT regulating cytokines 
It has been observed that a decrease in bone volume is often complemented with an increase 
in bone marrow fat[153]. However, a metabolic sequela of cancers is cachexia also known 
as the wasting disease. In cancer cachexia, an indiscriminate mobilization of fat and skeletal 
muscle occurs which usually results from an alteration in metabolism. Cytokines have long 
been implicated in this process, most notable ones being tumour necrosis factor-alpha (TNF–
α). TNF–α is a known multifunctional secreted protein that regulates several cellular and 
biological functions including immune functions and metabolism. Adipose tissue at different 
sites and states can secrete this cytokine[154]. Adipose tissue contains a large 
stromovascular fraction which is comprised of many different cell types including 
preadipose tissue, muscle cell and fibroblasts. This fraction has been shown to secrete 
substantial amounts of TNF–α compared to adipose tissue alone[155, 156]. In this section, I 
discuss other notable BM cytokines, IL-6 and SDF-1. 
1.3.1 Interleukin-6 (IL-6) 
IL-6 is a pleiotropic, multifaceted cytokine that is a key player in many biological signaling 
pathways such as haematopoiesis and inflammation[157]. This pro-inflammatory cytokine 
is also known to be secreted by adipocytes in culture[158, 159] and has been confirmed at a 
transcriptional level[160, 161]. Although a lot is known about IL-6, its proportion of 
secretion from adipocytes alone was shown to be only 10% of the total amount of cytokines 
secreted from isolated adipocytes in culture[159].  Is it secreted by WAT, skeletal muscle 
and the liver[156, 162].  
Interestingly, TNF–α has been implicated in simulating the release of IL-6[163]. Moreover, 
an increase of TNF–α increased insulin resistance, which is also true with an increase in 
systemic IL-6[164]. IL-6 is also believed to have dual functionality depending on the type 
of tissue and its metabolic state. For example, adipose rich tissue and liver IL-6 exerts pro-
inflammatory activities by increasing insulin resistance and in turn dampens the insulin-
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induced insulin receptor. IL-6 also has been shown to promote FA metabolism dysregulation 
in WAT due to its enhancement of BMSC proliferation. In skeletal muscles, IL-6 increases 
glucose uptake causing muscle hyperatrophy and eventual 5’ adenosine monophosphate-
activated protein kinase (AMPK)-mediated FA oxidation[165, 166]. An influx of IL-6 in 
culture has been shown to increase lipolysis, as detected by the levels of FFA and glycerol 
in the culture media[167]. IL-6 binds to a heterodimer of IL-6 receptor and GP130[168, 169] 
to activate two signaling pathways; the Janus Kinase and Signal Transducer and Activator 
of Transcription (JAK-STAT) and the p44 and p42 Mitogen-activated protein kinase 
pathways (MAPK)[167, 170]. TNF–α activates downstream adipocyte intercellular 
signaling mediated by a shared p44/42 MAPK and Jun N-terminal Kinase (JNK) pathway 
which phosphorylates perilipin and allows subsequent recruitment of HSL. 
The TNF–α and IL-6 lipolysis pathways are not the physiological norm for lipolysis 
activation in adipocytes (ß adrenergic receptor and downstream cAMP and PKA represents 
normal lipolysis pathway) but have been studied as an additive cytokine signaling to β-
adrenergic activity which can be a potential therapeutic intervention for lipolysis inhibition. 
 
Figure 1.6. Additive mechanisms of lipolysis. Adapted from[171]  
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1.3.1.1 Role of IL-6 in cancer 
IL-6 is widely accepted as a key functional promotor of B-cells and an antagonist to T 
regulatory cells[172, 173]. More importantly, it has been implicated in the proliferation of 
many malignancies including MM, endometrial cancer, lung cancer, breast cancer, ovarian 
cancer and many more[174-177]. Overexpression of both IL-6 and its receptor IL-6R have 
been implicated in various malignancies. As it is ubiquitously expressed in virtually every 
tumour studied, it has an ipso facto role in tumours that include proliferation, differentiation, 
invasion, migration and angiogenesis. Current IL-6-targeted therapy has shown potential in 
breast cancer ovarian cancer, renal carcinoma and even multiple myeloma. IL-6 has also 
been implicated as a cancer drug resistance marker and modulator of the pathways that 
confer resistance, such as in breast cancers that are multi-drug resistant and that are high-
level secretors of IL-6. In prostate cancers, IL-6 has been shown to have an autocrine and 
paracrine response in that it acts as a growth factor for the prostate cancer cells[178, 179]. 
Chimeric murine anti-human IL-6 antibody (CNTO 328) is a neutralizing IL-6 antibody that 
has shown great promise in reducing cancer cachexia. A clinical trial of CNTO 328 in 
ovarian cancer had shown positive disease stabilisation and a decrease in other tumour 
implicated cytokines such as SDF-1 and VEGF[178]. Recently, a new, indirect inhibitor of 
IL-6 through downstream JAK pathways known as Ruxolitinib has been reported as 
amyeloproliferative neoplasm treatment[180]. 
1.3.2 Stroma Derived Factor-1 (SDF-1)  
CXC chemokine ligand (CXCL) 12 (also known as Stroma Derived Factor-1 SDF-1) was 
among the first haematopoietic stem cell factor to be characterised in the bone marrow[181-
183]. Its receptor CXCR4, a heterotrimeric guanosine triphosphate protein also functions as 
the HIV-1 virus entry receptor[184-186]. In the late 90s, it was discovered that this 
receptor/ligand interaction was necessary for haematopoiesis, colonization of the bone 
marrow by progenitors of haematopoietic cells, cardiovascular and neurological 
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formations[187, 188]. Inhibition of CXCR4 using a selective inhibitor initiates mobilization 
of HSCs into the peripheral blood indicating its ligand may play a role in retaining HSCs in 
the bone marrow[189]. This mobilization effect of CXCR4 inhibition was translated into in 
vivo models showing a lack of ability of human CD34+ to engraft into the bone marrow of 
NOD-SCID (non-obese diabetic-severe combined immunodeficiency) mice[190].  
Further characterisation using in vivo knock-in models reveled the major source of SDF-1 
in the bone marrow are cells associated with the sinusoids of the bone marrow, such as the 
endothelial cells and the perivascular cells[181, 191]. These perivascular cells were 
discovered to express SDF-1 at levels about 100-1000 folds more than endothelial cells and 
other sinusoid associated cells such as osteoblasts. It was these cells that secreted high levels 
of SDF-1 that were also identified as the same cells that secreted Stem Cell Factor 
(SCF)[192]. The SDF-1/CXCR4 signaling role in haematopoiesis prompted in vivo knock-
in reporter studies of SDF-1 showing both SDF-1 and SCF were preferentially expressed in 
a subpopulation of stromal cells that possess long processes and were called CXCL12-
abundant reticular (CAR) cells[187, 193-195]. These cells are adipo-osteogenic progenitors 
that express both adipogenic and osteogenic genes and share similarities with SCF-
expressing cells in their expression of leptin receptor[195, 196]. Ultimately, experiments 
were conducted to investigate the role of these CAR cells in haematopoiesis and it was 
discovered that they also express Forkhead box C1(FoxC1) transcription factor which has 
been shown to be an important factor in the maintenance of the haematopoietic niche[197].  
SDF-1 is now an established chemokine in the bone marrow microenvironment and its 
abundance in CAR cell fraction of the bone marrow is equally important as these cells 
possess adipogenic qualities. It is therefore not unreasonable to suggest that HSC migration 
towards adipocytes may be due to chemokine secretion such as SDF-1 from CAR cells.  
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1.3.2.1 Role of SDF-1 in cancer 
There is indisputable evidence that SDF-1 plays a role in tumour metastasis due to its 
constitutively high expression at the site of tumour and metastasis. Its exact function at the 
tumour site is still not entirely delineated; however, it is known to be a functional unit in 
retention of the tumour cells within the environment, as opposed to facilitating metastasis. 
However, there is a counter hypothesis to the previous statement as studies have also shown 
the SDF-1/CXCR4 axis is involved in homing of tumour cells to specific secondary sites. In 
acute lymphoblastic leukaemia (ALL), SDF-1 was shown to be a key player in the migration 
of ALL cells towards adipocytes which also protected he ALL cells from chemotherapeutic 
agents[198]. 
There are currently many biological inhibitors including small molecule inhibitors, peptides 
and antibodies that have suppressed the expression and/or binding of SDF-1 to its receptor 
CXCR4. In AML, a small molecule compound AMD3100 has been reported to enhance the 
efficacy of frontline therapy AraC and prolong overall survival in in vivo models. In a phase 
I/II study, AMD3100 has shown significant remission rates and relapse-free survival rates 
in patients undergoing combination therapies[199]. However, although the biological 
rational for further investigations of SDF-1/CXCR4 axis is sound, there are some notable 
limitations; firstly, off-target and allosteric effects of AMD3100 inhibitor may interfere with 
anticipated functioning of this axis inhibition. For example, because SDF-1 can also bind 
active CXCR7 receptor, AMD3100 can potentially bind to this receptor instead of CXCR4 
as both are competitive receptors for SDF-1[200]. Therefore, investigating the role of 
inhibiting both CXCR4 and CXCR7 is becoming increasingly important in blocking the 
SDF-1/CXCR4/CXCR7 axis. 
1.3.4 Evidence gaps 
Despite the extensive leaps in the field of cancers and haematological malignancies there are 
many gaps in our understanding of the underlying mechanisms. Although there may be a 
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specific “driver” of the primordial initiation of this disease, there are many existing 
mechanisms intrinsic to the very biological make up of living systems that can support this 
initiation though mechanisms that started as sustainers for normal functioning. This 
hijacking of the normal environment by malignancies is a recurring theme in many cancer. 
In this research thesis, I investigate the role of one of many tissue types that support such an 
environment in favour of the malignancy. Adipose tissue, being abundant in the bone 
marrow, has long been thought of as merely a passive occupant of the bone marrow. 
However, my research investigates mechanisms by which its function contributes to the 
maintenance of AML blasts indicating an active role as a prominent participator in the 
leukaemic bone marrow. 
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1.4 Research aims and objectives 
Following the discovery that adipocytes contribute to the progression of several cancer types 
including haematological malignancies such as multiple myeloma and acute lymphocytic 
leukaemia, a sound rationale for further investigation of its role in the maintenance of acute 
myeloid leukaemic (AML) blasts is put forward. Coupled with the initial knowledge of the 
abundant presence of adipose tissue within the adult marrow, and the peak incidence of this 
disease in the older population, this project also aims to elucidate whether, and how, 
inhibiting the contributory role of adipose tissue within the bone marrow microenvironment 
imparts changes in the progression of AML blasts. Data collected from this research may 
help to determine if there is a potential clinical application in targeting the leukaemic 
progression from this angle of adipocyte-contributed sustenance and therefore widening the 
eligible therapeutic window to include populations not eligible for the currently available 
cytotoxic therapies. 
In line with the above, more specific aims are summarized below: 
1. To determine if bone marrow adipocytes contribute to the proliferation and survival 
of AML blasts. 
2. To determine how fatty acids are transported to AML from bone marrow adipocytes.  
3. To determine if fatty acid metabolism in the AML blasts is crucial for generating 
cellular energy. 
4. To determine alternative mechanisms by which bone marrow supports AML 
proliferation 
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CHAPTER 2 – Methodology 
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2.1 Primary cell isolation and culture 
Primary BM AML and normal samples were obtained from the NNUH following informed 
consent and under approval from the UK Health Research Authority 
(HRAref07/H0310/146). Haematopoietically active BM is restricted to the axial bones of 
the adult skeleton allowing the posterior iliac crest to be the optimal site for BM aspiration. 
This procedure is performed under local anesthesia by specialists at the NNUH. Normal BM 
samples for this project were obtained from patients undergoing total-hip replacement 
(THR) as during the procedure, the posterior iliac crest is easily accessible making 
acquisition of BM simpler. Consent for normal BM donation from THR patients is also a 
requirement and is obtained prior to the procedure. Patients are also asked to provide consent 
for use of their BM in in vivo experimentation. If consent was not provided for in vivo 
experimentation, this was noted on receipt of the sample and no in vivo experimentation was 
performed on these samples. 
The aspirate was dispensed in appropriate sample tubes containing RPMI 1640 
supplemented with 10-13U/mL of Heparin (Sigma), 2.5mL of Hepes buffer and 1mL of 
penicillin/Streptomycin/Gentamycin. A tissue bank number was then allotted to the sample 
and patient details were anonymised before transportation to the lab. Once received, tissue 
bank number was recorded and allocated a lab sample number. Sample cytogenetics, blast 
percentage and cell surface markers were provided following tests at the NNUH.  
Viable mononuclear cells, containing leukocytes and platelets, were isolated by density 
separation, which is based on the principle of differential migration of blood cells through 
media by centrifugation. The density gradient solution I used was Histopaque® - 1077 from 
Sigma-Aldrich. Histopaque is a solution of polysucrose and sodium diatrizoate at an optimal 
density of 1.076-1.078g/mL required for separation of components of blood and BM. For 
fractionation of viable cells from the BM, I placed 10mL of Histopaque into a 50mL falcon 
tube. I then gently layered the BM sample on top of the Histopaque followed by 
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centrifugation at 12,000 rpm for 30 minutes without breaks. Centrifugation yielded 
fractionation of the BM sample into three phases: 1) The upper phase of plasma with a 
bottom layer or ‘buffy coat’ which sits atop the second phase 2) Histopaque and 3) the heavy 
granulocyte ad erythrocyte phase. The density of blood plasma is 1.025g/mL making it less 
dense than Histopaque and allowing for the plasma to be fractionated above the Histopaque 
with the heavier fractions of the BM containing the granulocytes and erythrocytes pelleted 
below. A schematic of this is provided in Figure 1. The buffy coat containing the leukocytes 
was easily isolated form the upper phase using a pasture pipette and washed twice with 
1xPBS. The cells were then counted using trypan blue exclusion and flasked at a density of 
2x106/mL in DMEM supplemented with 10% FBS and 1% 
penicillin/Streptomycin/Gentamycin for 24 hours. Non- adhered cells were then collected, 
washed in 1xPBS, resuspended and analysed using cell surface characterisation by flow 
cytometry for markers for AML. Thus, the cell surface expression and blast population 
percentage was established and cross-checked with blasts population numbers provided by 
NNUH. I continued to culture the adherent cells until confluency and determined their 
surface expression for markers for BM-stromal cells (BMSC) as detailed below. 
Occasionally, samples received contained excessive fat content. This fat was easy to isolate 
due to the lighter density of fat and its tendency to float to the surface of the sample. Once 
these samples were received, I spun them down briefly at 12000 rpm for 30 seconds which 
allowed the layering of the fat on the surface of the sample. I removed this layer using a 
pasture pipette and placed them in 24 well plates. I then added 1 mL of DMEM media with 
1% FBS and then collected this media after 24 hours. This media was used for cytokine 
arrays. 
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Figure 2.1 Bone marrow fractionation using density separation gradient and centrifugation 
without breaks. 
 
Fatty samples also contained fat-rich niches. These were easily identifiable as minute 
globules above and below the histopaque layer. They were collected using a pasture pipette 
and cultured in chambered slides and used for immunocytochemistry (ICC).  
2.2 Bone Marrow Stromal Cells culture and differentiation into adipocytes 
The BMSC were cultured in T75 flasks as they were isolated from the primary samples and 
allowed to grow to ~95% confluency. The media was removed and the cells were washed 
twice with PBS to remove any remaining media from the flask which could potentially 
inactivate the trypsin. Trypsin is an enzyme that acts by cleaving amino acids, specifically 
lysine and arginine at their C-terminus. This is especially useful in cell culture as trypsin 
cleaves the proteins binding the cultured cells to their culture plastic. Cell-to-cell adhesion 
relies on calcium for adhesion. Therefore, culture media and FBS contain high 
concentrations of calcium and magnesium ions which can inhibit trypsin functioning. For 
this reason, EDTA is present in the trypsin solution to weaken adhesion as it is a divalent 
cation chelator thereby breaking cell-cell adhesion. In a T75 flask, I placed 2 mL of 
Trypsin/EDTA solution to split and resuspend the cell in PBS before counting.  I used 1x105 
cells for analysis of cell surface markers of BMSCs and plated the remaining in a 24-well 
62 
  
culture plate at 1 x 104 cells per well. I changed the media after 24 hours and allowed the 
cells to reach confluency in the plates (usually another 24 hours).  
Once these plated BMSCs were confluent, I replaced the media with differentiation media 
to induce adipogenic differentiation of BMSCs. The differentiation media (I3D) contained a 
cocktail of dexamethasone (1μM), indomethacin (0.2mM), insulin (100nM) and 3-isobutyl-
1-methylxanthine (0.5mM) in DMEM containing 10% FBS, and was replaced every four 
days with fresh differentiation media. This was done for 21-27 days until a minimum of 75% 
adipocyte population was achieved. Percentage of adipocytes was calculated using ImageJ 
software and surface coverage of adipose cells were counted. Dexamethasone, 
indomethacin, IBMX and insulin have long been used for adipogenic differentiation of 
BMSC as dexamethasone is an anti-inflammatory steroid that regulates the PPARγ in 
combination with IBMX and are inducers of C/EBPδ and C/EBPß which are transcriptional 
factors for growth and differentiation[201]. Indomethacin is also known to enhance 
adipogenic differentiation also by activating the PPARγ and PPAR pathways[202, 203]. 
Insulin is an adipogenic hormone that initiates a cascade of transcription factors that regulate 
the differentiation of pre-adipocytes into mature adipocytes.  
2.2.1 Co-cultures of BMSCs and adipocytes with AMLs or CD34+ cells 
I seeded BMSCs at 3 x 104 cell per well in a 12-well plate or 1 x 104 cells per well in a 24-
well plate. I then differentiated, for adipocytes co-cultures. I plated AMLs or CD34+ onto 
pre-seeded BMSCs or adipocytes at 5 x 105 per well in a 12-well plate and 1 x 105 per well 
in a 24-well plate and incubated for required time. For isolation of cells, I removed all 
suspension cells by gentle pipetting and washing with PBS. To ensure removal of all cells 
(and those adhering to BMSC or adipocyte layer) I then lightly trypsinised BMSCs or 
adipocytes using diluted trypsin (1:1 typsin to PBS) for 40 seconds followed by gentle 
tapping. Following removal of the remaining suspension cells, I then washed the adherent 
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cells with PBS before lysing for RNA extraction or protein extraction. Appendix Figure A 
shows confirmation of pure AML population from co-cultures.  
2.3 Immunocytochemistry (ICC) 
I carried out ICC for non-adherent AML blasts, BMSCs, primary niches isolated form AML 
BM samples and adipocytes derived from BMSC differentiation. The initial culturing of 
these cell types varied slightly; however, the ICC methodology was the same. 
For adipocytes differentiated from BMSC, I grew 5x103 BMSCs on 1mm coverslips 
(Menzel-Glaser) in 6 well plates. Once confluent on the coverslips, I replaced the media with 
differentiation media as described in section 2.2. Following differentiation, I carefully 
removed the coverslips from the wells containing media and immediately fixed them with 
4% paraformaldehyde (PFA) for 10 minutes at room temperature (RT). PFA forms 
crosslinks between proteins in the sample, preventing decomposition and fixing cellular 
proteins and structures in place. I chose to use PFA instead of organic fixatives such as 
ethanol as these would remove lipids with the samples. I fixed with PFA for 10 minutes as 
PFA has the potential to mask antigens due to cross-linking and thereby inhibit antibody 
binding. 
For intracellular proteins, the plasma membrane of the cells must allow penetration of 
fluorescent probes and for this reason, cells are treated with a detergent. I used Triton X-100 
at a concentration of 0.05% in PBS for 20 minutes as it perforates the plasma and nuclear 
membrane large enough for the antibody to enter. Following Triton-X treatment, I washed 
samples in 10% normal goat serum (NGS) twice before I blocked samples in 30% normal 
goat serum (NGS) in PBS overnight at 4°C.  
For primary staining, I used BODIPY® 493/503 (4,4-Difluoro-1,3,5,7,8-Pentamethyl-4-
Bora-3a,4a-Diaza-s-Indacene) dye to stain lipids (lipids did not require permeablisation or 
secondary antibody incubation but as samples were co-stained, other intracellular proteins 
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required permeablisation and incubation with secondary antibody). For cell surface proteins, 
I used CD34 monoclonal antibody (clone ICO-115 #10004835 Cayman chemical), CD36 
monoclonal antibody (clone JC63.1 #188150 Cayman chemical), CD90 (#13801 Cell 
Signaling Technology), CD105. For intercellular proteins, I used fatty acid binding protein-
4 (#3544 Cell Signaling Technology), Perilipin (#9349 Cell Signaling Technology), 
hormone sensitive lipase (#4107 Cell Signaling Technology) 
For secondary antibody staining, I used a secondary rabbit antibody conjugated to 
fluorophore. Since the primary antibodies were rabbit, the secondary antibodies would cross 
react and bind to the primary labels. I used Alexa Fluor 568 because the emission colour, 
red/orange, is far enough from the green fluorescence produced from the lipid staining. 
When not staining for lipids, I used Alexa Fluor 488 which is a green-fluorescent dye. For 
nuclear staining, I used DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride) which is a 
nuclear and chromosome counterstain that binds to the AT regions of the DNA. Upon 
binding, it emits a blue florescence that is ideal for co-staining as it is on the far end of the 
spectrum and less likely to interfere with other co-stains. 
Cells were imaged by an AxioCam ICm1 monochrome CCD camera attached to the 
Apotome.2 Imaging System using Axiovision 4.8.2 software (Carl Zeiss). For X40, X60 and 
X100 magnifications, oil immersion was used. For confocal microscopy, I used the Zeiss 
LSM 800 with Airyscan with X60 water immersion. I used the Axiovision 4.8.2 software by 
Carl Zeiss and analysed staining intensities with ImageJ software.  
2.4 Proliferation assay using BrdU  
For the assessment of proliferation of primary AMLs from AML/adipocyte co-cultures and 
AML monoculture, I used 5-bromo-2’–deoxyuridine (BrdU staining kit for flow cytometry 
FITC; eBioscience) and CD34 antibody to assess mitotic DNA content of CD34+ cells. 
BrdU is a synthetic analogue of thymidine that can incorporate into the DNA of dividing 
cells. During the S phase of the cell cycle, new copies of genetic material are made with the 
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help of the intracellular environment from which amino acids such as thymidine are used. 
BrdU is used, when present, to incorporate into the newly created DNA strands. The main 
advantage of using this synthetic nucleoside is its ability to be stained with an antibody 
conjugated to a chromophore, which can then be detected using ICC methods or flow 
cytometry. I used an anti-BrdU FITC antibody that binds to the incorporated BrdU and 
enables quantification by flow cytometry. I also co-stained cells with CD34 APC antibody 
to enumerate the number of CD34+ cells that are proliferating. The experimental procedure 
is described in detail below. First, cells required for quantification of proliferation were 
incubated with 10µM of BrdU per 1x106 cells at 37°C for 45 minutes. I then washed the 
cells with sterile PBS and resuspended the cells in 100µl of PBS and split this volume into 
two aliquots of 50µl each. I incubated one aliquot with CD34-APC antibody and the other 
with Igg-APC isotype control in the dark at 4°C for 30 minutes. I fixed the cells with BrdU 
staining buffer, which permeablises the cells for anti-BrdU counter stain. After 1 hour of 
incubation with staining buffer at room temperature, I washed the cells with PBS and treated 
with DNase I, which helps unwind the DNA and enables binding of antibodies with 
conjugated fluorophore. I empirically estimated incubation with DNase I to be optimal at 2 
hours of incubation. I then washed the cells and incubated with 5µl of anti-BrdU FITC 
antibody for 30 minutes at room temperature in the dark. I then washed the cells and analysed 
CD34+ and BrdU + cells using flow cytometry. 
2.5 Cell cycle and cell death analysis 
2.5.1 Cell cycle analysis 
PI is a fluorescent dye usually used to quantify DNA content as the amount of PI, and 
therefore fluorescence, is proportional to the amount of DNA present. A profile of DNA 
content can then be produced using the differential intensity profile of cells. For example, 
cells in the S phase of the cell cycle contain more DNA content compared to other phases 
such as the G0, G1, G2 and M phase. This is because during S phase, the cell is preparing to 
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divide and therefore synthesizing more DNA copies readying the cell for mitosis. The 
intensity is often plotted as a frequency histogram of PI intensity and can identify cell cycle 
disturbances such as apoptosis, and interruptions at certain checkpoints (Figure 2.2). 
For the cell cycle analysis of mono-cultured AMLs and AMLs that were co-cultured with 
adipocytes at day 0 and day 6, I collected the AMLs and washed with filtered and sterilised 
PBS. I then resuspended the cells in 1mL of PBS and slowly added 2.3mL of absolute 
ethanol to the suspension while vortexing. Vortexing during the addition of ethanol is critical 
to avoid clustering of the cells while fixing. I then incubated on ice for 15 minutes before 
pelleting the cells and discarding the supernatant. I then suspended the cells in PBS solution 
containing 50ug/mL of PI, 0.1 mg/mL of RNase A to remove contaminating RNA and 0.05% 
Triton X-100 for permeablisation. The cells were incubated in this solution for 40 minutes 
at 37°C. Following incubation, I added 3 mLs of PBS to the suspension and pelleted the cells 
to discard the supernatant. I then resuspended the cells in 500µl of PBS and analysed using 
flow cytometry to determine frequency distribution of PI intensity. 
 
 
 
 
 
 
 
 
Figure 2.2 Cell cycle profile showing apoptotic, G0/G1, S and G2/M phase. 
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Figure 2.3 Normal and apoptotic cell membranes showing translocation of PS in apoptotic 
and necrotic cell membranes. 
 
2.5.2 Cell death analysis 
Apoptosis, or programmed cell death, is a normal physiological process for the removal of 
unwanted cells. An earlier occurrence of apoptosis is the translocation of membrane 
phosphatidylserine (PS) from the inner side of the plasma membrane to the surface (Figure 
2.3). Annexin V, a Ca2+- dependent phospholipid-binding protein, exhibits anti-
phospholipase activity and binds to PS, therefore flourochrome-labeled Annexin V can be 
used for detection of PS using flow cytometry. Counterstaining by propidium iodide (PI) 
allows discrimination of early apoptotic cells from late apoptosic/ necrotic cells. 
For the cell death analysis, I washed the cells and suspended them in 200µl of X1 binding 
buffer before adding 2.5µl of Annexin V to the suspension. I incubated the suspension at 
room temperature for 10 minutes and then washed the cells with binding buffer before 
suspending again in 195µl of binding buffer and adding 5µl of PI. I then analysed the 
suspension using flow cytometry. Due to the proximity of Annexin V and PI emission, I 
colour compensated using the flow cytometry Accuri C6 software. 
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2.6 Free FA and glycerol detection 
Free FA and glycerol were detected using lipolysis assay kit for detection of both free 
glycerol and FAs (Zenbio, research Triangle, NC). The principle of the assay is the detection 
of glycerol and Non-Esterified Fatty Acids (Free Fatty Acids; FFA) using a substrate to 
induce a colometric change, which can then be analysed using immunosorbance detection 
and calculating the concentration of glycerol and FFA using a standard curve previously 
calculated. 
In a reaction catalyzed by glycerol kinase, adenosine triphosphate (ATP) phosphorylates 
glycerol present in the media to produce glycerol-1-phosphate (G1P) and adenosine 
diphosphate. Subsequent oxidation of G1P produces dihydroxyacetone and hydrogen 
peroxide. It is the hydrogen peroxide produced that then catalyses a coupling reaction of 4-
aminoantipyrin and sodium N-ethyle-N-(3-sulfopropyle)m-anisidine, present in the glycerol 
reagent provided in the kit, that produces a quinoeimine dye that can be measured at an 
absorbance of 540nm. 
Glycerol + ATP  G1P + ADP 
G1P + O2  DAP + H2O2 
H2O2 +4-AAP + ESPA  Quinoneimine dye + H2O 
For the assessment of FFA, acyl-CoA thiol ester is produced in a reaction of CoA, FFA 
released by adipocytes, and ATP, which is catalyzed by acyl-CoA synthetase. The resulting 
acyl-CoA thiol oxidises in the presence of acyl-CoA oxidase and produces hydrogen 
peroxide. Similar to the glycerol detection principle, 3-methyl-N-ethyl-N-(hydroxyethyl)-
aniline undergoes oxidative condensation with 4-aminoantipyrine due to hydrogen peroxide 
and peroxidase. This reaction produces a purple colour which can be detected at an 
absorbance of 550nm. 
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HCOOH + ATP + CoA  Acyl-CoA + AMP + PPi 
Acyl-CoA + O2  2,3-trans-Enoyl-CoA + H2O2 
2 H2O2 + 3-methyl- C10 H15NO + C11H13N3O  Purple product + 4H2O 
 
For the detection of glycerol and FFA in monocultures and co-cultures, I cultured the cells 
in the lipolysis assay buffer (LIP2/3) provided for 24 hours at 37°C. From each sample, I 
collected 50 µls and 30 µls of media for glycerol and FFA detection respectively and placed 
in an appropriate 96 well plate for absorbance detection. I added Glycerol and FFA reagents 
to the wells and read the absorbance using a FLUOstar Omega plate reader from BMG 
Labtech. I used the OD to calculate the concentration of FFA or glycerol from a known 
standard concentration curve previously produced from standards of known concentrations 
provided in the kit. 
2.7 Free FA uptake assay 
For lipid visualisation and transfer, I incubated adipocytes with a BODIPY® - dodecanoic 
fluorescent free fatty acid analogue (DAA) (QBT™ Fatty acid uptake assay kit, Molecular 
Devices). The QBT assay uses BODIPY® coupled with a proprietary technology that acts 
as a substrate for fatty acid transfer. I first ensured removal of all exogenous fatty acids in 
the adipocyte culture by culturing cells in serum free media supplemented with fatty acid 
free BSA for 3 hours. I then washed the adipocytes with HBSS and incubated the adipocytes 
with the QBT DAA dye, diluted in serum-free media in a 1:100 dilution, for 4 hours. 
Following X2 PBS wash of adipocytes, I co-cultured AMLs with these labelled adipocytes 
for 24 hours. I then removed the AMLs and washed them with PBS before suspending in 
PBS and analysis of fluorescence of AMLs using flow cytometry (Figure 2.4). I also 
visualised the stained adipocytes using AxioCam ICm1 monochrome CCD camera and 
quantified fluorescence using ImageJ software. 
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Figure 2.4 Schematic of Fatty Acid Uptake Assay 
 
2.8 RNA isolation, Reverse Transcription  
For RNA extraction, I used ReliaPrep RNA extraction kit from Promega. I lysed cells using 
a solution of BL buffer and 1-Thioglycerol. This solution contained guanidine thicyanate 
and guanidine hydrochloride, which is necessary for allowing lysis of the cells and solubility 
of genetic material. I then added isopropyl alcohol to the lysed cells, which creates an 
appropriate condition for binding of the nucleic acids to the silica membrane of the spin 
columns. This mixture was then spun in the column and the flow-through was discarded. I 
then washed the membrane with a wash buffer followed by treatment with DNase I for 
removal of the DNA fraction of the bound genetic material. After two more washes, I eluted 
the RNA bound to the silica membrane using a low salt buffer. I quantified RNA using 
Thermo nanodrop system. 
 
Figure 2.5 Representative spectral pattern for RNA and DNA assessed for purity and 
integrity using NanoDrop Spectrophotometers. 260/280 purity ratio for both lie within the 
pure range of ~2.0 and ~1.8 for RNA and DNA respectively.  
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For reverse transcription, I used qPCRBIO cDNA synthesis kit from PCR Biosystems. I used 
100ng of RNA in 4 µl of 5X buffer which contains anchored oligo(dT), random hexmerase, 
15mM MgCl2, 5mM dNTPs and 1 µl of 20X RTase in a reaction volume of 20 µl. I then 
used BioRad Thermocycler for incubation at 42°C for 30 minutes and 85°C for 10 minutes 
for RTase enzyme denaturation.  
2.9 Quantitative/real-time polymerase chain reaction 
Following cDNA synthesis, I carried out real-time (RT) quantitative PCR to monitor the 
amount of mRNA within a sample relative to a control gene. In RT-PCR, the amount of 
product is proportional to the fluorescence produced by a reporter dye. It is a sensitive and 
quantitative method as it detects the amount of product generated during the reaction in real-
time. The initial amount of cDNA is inversely proportional to the threshold cycle (a 
parameter used to measure each reaction). I used SYBR Green-based detection using the 
qPCRBIO SyGreen Kit from PCRBIOSYSTEMS and the LightCycler-II 480 from Roche. 
This real-time system has a suitable optics for the detection of SYBR-Green.  SYBR-Green 
intercalates between base pairs of ds-DNA and will only fluoresce when bound to DNA. 
Therefore, during the end of the annealing or the extension step, when the maximum amount 
of ds-DNA is present, is when the fluorescence signal occurs in detectable intensities. 
However, to avoid unbiased binding, I used master mix containing 10µM of forward and 
reverse primers and SyGreen with a cDNA at a concentration of 100ng. For this project, I 
investigated mRNA expression of several genes with primer sequence shown in the 
Appendix. For relative quantification, I used the following PCR protocol: 
Pre-incubation 
 1 cycle of 95°C for 5 minutes 
Amplification 
45 cycles of: 
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95°C for 10 minutes 
60°C for 10 minutes 
72°C for 10 minutes 
Melting curve 
1 cycle of: 
95°C for 5 seconds 
65°C for 1 minute 
97°C ~ 
Cooling 
1 cycle of 40°C for 30 seconds 
This was followed by a 4°C hold. PCR product is ds at low temperature and binds to SYBR 
Green increasing fluorescence. Fluorescence then decreases with rising temperature as the 
PCR product dissociates. A melting curve is plotted by the machine which shows a single 
peak as a single product and therefore multiple peaks indicates more than one PCR product, 
contamination or primer diamers. I analysed the melting curve to ensure single peak and 
purity of product.  
mRNA levels are relative gene expression profiles and represented as fold-changes from 
control. Raw values are acquired as Ct values. A housekeeping target and the data were 
normalized using standard comparative Ct method. To compare gene values between 
samples, I calculated ∆∆ Ct from a ∆ Ct achieved from subtracting the housekeeping gene 
from each sample. ∆∆ Ct is then calculated from subtracting ∆ Ct from the experimental 
control. The fold-change relative to control is then calculated by 2-∆∆Ct. Every sample was 
processed in triplicates. 
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2.10 Western immunoblotting 
For protein analysis by western blotting using sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE), I used radioimmunoprecipitation assay buffer (RIPA) buffer 
to extract whole-cell lysate. The constituents of which were 10mM Tris-HCl (pH 8.0), 1mM 
EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS. 140 mM NaCl, and 
protease and phosphatase inhibit cocktail (1 tables each for 10 ml of RIPA buffer solution).   
RIPA buffer enables extraction of nuclear, cytoplasmic and membrane-bound proteins from 
whole cells. I used protease and phosphatase inhibitors as they maintain signaling pathways 
that become dysregulated by cell lysis. Inhibiting proteases and phosphatases can prevent 
damage to cellular proteins and avoid discriminate recovery and presence of proteins. For 
adherent cells, I removed the media and washed the cells with PBS. I then placed 100µL of 
RIPA buffer onto the cells. I then collected the cell in an eppendorff and stored on ice for 20 
minutes followed by a spin at 4°C at 12000 r.p.m. I then collected the supernatant and 
discarded the pellet. For suspension cells, I spun down and washed cells in PBS before 
adding RIPA onto the pellet for suspension and following similar protocol as adherent cells. 
I then added 4X sample buffer containing ß-mercaptaethanol, glycine and bromophenol 
blue. 
I cast 10% acrylamide gels (30% Acrylamide/Bis Solution, 19:1 from BioRad #1610154) 
for resolving proteins of small molecular weight and 12-14% acrylamide for proteins of 
heavier weight resolution. I used 10% SDS to linearise and mask the charge of the proteins, 
7.5M of Tris-EDTA at pH 8, 10% Ammonium persulphate and TEMED to help polymerize 
the gel. I ran the gel at 200V for 55 minutes in running buffer containing 10% SDS, 20µM 
Glycine and 157µM Tris-Base. With every gel run, I ran an addition lane for a protein marker 
or a ladder to identify the weight of the proteins detected by the primary and secondary 
antibodies. I used Precision Plus Protein ™ (Bio-Rad Cat# 1610373). I transferred proteins 
from the gel onto a polyvinyladine fluoride (PVDF) membrane pre-treated with ethanol in 
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transfer buffer containing 20µM Glycine and 157µM Tris-Base at 100V for 50 minutes. I 
then blocked membranes in 5% BSA or 5% non-skimmed milk for phosphorylated proteins.  
Western analyses following SDS-PAGE were carried out as described. Whole-cell lysates 
were extracted from MSC-Ad/AML co-culture and monocultures of the same by using RIPA 
and SDS-PAGE was performed. Protein transfer onto PVDF membranes was carried out and 
membranes were then incubated in primary antibodies at the following dilutions: β-actin, 
1:5000; AMPKα, 1:1000; HSL, 1:1000; MAPK, 1:1000; CD36, 1:2000; p-AMPKα, 1:1000, 
p-HSL, 1:1000. For antibodies of species of rabbit, mouse or goat, I used the respective 
secondary antibodies that were horseradish peroxidase (HRP) conjugated (Details of 
antibodies used provided in Appendix table D). I incubated the blots in the respective 
secondary antibodies for an hour at room temperature followed by a few washes in PBS + 
0.01% polysorbate 20 (TWEEN 20 Sigma Cat# P2287)). To image the membranes, I used 
enhanced chemiluminescence (ECLGE healthcare Cat# RPN2232) which is a substrate that 
reacts with HRP to produce light. This light is then detected using a CCD with filter that was 
pre-set to emission filter 3 on the Chemdoc-It2 Imager, UVP. The bands detected were 
quantified using ImageJ software. 
2.11 Cryopreservation and recovery 
Due to continuous culturing, cells are disposed to a genetic drift, senescence or 
contamination. To capture precious samples at the peak of their viability, I cryopreserve 
samples of working cell lines and/or primary samples for long-term storage. I used the 
cryprotective agent dimethyl sulfoxide (DMSO) as it reduces the freezing point of the media, 
retarding the cooling rate and the risk of crystalisation of the sample, which can damage the 
cells. I made freezing media by adding to foeatal bovine serum 10% DMSO. I stored the 
freezing media at -20oC and, prior to freezing, I thawed the media at 4 oC. I suspended cells 
in the freezing media at a density of 5-10x106 cells/mL. Freezing media was added to cell 
suspension in a drop-wise manner carefully swirling the mixture as direct injection of 
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freezing media has potential to lyse cells due to sudden change in osmolarity. I then 
transferred this suspension into cryotubes and stored in CoolCell FTS30 cryopreservation 
boxes from Biocision and placed in a -80oC freezer. CoolCell boxes were at room 
temperature prior to freezing. This box provides a steady freezing rate of -1oC/minute, which 
is ideal for cryopreservation of most cells and contains a diffuser alloy plate at the base, 
which increases settlement of cells in an undisturbed and distributed manner. Once overall 
equilibrium in temperature is achieved (approximately 3-4 hours or over-night), I then 
transferred the vials into labelled boxes in the -80oC freezer. 
For thawing, I warmed culture media at 37 oC prior to removing vials from the -80 oC freezer. 
I then placed them in a water bath set at 37 oC until the sides of the vial contents thawed but 
the center remained frozen. I then gently added culture media into the vial in a drop-wise 
manner and then transferred the contents into a 15mL tube. I continued to add 10mL culture 
media to the tube until the contents thawed. I then centrifuged the suspension, discarded the 
supernatant and resuspended the pellet in fresh culture media. 
2.12 Cell viability assay 
To determine the number of viable cells in a culture condition, I used CellTitre-Glo® 
Luminescence Cell Assay from Promega. This assay determines the viability by means of 
ATP quantitation, which indicates the presence of metabolically active cells. The amount of 
ATP produced is directly proportional to the number of cells present and relies on 
thermostable luciferase producing a stable “glow” or luminescent signal detected by optics 
of the luminometer used (FLUOstar Omega plate reader from BMG Labtech) while 
concurrently inhibiting endogenous enzyme release during lysis. Briefly, luciferin (the 
substarate) is oxygenated in the presence of ATP and oxygen and is catalysed by luciferase 
to produce oxyluciferin and other byproducts in addition to light detected at 560nm by the 
plate reader (reaction shown below).   
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Figure 2.6 Luciferase reaction. Oxygenation of luciferin to produce light 
I plated an equal number of cells for each condition into opaque-walled, clear-bottom 
multiwell plates (0.5-5x104 cells/well depending on type of cells) in 50µL of media. Each 
condition was read in triplicate. To control for phenol red of culture media, I also plated in 
triplicate 50µL of culture media only. I used the same batch of culture media used for cell 
culture being analysed. I then placed 50µL of the substrate provided onto the cells and mixed 
gently by pipetting. I read the luminescence using the plate reader at 540nm and recorded 
the read outs. I then used the readings of the culture media alone to correct for interference 
of phenol red. 
2.13 Trypan Blue exclusion 
As a secondary measure, I used trypan blue exclusion to determine the cell viability 
accurately. Trypan blue is a diazo dye (from ThermoFisher #15250061) that is commonly 
used to stain cells for quantification. Viable, live cells with cell membranes intact are not 
permeable to trypan blue and therefore do not absorb the colour. However, this is not the 
case for dead cells as the dye can navigate across their membrane. Following through 
mixing, I combined 10µL of the cell suspension with 10µL of trypan blue and loaded 10µL 
of the mixture onto a haemacytometer. I quantified viable cells on the haemacytometer by 
counting cells that were not stained by the dye. I calculated total number of viable cells using 
the formula: 
Number of  viable cells = average of viable cells x 2 x 104 
2 is regarded as the dilution factor 
104 is the haemacytometer factor  
The total number of viable cell x 104 /mL. 
Luciferin
Mg2+
CellTire-Glo Recombinant
Luciferase
Oxyluciferin
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2.14 Cytokine arrays 
2.14.1 Cytokine immunoassay 
For assessment of cytokines released from different culture conditions, I used the Proteome 
Profiler™ Human XL Cytokine Array Kit from R&D Systems. The profiler is a membrane-
based antibody array and can detect 102 human cytokines simultaneously. The principle of 
the array works on the same principle as a sandwich immunoassay. Membranes are pre-
bound with capture antibodies that bind to specific proteins present in the sample. I used 
biotinylated detection antibodies to detect the capture antibodies with bound targets and 
visalised them using chemiluminescent reagents that produce light signals based on the 
amount of analytes present.  
 
Figure 2.7. Schematic of cytokine array 
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I first blocked the membranes in blocking solution (containing a buffered solution of proteins 
base with preservatives) provided in the kit for 1 hour at room temperature. I then collected 
500µL of the sample and topped it up to 1.5mL using the blocking buffer and replaced the 
blocking buffer in the wells with the sample media. I incubated the membranes in this 
conditioned media on a rocker at 4oC overnight. I then washed the membranes in wash buffer 
provided (containing PBS and surfactant), before incubation in the detection antibody 
cocktail (contains a cocktail of biotinylated antibody) for 1 hour at room temperature. 
Following another wash, I then incubated the membranes in streptavidin conjugated to 
horseradish-peroxidase for 30 minutes at room temperature. I then washed the membranes 
again and blotted out excess wash buffer before placing the membranes on a plastic film. I 
then placed 1mL of hydrogen peroxidase and luminol mixture at a 1:1 dilution directly onto 
the membranes and sandwiched the membranes in a plastic film. I blotted out excess mixture 
before detecting chemiluminescence using the Chemdoc UVP.  
2.14.2 Analysis of arrays 
Data were generated for 102 cytokines for conditioned media samples using the Proteome 
ProfilerTM Array with the Human XL Cytokine Array Kit. As part of this, the intensities of 
the negative control of each sample were subtracted from the intensity of each cytokine-
sample pair [204].  
I next removed variation originating from systematic, technical biases rather than from 
biological differences between cytokines or samples, by quantile-normalising the relative 
intensity values[205]. With this technique, the cytokine intensities for each sample are 
ranked, and the cytokine intensities are substituted for the average of each rank across 
samples. The average values are then re-ordered in the original order, which means that the 
distributions of cytokine intensities are normalised across samples. This removed the 
unwanted variation is that is attributable to the technology used rather than the biological 
variation that I wished to capture. Next, I applied a logarithmic transformation to the base 2 
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to the data to allow for direct comparisons to be made between cytokines across samples by 
homogenising their variances.  
2.15 Genetic manipulations 
2.15.1 Lentiviral production 
Lentiviral vectors are major tools for basic and translational research enabling the stable 
overexpression or silencing of genes, immunisation against diseases and generation of 
transgenic organisms. Lentiviruses are a member of the retroviridae family of viruses which 
contain a positive, single-stranded RNA that is reverse transcribed into DNA and integrated 
into the host cell genome. The genome contains three main genes; gag, pol and env. The gag 
gene encodes protective core and matrix proteins for assembly and infection while the pol 
gene encodes for enzymes that are crucial for reverse transcription and genome integration; 
such as reverse transcriptase, RNase and integrase. The env gene encodes surface proteins 
that determines tropism and enables entry into the cell. Other important regulatory viral 
genes are the tat and rev as well as other accessory genes; vif, vpr, vpu and nef. Lentivirus 
can infect both dividing and non-dividing cells and have broad tropism, making them 
effective for delivering CRISPR sgRNA constructs for genome editing of a variety of cell 
types. They are also advantageous as they do not generate immunogenic proteins and can 
deliver fragments as long as 9kb. 
2.15.1.2 Cloning vector 
MISSION pLKO.1-pTRC cloning vector is the TRC (The RNAi Consortium) backbone for 
all vectors used in this research. pLKO.1 is a replication-incompetent lentiviral (HIV based) 
vector that expresses the short-hairpin RNA (shRNA) pLKO.1 and is introduced into cells 
by transfection and can be used to package lentiviral particles for infections. This vector also 
contains a puromycin-resistance marker that enables stable transfection[206]. All vectors 
containing genes of interest for silencing were cloned into pLKO.1 shRNA vectors and were 
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obtained from MISSION shRNA, Sigma. Target shRNA sequences were cloned into Agel 
and EcoRI sites (done by Sigma). pKLO.1 contains an ampicillin resistance gene for bias 
growth and selection in ampicillin rich cultures. Individual sequences for each shRNA is in 
the Appendix. 
pLKO.1 TRC-cloning vector (SH001, Sigma) was used as shRNA control. This vector was 
used as negative control containing non-hairpin insert that does not activate the RNA-
induced silencing complex (RISC). 
For Luciferase construct, pCDH-Luciferase-T2A-mCherry vector was sent as a kind gift 
from Irmela Jeremias and was cultured like other all other vectors. 
2.15.1.3 Bacterial culturing of plasmids 
Plasmids of interest were transformed into E.coli strain DH5αT1R and were received in 
glycerol stocks. I cultured these on Agar plates. Agar plates were made by mixing Lysogeny 
Broth (LB) (containing 10g/L Tryptone, 10g/L NaCl and 5g/L) yeast with 10g/L of agar for 
bacterial cultures (Sigma). Agar was sterilized and brought to 50oC before adding ampicillin 
at 100µg/mL and then dispensed into 10cm dishes and stored at 4oC for up to a month.  I 
streaked glycerol stocks onto agar plates and incubated them at 37oC for 16 hours. 
Next, I selected individual, isolated colonies of bacteria for culturing in 5 mL of LB broth 
per colony. Individual, isolated colonies were selected to ensure homogeneity of colony and 
avoiding picking colonies that grow in antibiotic deleted regions. I picked at least 5 colonies 
per plasmid to ensure high DNA yield. 
2.15.1.4 Plasmid isolation and DNA precipitation for concentration  
The isolation of DNA plasmids from the bacterial colony culture was carried out using 
Mycheryl Nygerl DNA plasmid purification kit according to the manufacturer’s protocol. I 
pelleted the bacterial culture and resuspended the pellet in a resuspension buffer provided 
(A1 buffer) followed by the addition of a lysis solution were plasmid DNA is released from 
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the E.coli host cells by SDS/alkaline lysis (A2).  I then neutralised the suspension using A3 
buffer and the resulting lysate creates an appropriate condition for binding of plasmid DNA 
to the silica membrane of the NucleoSpin® Plasmid kit. Precipitated proteins, genomic DNA 
and cell debris are pelleted by the centrifugation step prior to loading supernatant into the 
NucleoSpin® Plasmid column. The column is washed several times using the wash buffers 
provided and the DNA is then eluted using TE buffer of ddH2O. The optimal concentration 
of plasmid DNA required for transfection of packaging cells is <180ng/µL. If this was not 
achieved, I combined DNA of high purity for several colonies and carried out DNA 
precipitation and pooling.  
I used ethanol for the DNA precipitation as ethanol precipitation is a commonly used 
technique for concentrating and de-salting nucleic acids (DNA or RNA) preparations in 
aqueous solution. The basic procedure is that salt, in this case 3M solution of sodium acetate 
with pH 5.2, and ethanol are added to the aqueous solution which forces the precipitation of 
nucleic acids out of solution. The salt used makes up 1/10th of the volume of DNA solution 
and the ethanol makes up more than 1.5 times the volume. Glycogen can be added to this 
solution as it binds to the DNA making it visible, translucent and whitish. The mixture is 
then stored over-night in -20°C. After precipitation, I separated the nucleic acid from the rest 
of the solution by centrifugation. I washed the pellet in cold 70% ethanol then, after a 
centrifugation step, I once again, removed the ethanol and allowed the nucleic acid pellet to 
dry before being resuspended in clear aqueous buffer. 
2.15.1.5 Culturing of packaging cells 
The 293T cell line is a highly transfectable derivative of human embryonic kidney (HEK) 
293 cells and contains the SV40 T-antigen. Although a derivative of an embryonic cell, it 
exhibits an epithelial morphology and is adherent (Figure 2.7). This cell line is widely used 
for retro and lentiviral production, gene expression and protein production. For transfection 
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purposes, it was essential that the cells be well-maintained and of relatively low passage 
number and not let to become over confluent. 
 I restarted the packing cells purchased for ATCCC and stored in -80°C by defrosting them 
and culturing then in 20% DMEM supplemented with 0.01% L-Glutamine for 24 hours and 
subsequently 10% supplemented with 0.01% L-Glutamine for another 24 hours in a T75 
flask. It was essential to not use Pen/Strep during any step of the lentiviral production and 
infection process. I then split the cells into X5 10cm TC grade plates (Corning USA) at a 1:5 
split ratio. I monitored the cells and split them at 90% at a 1:4 ratio until P3. At P3 they were 
ready for transfection and cells were split one more time 24 hours before transfection with 
plasmids of interest.  
 
Figure 2.8 Morphology of 293T packaging cells at 24, 48 and 72 hours 
 
2.15.1.6 Transfection of packaging cells 
Lentiviral components are split across multiple plasmids to increase safety of lentivirus 
production. The components are as follows: 
Lentiviral transfer plasmid: this encodes your insert of interest. This sequence is flanked by 
long terminal repeats (LTRs) to facilitate host genome integration. To improve safety, 
transfer vectors are all replication-incompetent and may additionally contain a deletion in 
the 3’LTR, rendering the virus “self-inactivating” (SIN) after integration. 
Packaging plasmid: provides all of the proteins essential for transcription and packaging of 
an RNA copy of the expression construct into recombinant pseudoviral particles. In my 
24hrs 48hrs 72hrs
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transfection system, I use pCMV∆8.91 (containing gag, pol and rev genes) as the packaging 
plasmid. 
Envelope plasmid: To allow lentiviral host cell tropism. This is determined by the ability of 
the viral envelope protein to interact with the receptors at the host cell surface. The VSV-G 
envelope protein is commonly used in lentiviral particle production because it confers broad 
tropism over a range of species and cell types. The system I used utilises VSV-G (pMDG 
G.2) as the envelope plasmid. 
Figure 6 outlines the procedural workflow of the lentiviral production. First, leave 
concentrated plasmids in the fridge or on ice in the cold room to defrost. Before the 
transfection procedure, I replace the packaging cells media with 7.5-8 mL of fresh media. I 
then made up a DNA mix at 1:1:1.5µg concertation of packaging plasmids and DNA, 
respectively: 
1ug pCMV∆8.91 (gag-pol expresser) 
1ug pMDG (VSV-G expresser) 
1.5 plasmid 
 
 
 
 
  
Figure 2.9. Viral production schematic 
The total volume of the DNA mix was made up to 15µL using TE buffer at pH 8-8.5. I then 
incubated this mixture for 15 minutes at room temperature with Fugene-6 in Optimem. 
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Fugene-6 is a transfection reagent that utilises polarity to transport small DNA particles into 
the cell. I then carefully dropped the final mixture onto the packaging cells. I incubated the 
packaging cells with for 24 hours before changing the media to a fresh 7.5-8 mL 
replenishment. I collected and replaced the media at 48, 72 and 96 hours, each time replacing 
the media with a fresh amount. At 96 hours, I discarded the plate. The media collected from 
the plates were frozen in -80oC and a small aliquot of 70 µLs from each time point was also 
stored and used for titration. 
2.15.1.7 Lentiviral titration 
The first step of determining my lentiviral stock was to isolate the viral RNA. I deforested 
the 70 µLs for each time point and using the NucleoSpin® RNA Virus kit, I lysed the viral 
RNA quickly and efficiently using the lysis buffer RAV1 which is a highly-concentrated 
solution of guanidine isothiocyanate (GITC). Lysis buffer and ethanol create appropriate 
conditions for binding of nucleic acids to the silica membrane of the NucleoSpin® RNA 
Virus Columns. Carrier RNA improves binding and recovery of low-concentrated viral 
RNA. Contaminations (potential PCR inhibitors) like salts, metabolites and soluble 
macromolecular cellular components were removed in simple washing steps with ethanolic 
buffers RAW (containing guanidine hydrochloride) and RAV3. I then eluted the nucleic 
acids in low salt buffer or water and ready for use in the next steps. 
The most critical factor for successful lentiviral transduction is viral titre. It is important to 
have an estimation of the concentration of infection forming units (IFU) in the supernatant, 
as this measurement will determine how much supernatant needs to be used to achieve a 
desired multiplicity of infection (MOI), the number of virions per cell in transduction. First, 
I treated the viral RNA with DNase1to remove unwanted DNA. I used the following 
concentrations of buffer, enzyme and RNA: 
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a. DNase 1 buffer (X10) –  2.5µL 
b. DNase(5U/ul) –               4µL 
c. RNase free H2O –            6µL 
--------------------------------------------------------------------------------------------------------                                        
                                        + Viral RNA sample –        12.5µL 
Total volume of 25µL per reaction. 
Heat treatment program for DNase 1 treatment was 30oC for 30 minutes and then 70oC for 
5 minutes with a 4oC hold.  
For qRT-PCR determination of lentiviral titre, I used Lenti-X™ Titration Kit from Clontech, 
Takara, employing SYBR technology to determine viral RNA genome content. I serially 
diluted the samples in Easy Dilution Buffer provided in the kit and subjected to qRT-PCR 
to determine Ct value for each dilution. The total viral RNA genome copy is then calculated 
by finding the copy number that corresponds to a Ct value of the standard curve I generated 
from a serial dilution of the Lenti- X RNA control template provided with the kit. 
I prepared the master reaction mix as follows: 
Table 2. Master Reaction Mix for Lentiviral titration 
Reagent µl per RXN 
RNAse-free water 6.0 
Quant-X Buffer  10.0 
Lenti-X forward primer (10uM) 0.4 
Lenti-X reverse primer (10uM) 0.4 
ROX Reference Dye (LMP)* 0.4 
Quant-X enzyme 0.4 
RT Enzyme mix 0.4 
TOTAL 18 
*Dye is specific to the qPCR machine used. LMP is compatible with Roche LightCycler. 
LMP is for instruments whose excitation source is either a lamp or an LED. 
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| 
I prepared serial dilutions of standards and samples as follows: 
Table 3. Control and sample dilutions from qRT-PCR for lentiviral titration 
  Control Samples 
PCR 
tube 
EASY 
dilution 
buffer, ul 
Lenti-X 
control 
template, 
ul 
Copies ul-1 EASY 
dilution 
buffer, ul 
Viral 
RNA, ul 
Dilution 
1 18 2 5 x 107 - 20 1x 
2 27 3 5 x 106 27 3 0.1x 
3 27 3 5 x 105 27 3 0.01x 
4 27 3 5 x 104 
5 27 3 5 x 103 
6 10 - NEG 
CONTROL 
7 10 - NEG 
CONTROL 
8 10 - NEG 
CONTROL 
 
In a 96 well PCR plate, I dispensed 18µL of the master reaction mix and 2µL of the RNA 
dilution. I then sealed the plate, vortexed gently and spun down. Next, I ran the PCR using 
the following program: 
Pre-incubation: 
42C for 5 mins 
95C for 10secs 
Amplification: 
95C for 5 secs 
60C for 30 secs 
 
For 40 cycles 
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Melting Curve: 
95C – 15sec 
60C – 30 sec 
2.15.1.7 Analysis of Lentiviral titre 
The initial known concentration of control template is set to 5x107 and the dilution factor is 
10. I determined the Ct value for each dilution of control and sample based on the values 
described for Absolute quantification analysis. I used average Ct values for each sample 
dilution and calculated the corresponding Ct value for the standard and back-calculated the 
starting copy number value for the original sample using the calculations below: 
Copy number calculation 
150µL of initial sample was used to purify viral RNA and eluted in 50µL. Undiluted samples 
correspond to 1x107 copies. 
∴ Copies/mL =  
(𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑓𝑟𝑜𝑚 𝑃𝐶𝑅 (𝑥107)(
1000𝜇𝐿
𝑚𝐿 )(2𝑥𝐷𝑁𝑎𝑠𝑒)(50𝜇𝐿 𝑒𝑙𝑢𝑡𝑖𝑜𝑛)
(150𝜇𝐿 𝑠𝑎𝑚𝑝𝑙𝑒)(2𝜇𝐿 𝑎𝑑𝑑𝑒𝑑 𝑡𝑜 𝑤𝑒𝑙𝑙)
 
Using the determined values for copies/mL, I calculated the number of viral particles needed, 
in volume, for multiplicities of infections ranging from 1-30 by first dividing the total 
number of cells to be infected by the concentration and subsequently multiplying by the 
desired MOI.  
2.15.1.7 Lentiviral infection of target cells 
Viral stocks were stored in -80oC. Following thawing at 4 oC on ice, I seeded cells at 
1x105/mL and added polybrene at 1µg/mL (final concentration) to cell suspension (500µL 
of culture media with 10% FBS and no antibiotics as this drastically reduces efficiency of 
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infection). I then added the required volume of virus for desired MOI and gently swirled the 
plate to ensure even distribution. After 24 hours, I topped up each well with an additional 
500µL of culture media without antibiotics and cultured for an additional 72 hours. If cells 
needed pooling, this was done at the 48 hours’ time point and culture volume was doubled. 
Knock-down efficiency was detected by PCR at the mRNA level at 72 hours and western 
blotting after 72 hours. 
2.15.2 Retroviral production (performed by Sebastian Mohr and Thomas Oellerich) 
For the syngeneic in vivo model, bone marrow was harvested from C57BL/6J and lineage 
depleted using lineage-negative depletion kit from Miltenyi Biotec. 3x105 of these lineage-
depleted cells were co-cultured with ectopic packaging cells GP+E86 containing the MSCV-
Hoxa9-PGK-neo vector. This co-culture was done for three days. Next, these cells were then 
co-cultured with GP+E86 containing MSCV-Meis1-IRES-YFP vector for 24 hours. Both 
incubations were carried out in 6-well culture plates with 2mL culture media supplemented 
with 15% FBS and no antibiotics. Hoxa9 cells were then selected using G418 from Sigma. 
G418 is an aminoglycoside antibiotic and culturing cells with the neomycin resistance gene, 
confers resistance to G418. Therefore, only cells expressing Hoxa9-PGK-neo when cultured 
with G418 will survive and can therefore be selected. Following selection of Hoxa9 cells, 
cells were once again sorted using the BD FACSARIA III cell sorter on YFP for Mei1-IRES-
YFP. Yellow fluorescence protein present in the Meis1 vector can be selected from 
previously selected Hoxa9 cells. Therefore, both Hoxa9 and Meis1 genes were achieved in 
these lineage-depleted C57BL/6J bone marrow cells that were used as syngeneic AML cells. 
For further lentiviral transduction, I used the same methodology described above to induce 
knock-downs in Hoxa9/Meis1 cells. To maintain these cells in culture, I used a cocktail of 
the cytokines murine SCF at 100ng/mL, murine IL-6 at 10ng/mL and murine IL-3 at 
10ng/mL in culture media. 
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2.16 Fatty acid oxidation 
β-oxidation of fatty acids was assessed using the Seahorse XFp Analyzer (Seahorse 
Bioscience) according to manufacturer’s specifications. I cultured AML blasts with or 
without adipocytes in substrate limited media (supplemented with 0.5mM glucose, 0.5mM 
carnitine, 1mM glutamine and 1% FBS) for 24 hours before assaying. I then plated AML 
blasts in poly-D-lysine (Sigma) coated assay wells at a density of 2x105 per well in base 
media containing 2.5mM glucose, 0.5mM carnitine and 5mM HEPES and adjusted to pH7.4 
with 1N NaOH. Etomoxir (ETX) (40µM) or BSA and Palmitate:BSA were added into the 
injection ports. I designed the experimental template using Wave software for desktop from 
Seahorse Bioscience 
2.17 Human Colony Forming Cells (CFC) Assay using Methylcellulose-based media 
This in vitro assay was used to study the progenitor capacity of haematopoietic cells from 
different culture conditions. The potential for haematopoietic cells is assessed based on their 
ability to proliferate and differentiate into colonies in a semi-solid media in response to 
stimuli imparted by cytokines and is counted and characterised according to their unique 
morphology. 
Cells from different culture conditions were suspended at a density of 4x104 cells in 300µL 
of Iscove’s Modified Dulbecco’s Medium (IMDM). I then added this suspension to 4mL of 
human methylcellulose media enriched with the human cytokines SCF (50ng/mL), GM-CSF 
(10ng/mL), IL-3 (10ng/mL) and Epo (3 IU/mL) and supplemented with 25% FBS, 2% BSA, 
2mM L-Glutamine and 2-Mercaptoethanol (5x10-5M). Next, I vortexed the methylcellulose 
cell suspension briefly, followed by short centrifugation to ensure removal of trapped 
bubbles and settlement of media and to avoid pelleting of cells.  Using a 3mL syringe with 
a 16-gauge needle, I dispensed 1.1mL of methylcellulose cell suspension into 35mm culture 
dishes in triplicate. Excess 4mL of cell suspension is imperative to account for loss of cell 
suspension in the syringe dead volume due to adherent and viscous nature of 
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methylcellulose. I spread the suspension evenly by gentle rotation of the dish and placed 2 
x 35mm dishes in a 10cm dish with an additional 35mm dish containing 4mL of sterile water 
to maintain humidity. I then incubated the dishes at 37oC and 5% CO2 for 14-16 days without 
disturbance.  
I prepared a scoring grid using the 100mm scoring grid provided on the R&D website 
(https://resources.rndsystems.com/images/site/figure4CFC6184.gif) and enumerated the 
number of unique colonies observed.  
2.18 In vivo models 
2.18.1 Ethical Issues  
All animal work was carried out in accordance with regulations set by the UK Home Office 
and the Animal Scientific Procedures Act 1986. Animals were housed in the Disease 
Modelling Unit (DMU) facility at the University at East Anglia. 
2.18.2 Mouse models 
Xenograft and syngeneic models of disease are important in understanding the underlying 
mechanisms in tumour biology. Syngeneic models are developed by injecting genetically 
compatible donor to recipient whereas xenograft  models are developed by injecting human 
cells into immunocompromised mice [207]. I used both syngeneic and xenograft models to 
study the effect of target genes in syngeneic and xenograft models of AML. 
2.18.2.1 Non-obese diabetic (NOD) severe combined immunodeficiency (scid) gamma 
model (NSG) for patient derived xenograft models 
This NSG model is a strain of non-obese diabetic (NOD) mice, also known as NOD-scid 
IL2Rgnull and NOD.Cg-PrkdcscidIl2rgtm1WjlISzJ and are the most commonly used severely 
immunodeficient mouse strain developed by Dr. Leonard Shultz at The Jackson Laboratory. 
The NSG strain is a derivative of the NOD/ShiLtJ strain, characterised by insulits, and is a 
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contributor of its reduced innate immunity, lack of haemolytic complement system and 
macrophage activity in addition to the expression of Sirpa allele, which presents support for 
human haematopoiesis and engraftment[208, 209]. The Prkdcscid mutation is the contributor 
of the severe combined immunodeficiency trait of this model. Prkdcscid mutation eradicates 
adaptive immunity as this is a loss-of-function mutation in the murine homologue of the 
human PRKDC gene encoding protein DNA-dependent protein kinase (DNA-PK) whose 
function includes DNA double strand break repairs and recombination during T and B cell 
development[210]. Therefore, a loss of PRKDC function severely impairs numbers of T and 
B cells and subsequently impacts adaptive immunity[209, 211]. The complete ablation of 
the IL2 receptor gamma (IL2Rγ) is an identifiable feature of this model. Among the many 
signaling pathways involving IL2Rγ, the differentiation of NK cells is, in this context, a 
primary hindrance in the engraftment of primary human cells. Therefore, the absence of 
IL2Rγ is critical for efficient engraftment[212].  
2.18.2.2 C57BL/6J Syngeneic AML model (performed by Sebastian Mohr and Thomas 
Oellerich) 
This in vivo model acquisition and experimentation was carried out in collaboration with 
Goethe University, Frankfurt, Germany and the University of Cambridge, UK. Syngeneic 
models, in some cases, may be more effective in portraying roles of the immune system in 
the progression of cancer and therefore are not presented with limitations of an absent 
functional immune system. This model allowed for introduction of allograft tumours and 
investigation of tumour conditions effected by the immune system.  
C57BL/6J mice are the most commonly used models for syngeneic studies of the biology of 
tumours. This model was first described by Janvier Labs, Le Genest-Saint-Isle, France. To 
generate a syngeneic AML model, lineage-negative cells are removed from the bone marrow 
of C57BL/6 mice and transduced with Meis1 and Hoxa9 oncogenes; 10-week-old C57BL/6J 
mice were sacrificed to extract bone marrow cells. These cells were then lineage depleted 
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using mouse lineage depletion kit from Miltenyi Biotec. Lineage depletion is necessary to 
acquire immature haematopoietic cells from mature haematopoietic cells of committed 
lineages. These lineage negative cells were then retrovirally co-infected (described in 
retrovirus generation and infection) with MSCV-Hoxa9-PGK-neo and Meis1-IRES-YFP. 
Cells were sorted using fluorescence-activated BD FACSARIA III cell sorter on YFP 
channel. Following oncogenic expression, additional genetic manipulation was carried out 
by lentiviral infections and cells were then transplanted via tail vain injection into lethally 
irradiated recipient C57BL/6J mice[213]. Thus, a syngeneic model expressing Meis1/Hoxa9 
oncogenes was generated. 
2.18.3 Transplantation and euthanasian 
For both models, introduction of tumour cells was carried out through injections in the lateral 
tail vein which runs the length of both lateral sides of the tail. For NSG model, experiments 
were carried out on animals at 6-8 weeks of age whereas, for C57BL/6J syngeneic AML 
models, mice were 10 weeks of age. Before and in between injections, all equipment was 
sterilised. Prior to injections, animals were warmed in individual warming boxes set at 37oC 
for 10 minutes. This was done to dilate veins for easy and visible introduction of 
hyperdermic needles. Sterile 27-gauge needle with 1ml syringe was used to inject 200µL of 
cell suspension in to the tail vein of each mouse. For NSG models, 2.5x105 AML blasts were 
injected per animal and for the syngeneic model 8x104 murine AML cells in addition to 
2x105 support cells were injected. Animals were closely monitored immediately following 
injections for signs of bleeding from injection site. Animals were then monitored daily and 
sacrificed upon first sign of tumour (weight loss, reduced motility, bilateral hind leg 
paraplegia due to tumour burden, over grooming and rough, patchy fur). Mice were 
euthanised using gradual CO2 asphyxiation followed by cervical dislocation. In the NSG 
experiment spleen and bone marrow were removed and analysed for AML engraftment.  
93 
  
2.18.4 Imaging of in vivo models – Bioluminescent Imaging (performed by Dr. Stuart 
Rushworth and Amina Abdul-Aziz) 
For experiments involving transplantation of cells infected with luciferase construct, animals 
were imaged using the Bruker In-Vivo Xtreme Imaging Systems from Bruker Corporation, 
MA. The application of luciferase gene incorporation into AML xenografts prior to 
implantation gives a quantitative visualization of tumour engraftment at a molecular level 
within the animal. Much like the Cell Titre-Glo assay, this is an enzyme-catalysed reaction 
where D-Luciferin is required as a substrate for the luciferase light reaction. This technique 
does not require incident light and therefore avoids phototoxicity. D-luciferin was purchased 
from Sigma and reconstituted in PBS at a concentration of 15mg/mL. Prior to imaging, 
animals were weighed and intraperitoneally (IP) injected with 200µL of D-luciferin. After a 
10-minute wait, animals were anaesthatised with 2-3% isoflurane/oxygen in an induction 
chamber. When under, animals where fitted into the nose cone of the Bruker and a steady 
stream of anaesthetic was supplied to maintain anaesthesia. After 20 minutes of the IP, 
animals were imaged using incident light, X-ray and luminescence. After imaging, animals 
were closely monitored until recovery from anaesthesia. Images were quantified using 
Bruker MI SE software. 
2.19 Flow cytometry 
For analysis of surface proteins using flow cytometry, a minimum of 1x105 cells were 
washed in filter-sterilised PBS with 0.05% BSA and 2mM EDTA and then suspended in 
90µL of the same buffer with 10µL FCR blocking reagent and 1:200 dilution of primary 
antibody conjugated to fluorescent chromophore and incubated at 4-8oC for 30 minutes in 
the dark. For co-staining experiments, chromophores were selected based on spectral 
emissions ensuring both chromophore are on the opposite end of the spectrum to avoid 
bleed-though or over lapping of respective spectra; for example, FITC emission spectrum 
peak wavelength is approximately 465nm/519nm while Allophycocyanin (APC) emission 
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spectrum wavelength is 657.5nm. I used Isotype controls of chromophores as negative 
controls to measure the level of non-specific background signals caused by primary 
antibody. These controls lack specificity but match the type of antibody used. Following 
incubation, I then washed cells with 1mL filter-sterilised PBS and ran through the flow. For 
this research, I used 2 flow cytometry systems and analysing softwares; BD Accuri C6 with 
C6 analysis software and Cube 6 from Sysmex-Partex with FCS Express 6 flow software. 
2.20 Enzyme-Linked Immunosorbant Assay (ELISA) 
Following cytokine arrays or western blotting, I carried out ELISAs to quantify specific 
secreted proteins such as cytokines. A sandwich ELISA is an efficient modified method 
which works by first attaching an antigen-specific antibody onto the plate surface. 
Antibodies bind with high affinity to antigens present in the sample. First, the plate surface 
is coated with the capture antibody of known concentration and then incubated with the 
sample to allow antigens present in the sample to bind to the antibody. Unbound antigens 
and non-specific proteins are then washed away before a HRP-conjugated detection antibody 
is added to sandwich the antigen. A substrate is then added which binds to the detection 
antibody and enzymatically reacts to produce a colour. This colour is then detected using a 
microplate reader. 
For detection of FABP4 from intact primary human marrow fat, I used R&D Systems 
Qunatikine® ELISA for Human FABP4. For detection of IL-6 from culture conditions, I 
used Human IL-6 ELISA Ready-Set-Go! From eBioscience. 
For Human FABP4, microplates coated with monoclonal antibody specific for human 
FABP4 were provided in the kit. Following isolation of intact primary marrow fat, I cultured 
it with 1mL of culture media and subsequently used this media for the cytokine analysis. I 
diluted the culture media in calibrator diluent provided with the kit at a 20-fold dilution. I 
placed 100µL of assay diluent in each well followed by 50µL of the diluted sample. I 
incubated the plate at room temperature for 2 hours. I then aspirated contents of the wells 
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and washed the wells with 400µL of the wash buffer provided 3 times. I then added the 
detection antibody conjugated to HRP for another 2 hours at room temperature. I then added 
200µL of substrate solution that contains hydrogen peroxide and a chromogen 
(tetramethylbenzine) and incubated at room temperature for 30 minutes. Finally, I added 
50µL of stop solution containing sulfuric acid at 2N and immediately read the wells using a 
microplate reader FLUQstar Omega at 450nm with a correction set at 540nm or 570nm. 
For IL-6 ELISA-Read-Set-Go!, I pre-coated a microwell plate with 100µL of capture 
antibody and incubated it over-night at 4oC. I then washed the wells with wash buffer 
provided (PBS containing 0.05% surfactant TWEEN20) and blocked the wells with 
ELISPOT provided in the kit for 2 hours at room temperature. After aspirating the blocking 
buffer, I washed the wells three times and incubated the samples in the wells overnight at 
4oC. Following incubation, I washed the wells and incubated with 100µL of streptavidin 
conjugated to HRP and incubated for 30 minutes in the dark. Next, I added the substrate to 
activate the HRP conjugate and placed stop solution containing sulfuric acid after 15 
minutes. I read the plates immediately after at 450nm corrected at 570nm using the 
FLUOstar Omega plate reader. 
For both kits, I prepared serial dilutions of standards for FABP4 and IL-6 prior to use of any 
samples. I produced the standard curve from the reading and used y=mx+b to calculate the 
concentrations of the proteins.  
2.21 Magnet-assisted cell separation (MACS) 
I used magnetic separation to isolate cell populations using the MACS microbeads from 
Milteny Biotec. The principle of this technology is based on magnetic labelling of cells with 
microbeads conjugated to antibodies that are then separated from the rest of the population 
using a magnetic field. A total number 2x108 cells were used per separation. Following 
isolation of viable cells from bone marrow or blood sample, I counted the cells, washed in 
PBS and suspended in 300µL of MACS buffer (PBS + 0.5% BSA + 2mM EDTA). I then 
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added 100µL of FcR blocking reagent and 100µL of microbeads. I then incubated the 
suspension at 4oC for 30 minutes. I then washed the suspension with 5-10 mL of the buffer 
and finally suspended the cells in 500 µL of the same. I used the MACS MS column attached 
to a magnet to create a magnetic field across the filter of the column. After wetting the 
column with MACS buffer, I then added the cell suspension into the column and let the cells 
filter out. Once the suspension flowed through the column, I washed the column two 
additional times before releasing the column from the magnet and using the plunger, flushed 
out the cells bound to the filter and analysed purity using flow cytometer. 
2.22 Chemotaxis assay 
For chemotaxis assays, I used The ChemotTx® Disposable Chemotaxis System from 
Neuroprobe. I used two pore sizes for AMLs and T-cell migration analysis (8µm and 5µm 
respectively). I suspended 5x104 /mL and used 25µL of this cell suspension to load the top 
chamber with the porous membrane for chemotaxis analysis. For analysis of chemotaxant, I 
loaded 30µL of the chemotaxant in the bottom well and carefully loaded the top well with 
membrane onto the bottom well. I incubated the set up for 4 hours at 37oC and 5% CO2 
before separating bottom well to analyse using microplate reader. 
For T-cell analysis, I pre-stained cells with calcein and used fluorescence setting on the plate 
reader to analyse T-cell migration to the bottom well. 
2.23 Statistical analysis 
2.23.1 RNA sequencing data  
I obtained publicly available mRNA sequencing data for a panel of 43 AML patients, which 
comprised 22 AML samples obtained from peripheral blood and 21 AML samples obtained 
from bone marrow aspirate (Gene Expression Omnibus Accession ID: GSE49642) and 
nonmalignant CD34+ cells (Gene Expression Omnibus Accession ID: GSE48846)[213]. 
Data were available as Reads Per Kilobase per Million mapped reads (RPKM). 
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The same data as Chapter 7 of RPKM data for 43 AML patients, comprising 22 AML 
samples obtained from peripheral blood and 21 AML samples obtained from bone marrow 
aspirate were used (Gene Expression Omnibus Accession ID: GSE49642). The data assayed 
21,865 genes. 
2.23.2 Differential RNA expression analysis 
In order to determine which genes were preferentially expressed in the bone marrow-derived 
samples over the peripheral blood-derived samples, I used the DESeq2 method, which is 
tailored for use with RNA sequencing reads, which is count-type as opposed to continuous-
type data[214]. As input to DESeq2, I used the raw RNA sequencing read data, which uses 
the negative binomial distribution (a discrete probability) distribution to carry out an 
assessment of significance. A gene with an adjusted p-value less than 0.05 was considered 
significant. 
2.23.3 Pan-cancer RNAseq Analysis for CD36 
I downloaded all TCGA RNASeqV2 level 3 expression data from the TCGA data portal 
(https://tcga-data.nci.nih.gov), which had been processed as described by Li & Dewey, 
2011[215]. As a result, I collated data for 8,269 primary samples representing 26 tumour 
types, 391 metastatic samples representing 10 tumour types, and 681 samples from adjacent 
normal tissue representing 20 tumour types. I next added one to each RNA sequencing data 
value (to prevent log2 transforming zero values), and log2-transformed the data to make 
them more comparable across samples.  
Unless otherwise stated, results represent a mean ± SD of at least 3 independent experiments. 
The Mann-Whitney test was used to compare test groups where stated.  Results where P < 
0.05 were considered statistically significant.  
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CHAPTER 3 – BM adipocytes support the survival and proliferation of primary 
AML. 
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3.1 Isolation of viable components of primary AML bone marrow 
In 2000, Hanahan and Weinberg defined the traits or hallmarks that control the 
transformation of a normal cell to a malignant one. One of the main identifying feature of a 
malignant cell is its limitless ability to replicate. These malignant cells are also self-sufficient 
in that they produce their own growth factors that induce an autocrine signaling response to 
continually grow and divide. Cell division in these malignant cells is dysregulated due to 
possible mutations in proteins that regulate the cycle [216]. However in AML it has been 
shown that when mono-cultured in vitro, the blasts undergo spontaneous apoptosis [217, 
218]. This suggests that in the absence of their microenvironment, leukemic cells are unable 
to sustain their proliferative capacity implying that their microenvironment is critical for 
their survival.  
For the purpose of this research, AML patients admitted to the Norfolk and Norwich 
University Hospital undergoing bone marrow biopsies consented to donating approximately 
10mL of bone marrow sample for research purposes to the Department of Molecular 
Haematology at the University of East Anglia. From these bone marrow samples, I isolated 
the following: 
1. Visible surface or subsurface fat cells 
2. Mononuclear cells from the buffy coat following density gradient separation and 
3. Visible niches within and underneath the buffy coat. 
By naked eye, I identified and cultured niches isolated post-density gradient separation. A 
niche was defined by the visible presence of at least three cell types: round globules of lipids 
forming a fat cell, BMSC that adhere to tissue culture plastic upon which fat cells lie and 
surrounding blasts (Figure 3.1). I stained for lipids using a neutral lipid stain (BODIPY®) 
which emits a green fluorescence following excitation with a blue laser. I also stained the 
BMSC to confirm their presence by CD90 which is a stromal cell surface marker. Finally, I 
stained all nuclei with DAPI (4',6-diamidino-2-phenylindole). I also stained AML blasts for 
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the haematopoietic stem cell marker CD34, lipids and the nuclei (Figure 3.2).  I was able to 
observe the haematopoietic stem cell marker CD34 on the surface of the cell confirming 
their presence and the lipids which make up the phospho-lipid bilayer and within the cells 
surrounding their nuclei. As part of the study I examined the accumulation of lipids within 
the AML blasts isolated from primary samples and samples that had been cultured for 24 
and 48 hours. Freshly isolated blasts were stained with BODIPY® and analysed by 
microscopy and flowcytometry. Figure 3.3 shows fluorescent microscopic images of freshly 
isolated blasts from two primary AML samples and their subsequent loss of their of lipid 
fluorescence 24 hours later. I then measured the relative fluorescence intensity using flow 
cytometry on four primary AML samples in three independent experiments over a 48 hour 
period. Figure 3.4 shows a decrease in fluorescence over time suggesting a decrease in lipid 
content within the AML cells.  
   A        B 
 
 
 
Figure 3.1. Primary human AML bone marrow sample showing AML cells, stromal cells 
and adipocytes. (A) Microscope image of primary AML bone samples displaying primary 
AML, stromal cells and adipocytes. (B) Immunofluorescence-stained image showing 
adipocytes (in green) stained with the neutral lipid-specific BODIPY® 493/503 (4,4-
Difluoro-1,3,5,7,8-Pentamethyl-4-Bora-3a,4a-Diaza-s-Indacene) dye, BMSC stained for 
CD90 (red) and the nuclei of all cells (in blue) stained with DAPI. 
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Figure 3.2. Primary human AML harbour internal lipids which are consumed in 
monoculture. Immunofluorescence of primary AML blasts stained for CD34+ (red), neutral 
lipids (green) using BODIPY® 493/503 and nuclei in blue with DAPI. Contrast was imaged 
using differential interface contrast (DIC) microscopy. All images are representative of 6 
AML patient samples. Scale bar = 10 microns. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Primary AML lose lipids in culture. Freshly isolated AML and AML cultured 
for 1 day stained with the neutral lipid BODIPY® 493/503 dye and nuclear stain DAPI in 
blue followed by analysis by fluorescent microscopy (x40 magnification).  
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Figure 3.4. Primary AML lose lipids in culture. Freshly isolated AML, AML cultured for 1 
day and AML cultured for 2 days stained with the neutral lipid BODIPY® 493/503 dye and 
analysed by flow cytometry. Data represented as mean ± standard deviation. P<0.05 
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3.2 Verification of bone marrow derived stromal cells and derivation of adipocytes 
The adipocyte component of isolates from BM samples was isolated using centrifugation to 
separate low density adipose from total BM. Investigation into the BMSC properties, i.e. 
differentiation potential, and adipocyte properties in co-culture with AML blasts, required 
acquisition of BMSC-derived adipocytes as BM adipose tissue was difficult to isolate and 
in vitro differentiation of ex vivo BM adipocytes was more sustainable. Therefore, from each 
AML sample, mononucleated cells were isolated using a density gradient separation. All 
cells were flasked and incubated overnight at which time AML blasts were removed and 
BMSCs where cultured using the previously described method. The BMSCs were expanded 
and analysed for the cell surface markers CD90, CD73 and CD105 and for haematopoietic 
marker CD45 to ensure no white cell contamination. Figure 3.5 shows that the cells isolated 
were positive for CD90, CD73 and CD105 and negative for CD45, which indicates that these 
cells are of the BM stromal cell lineage as previously described [219]. Once expanded, I 
differentiated the BMSCs using the I3D media into adipocytes. The process of 
differentiation took between 21 – 35 days on average. Figure 3.6 shows the differentiation 
stages over a 21 day period. It is worth noting that differentiation achieved was identified 
using oil red-O staining or neutral lipid stain to examine internal lipid droplets, and 
percentage coverage of lipid droplets over a given surface was calculated using ImageJ 
software (Figure 3.7). Table 4 provides details of percentage differentiation based on 
percentage coverage of lipid droplets.  
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Figure 3.5 Cultured BMSC cells maintain their surface markers. Flow cytometric expression 
of BMSC surface markers with corresponding chromophore indicating CD73+, CD90+, 
CD105+ expression and CD45– expression. 
 
Table 4. Differentiation and characterisation of AML BMSC cells into adipocytes. Table of 
all AML BMSC used to differentiate into adipocytes and the percent of differentiation 
achieved for each sample as determined by lipid staining. 
AML Patient # % adipocyte differentiation 
AML#5 75% 
AML#9 81% 
AML#8 87% 
AML#10 89% 
AML#11 95% 
AML#12 86% 
AML#13 79% 
AML#14 88% 
AML#16 92% 
AML#17 94% 
AML#18 91% 
AML#19 87% 
AML#20 88% 
AML#23 84% 
AML#25 82% 
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Figure 3.6. Expanded and differentiated BMSC-derived adipocytes. Light microscopic 
image (x10) of BMSC-derived adipocytes on days 0, 7, 14 and 21. 
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To confirm my cultures were adipocytes I examined for the presence of adipocyte associated 
mRNA, including adiponectin, FABP4 and CCAAT/Enhanced Binding Protein Alpha 
(CEBPa). Adiponectin is abundant in adipose tissue is an important member of the adipokine 
family and has been suggested to play an important role in the modulation of lipid 
metabolism [220]. CEBPa is an important transcription factor known to be upregulated in 
differentiated adipocytes and can induce adipogenesis [72]. FABP4 is a small, conserved 
protein highly associated and implicated in fatty acid uptake, transport and metabolism [221-
223]. My results show that adiponectin, CEBPa and FABP4 were highly expressed in 
adipocyte cultures compared to BMSC (Figure 3.8).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. Brightfield and lipid labelled images of BMSC-derived adipocytes stained with 
neutral lipid BODIPY ® 493/503 (n=3). 
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Figure 3.8. Characterisation of adipocytes. Adiponectin, CEBPa and FABP4 mRNA 
expression of adipocytes compared to BMSC from the same patient sample (n=3). 
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3.3 Adipocytes maintain AML blast survival 
Haematopoietic progenitor cells rely on the bone marrow stromal cells to provide them with 
soluble factors necessary for their cellular functions [32, 224]. Leukemic cells within the 
bone marrow communicate in much the same way as their normal counterpart, using soluble 
factors such as cytokines, membrane-anchored mediators and gap-junctions. It has been 
found that in the leukemic conditions, the stromal cells provide an added advantage to the 
leukemic cell survival by maintaining them in a quiescent state thereby increasing their 
resistance to anti-proliferative drugs [225, 226]. Drawing on these finding, I sought to 
investigate the role adipocytes play on the proliferative state of the leukemic blasts. I set up 
co-culture assays of AML with BMSC and AML with adipocytes compared to AML in 
monoculture. Initial seeding density of the AML were 4x105 and were incubated with or 
without BMSC or adipocytes for six days. Figure 3.9 shows the significant increase in cell 
counts in both the BMSC and adipocyte co-cultures. Interestingly, although both co-culture 
types maintain AML numbers at a more significant rate compared to the monoculture, it is 
important to observe the adipocyte co-culture had significantly higher numbers of AMLs 
compared to the BMSCs. The BMSCs maintained numbers more close to initial seeding 
density whereas, adipocytes surpassed the initial density. This observation pointed towards 
a more proliferative cellular state in the adipocyte co-culture and a more quiescent cellular 
state in the BMSC co-culture. 
From this, I hypothesised that in addition to the favourable signaling sustained within the 
bone marrow, the AMLs would require a more viable source of energy. Leukaemia 
associated adipocytes have been shown to secret pro-inflammatory cytokines, several of 
which have also been used in culture media to sustain leukaemic cells in vitro such as IL-6, 
IL-3 and SCF, [150, 227, 228]. This established the premise for an adipocyte-AML co-
culture for the investigation of AML cellular functions enhanced by the presence of 
adipocytes 
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Figure 3.9. Co-culture with BMSC or adipocytes support survival of primary AML blasts. 
AML blasts incubated alone or with adipocytes or BMSC for 6 days and AML blasts counted 
using flow cytometry and trypan blue exclusion (n=12). The line through the data indicates 
the median. Wilcoxon signed-rank test was used to calculate significance between paired 
AMLs in mono-culture, and co-cultures. 
 
 
Next I wanted to determine if adipocytes could protect AML from undergoing spontaneous 
apoptosis. To do this, I used Annexin V in combination with propidium iodide (PI) to detect 
early and late stage apoptosis or necrotic cells.Figure 3.10 shows that culturing the AML on 
adipocytes protected the AML from undergoing apoptosis as indicated by the large 
percentage of Annexin V/PI low cells in Q3. This was repeated on 11 patient samples 
confirming the significance of the results.  
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Figure 3.10. Co-culture with adipocytes maintain primary AML blast viability compared to 
monoculture. (A) Flow cytometric staining of primary AML blasts from co-culture with 
adipocytes for 6 days followed by Annexin V and PI staining and corresponding 
monoculture (1 representative plot for gating). (B) Primary AML blasts from co-culture with 
adipocytes for 6 days followed by Annexin V and PI staining and corresponding 
monoculture (n=11). The line through the data indicates the median. Wilcoxon signed-rank 
test was used to calculate significance between paired AMLs in mono-culture, and co-
culture. 
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3.4 Adipocytes enable AML blast cell cycle progression 
Although adipocytes maintained the survival of a large percentage of the AMLs, I wanted 
to define the cell cycle profile of these cells to ascertain the percentage of cycling cells. I 
therefore carried out a cell cycle analysis on the same experimental setup. Figure 3.11 shows 
a PI cell cycle analysis of the culture conditions with a cell cycle template. PI is the most 
commonly used dye for DNA content analysis as it intercalates into major groves of ds-DNA 
which produces a florescence when excited at 488nm. The intensity of the fluorescence 
provides a profile of DNA content and therefore an indication of the cell cycles phase of the 
cells under investigation.  
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Figure 3.11. Cell cycle analysis of AML blasts at day 0, day 6 in monoculture and co-culture 
with BMSC and adipocytes at day 6 before fixation, permeabilisation and staining with PI. 
Cell cycle profile template is depicted in red. Percentage distribution among cell cycle stages 
shown with significance assessed between stages using Kruskal-Wallis test among paired 
AMLs in mono-culture and co-cultures. 
 
 
 
 
0
20
40
60
80
100
sub G1 G1 S G2/M
AML day0
AML day6
AML day6 BMSC
AML day6 adipocytes
%
 C
e
ll 
c
y
c
le
 d
is
tr
ib
u
ti
o
n
 
* 
113 
  
The cell cycle of AMLs in monoculture for six days shows an increased apoptotic profile at 
60% with 37.7% of the cells in a quiescent phase compared to freshly isolated blasts showing 
0.9% and 94% in the apoptotic and quiescent G0/G1 phase, respectively. In AML/BMSC 
six day co-cultures 37.6% of cells are apoptotic with 56.8% of the cells are quiescent and 
4.5% in the S phase. The G2/M phase, during which the mitotic proteins are produced to 
ready the cells for mitosis, represents 2.9% of cycling blasts in fresh AMLs. This percentage 
is important to note as freshly isolated cells are still actively cycling and synthesizing the 
necessary proteins in preparation for dividing. After 6 days in monoculture, these 
percentages are drastically changed as the number of apoptosing cells increases and the 
percentage of cycling cells decreased. In an AML/BMSC co-culture, the percentage of 
cycling cells reduces to almost half the percentage of the same in fresh AMLs. In an 
AML/adipocyte co-culture however, the progression into the M phase is evident as the 
percentage of cycling cells increase almost six times compared to fresh AMLs. This increase 
can be represented as an attribute of adipocyte co-culture with AML blasts. These results 
suggested that adipocyte co-culture represented a proliferative benefit for the AMLs and is 
likely the case within the bone marrow environment.   
In order to test the proliferative capacity of blasts cultured on adipocytes, I performed a BrdU 
(5-bromo-2’-deoxyuridine) proliferation assay. Blasts were incubated with BrdU stained 
with CD34 cell surface marker antibody to identify the proliferating CD34+ blasts within 
the sample subpopulation. Figure 3.12a shows an increase in CD34+ blasts population that 
are BrdU stained indicating mitotic cells in the AML/adipocyte co-culture compared to the 
monoculture of AML blasts after six days. Figure 3.12b shows in a graphical format the 
percentage of CD34+ BrdU+ cells with corresponding monoculture for n=8 primary AML 
samples. 
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Figure 3.12. Adipocytes support AML proliferation.  Primary AML blasts were cultured 
alone and with adipocytes for 6 days before staining with BrdU and CD34 (1 representative 
plot for gating). (B) BrdU and CD34+ cells (n=8). The line through the data indicates the 
median. Wilcoxon signed-rank test was used to analyse significance between paired group 
p<0.01 
 
3.5 Adipocytes maintain CD34+ expression 
Co-culture conditions can induce cellular differentiation of haematopoietic cells which could 
impact the cellular functionality attributed to adipocyte/AML co-culture [44]. Sanchez et al., 
have shown that differential therapy in AML can pose as a potential therapeutic target for 
AML treatments [229]. In my study however, I sought to ascertain if the co-culture 
conditions I set up could affect the cellular functioning thereby providing a hindering AML 
proliferation and as a translational consequence, reduced tumour burden. For this reason, I 
investigated the expression of CD15 on the CD34 blasts post six day co-culture. CD15 has 
been previously used to distinguish haematopoietic subpopulations [229, 230]. Figure 3.13a 
shows that AML blasts following six-day co-culture on adipocytes maintain their CD34+ 
expression, with almost no CD15 expression in this subset. Figure 3.13b shows no change 
in CD34+ expression and no change in CD15 induction from seeding day and day six. 
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Figure 3.13. Primary AML blasts cultured on adipocytes maintain their haematopoietic 
marker CD34 and do not differentiate. Primary AML blasts at day 0 (black) and then 
cultured with adipocytes for 6 days (red) were stained with differentiation marker CD15 
(n=6). 
The progenitor capacity of these cells post-co-culturing can provide information on the 
proliferative capacity of the AML blasts indicating their retention of blast progenitor 
capacity. Figure 3.14 shows colony formation potential of three different primary AML 
samples cultured with or without BMSCs and adipocytes. Individual colonies counted were 
represented as individual units on the graph. AMLs culture on BMSCs show increased 
colony formation compared to AMLs cultured alone. However, AMLs cultured on 
adipocytes show increased number of colony forming units signifying their proliferation 
potential and maintenance of their capacity to produce progenitor cells. 
My in vitro findings suggested that adipocytes not only enable AML survival and 
proliferation in culture but also maintained the initial blast population without inducing 
differentiation. The next aspect of adipocyte contribution to AML survival is translating 
these findings to an in vivo model. The patient derived xenograft model was injected with 
adipocyte co-cultured AMLs to investigate engraftability of in vitro adipocyte co-cultured 
AMLs (Figure 3.15 shows the in vivo experimental design).  
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Figure 3.14. Primary AML blasts maintain progenitor blasts in vitro. AML blasts from 
3 different patients were cultured alone or with adipocytes or BMSC for 6 days and then 
placed in a colony forming cell (CFC) assay for 15 days. Colonies were then counted. Data 
represented as mean ± standard deviation. Kruskal-Wallis test was used to compare between 
groups.  
 
 
Figure 3.15. Schematic representation of in vivo experimental setup design. 
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The NSG in vivo model was selected for this experimental setup in order to assess, without 
host response, the potential of engraftability and maintenance of progenitor markers 
following co-culture with adipocytes. Several in vivo studies have reported approximately 
20 weeks for engraftment of AML in animal models [231-233]. To test progenitor capacity 
of the AML blasts in vivo, I cultured AMLs on adipocytes for six days prior to intravenous 
injections into the tail vein of an NSG mouse. It is important to note here that due to the 
apoptotic nature of mono-cultured AMLs, the decreased viability was considered and 
therefore large numbers of AMLs were plated for both arms prior to injecting in vivo to 
ultimately have the same number of cells for both conditions.  Indeed, adipocyte-co-cultured 
AMLs engrafted in the NSG model and retained their cell surface markers CD33 and CD45. 
Human CD33 and CD45 were used as CD33 was recently reported as a maker for AML in 
a study conducted by Ehninger et al. and CD45 is a known leukocyte marker that has been 
established in the identification of lineage specific AML [234] [235](21). These human 
antibodies are pivotal in differentiating between mouse and human cells. Because the cells 
injected were human CD33+ and CD45+ AML, I was confident that the cells positive for 
these markers can only be the cells that were introduced in vivo and that subsequently 
proliferated, producing progeny with the same phenotypic profiles. Figure 3.16 is a 
representative plot of the engraftment achieved by CD33 and CD45 staining and was further 
analysed using the gating established. On average around 20,000 gated events from Figure 
3.16 were used for the engraftment analysis in Figure 3.17. If the number of human cells 
were found to be > 1% of the population, engraftment were considered positive. 
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Figure 3.16.  Adipocyte cultured AML cell engraftment shows progenitor capacity in 
vivo. Primary AML cells were cultured on BM adipocytes or cultured alone and then 2x106 
viable cells were injected into NSG mice. Shown in the flow figure are the characteristics of 
AML#12 engraftment into BM and spleen (1 representative plot for gating).  
 
 
 
 
 
 
 
 
Figure 3.17. Engraftment of primary AML cells following in vitro adipocyte co-culturing 
was measured using human CD33 and human CD45. Each AML engraftment into NSG mice 
is shown for bone marrow and spleen, the engraftment of the AML cultured alone is shown 
by a shaded circle. Populations of CD33 and CD45+ cells less than 1% are considered to not 
have engrafted. 
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3.6 Discussion 
In this chapter, I find that bone marrow adipocytes support the survival and proliferation of 
AML. The ability of AML blasts to proliferate in co-culture with adipocytes is interesting 
as, whilst studies have shown BMSC to support the survival of the blasts, they do not aid in 
proliferation to the extent seen here with adipocytes. BMSC are popularly known to keep 
the HSC pool quiescent. This trait has been implicated in inadvertently also supporting 
leukaemic cells [236-238]. Cell cycle profiling of AML blasts from a six-day co-culture with 
BMSC and adipocytes show more apoptosis in the BMSC compared to adipocytes (37.6% 
vs 4.7%, respectively) and a higher population of quiescent cells in the adipocyte co-culture 
which is direct contradiction with the previous statement made about the ability of BMSC 
maintaining quiescence of HSC and subsequently survival. However, this result should be 
taken in context with other phases of the cells cycle. Compared to mono-culture of AML 
blasts, the BMSC co-culture is a true supporter of blasts maintenance as indicated by their 
high levels of quiescent blasts compared to the monoculture (56.8% vs 37.7% respectively). 
Progression from quiescence into S phase and G2/M phase is predominantly higher in the 
adipocyte co-culture compared to the BMSC counterpart (17.2% and 8.4% vs 4.5% and 
1.3% respectively). This is the highlight of the cell cycle analysis as this shows that support 
provided by adipocytes is over and above what is provided by the BMSCs. This is also 
supported by the BrdU proliferation assay in figure 4.12 where I saw almost 12-fold increase 
in proliferating cells between mono-culture and co-cultured cells with adipocytes. I did not 
carry out a proliferation assay for AML blasts co-cultured with BMSC because a cell count 
and cell cycle profile sufficed to prove that blasts on adipocytes were proliferating. The 
biological question to be answered was how much support for proliferation is acquired by 
the adipocytes and therefore the comparison to be made was with AML blasts in mono-
culture. Isolated from their environment, AMLs undergo apoptosis. This is because cells 
lack the complexities of cell-cell communication present in the microenvironment that 
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contribute to the various cellular processes involved in tumourigenesis[239]. In this context, 
adipocytes seem to be a major contributor in enhancing these cellular functions and in their 
absence, apoptosis is inevitable.  
As described earlier, the definition of a stem cell arises from its ability to self-renew and its 
ability to differentiate. This property is a distinguishing feature of immature haematopoietic 
stem cells. The colony forming cell assay (CFC) is a functional assay to determine the 
progenitor capacity of a population of HSCs. In CFC, cells capability to differentiate into 
different colony types reveals their progenitor capacity. In this research, I do not discriminate 
between the types of colonies produced however most colonies produced were of the Colony 
forming unit-granulocyte (CFU-G) which is of the common myeloid progenitor lineage. This 
indicated the progenitor capacity of these cells following co-culture.  
To support the in vitro findings, I analysed cells from the same experimental set up after in 
vivo transplantation. Following engraftment of primary human AML blasts into the bone 
marrow of an NSG mouse, I analysed the surface expression of human CD33 and CD45 both 
of which are haematopoietic markers with CD33 being specific to common myeloid 
progenitors. This in vivo experiment determined three things: a) human primary AML blasts 
cultured on adipocytes could re-populate the bone marrow of an NSG mouse; b) not only 
were these cells able to re-populate the bone marrow in the xenograft model but also do it 
more aggressively than anticipated (4-6 weeks earlier than other reported studies[240]) 
compared to AMLs blasts that were cultured in isolation. This aggressive engraftment may 
be due to factors secreted by adipocytes that enrich invasion signatures in the tumours 
making them more aggressive. This effect has also been observed in prostate carcinoma and 
breast cancer[241, 242]. And finally, c) this in vivo xenograft model is a suitable method for 
investigating other primary tumour mechanisms that will be explored in the coming chapters. 
Taken together, these first set of results prove that the adipocyte compartment in the bone 
marrow provides an enhanced suits of cellular functioning in the AML blasts.  
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CHAPTER – 4 
AML induces lipolysis in adipocytes in co-culture 
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4.1 Malignant blasts induce lipolysis of adipocytes in co-culture 
In the previous chapter, adipocytes were identified to play a role in promoting the 
proliferative capacity of the AMLs.  The effect of adipocytes on the AMLs was evident in 
enhancing cellular functioning. Therefore, my next query was the effect AMLs had on the 
adipocytes. In ovarian cancer, tumour cells were shown to induce lipolysis in the omental 
adipocytes [112]. Pancreatic cancer cells have also been implicated in the stimulation of 
lipolysis of adipocytes through an exosomal mechanism [243]. I therefore investigated if 
these findings are true in the context of a haematological malignancy such as AML.  
Lipolysis is the catabolism or hydrolysis of triacylglycerol (TAG) stored as intracellular lipid 
droplets. This hydrolysis generates non-esterified free fatty acids (FFA), which are 
eventually used as energy substrates, and glycerol which are indicative of lipolysis [244]. 
For the detection of these by-products of lipolysis, I used a colorimetric assay which can be 
read at an absorbance of 540-550nm, were the increase in absorbance was directly 
proportional to the concentration of the released glycerol and FFA. Figure 4.1 shows 
increased concentrations of glycerol and FFA released into the media upon co-culture of 
AML and adipocytes for 24 hours compared to their monoculture counterpart. This 
significant increase in the glycerol and FFA release is indicative of an increased event of 
lipolysis. 
Next, I sought to investigate lipolysis in bone marrow adipocytes by determining the 
activation of intracellular neutral lipase, hormone sensitive lipase (HSL), by examining its 
phosphorylation to pHSL. HSL is an adipocyte associated protein and its phosphorylation is 
mediated through protein kinase A (PKA) activation upon stimulation of lipolysis [245]. 
Figure 4.2 shows, at a transcriptional level, the mRNA expression of HSL in adipocytes, 
BMSCs and in AML cells. Following co-culture with AMLs, the phosphorylation of HSL 
can be seen at the protein level as indicated in Figure 4.3 by the increased intensity of the 
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Figure 4.1. AML blasts induce lipolysis. Primary AML blasts where cultured alone or in co-
culture with adipocytes for 24 hours. Media was removed and assayed for FFA and glycerol 
detection. Data represented as mean of three sample ± standard deviation. Wilcoxon signed-
rank test was used to compare significance between mono-cultured and co-cultured AML 
groups p>0.01 
  
 
 
  
 
 
 
Figure 4.2. Hormone sensitive lipase is an adipocyte associated gene. mRNA expression of 
HSL in adipocytes, BMSC and AMLs in mon-culture. All normalised to GAPDH and data 
represented as men of three independent RT-PCR runs for each with ± standard deviation. 
Wilcoxon signed-rank test was used to compare significance between AML and Adipocytes 
or BMSCs group p>0.01 
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Figure 4.3. Immunoblot for pHSL from adipocytes cultured with and without AML blasts (n 
= 4). Blots were re-probed for total HSL and ß-actin to show equal sample loading. 
 
To confirm that the activation of lipolysis in adipocytes is specific to AML, I co-cultured 
non-malignant CD34+ cells with adipocytes or corresponding monocultures. Figure 4.4 
shows no significant increase in the rates of glycerol release in non-malignant cell and 
adipocyte co-culture. 
 
 
 
 
 
 
Figure 4.4. Lipolysis is a malignancy associated phenomenon. Primary, non-malignant 
CD34+ were cultured alone or in co-culture with adipocytes. Media was taken and assayed 
for glycerol. Data represented as mean of three sample ± standard deviation (n=3). One-way 
Anova was used to calculate significance which was non-significant. 
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Following confirmation of the event of lipolysis in a malignant setting, I then sought to 
investigate if the support acquired from adipocytes would be available without cell-to-cell 
contact i.e. are adipocytes secreting soluble factors contributing to the maintained survival 
of AMLs in their proximity. For this, I cultured AMLs in adipocyte CM for six days and 
observed a significant difference in cell numbers compared to mono-cultured AMLs. This 
indicated factors secreted by adipocytes without AML stimulation can also maintain survival 
of AMLs, as shown in Figure 4.5. At a basal state, adipocytes may be responsible for 
providing crucial factors responsible for maintaining AML blasts. Conversely, AML CM 
stimulated lipolysis of adipocytes as indicated by the increased release of glycerol detected 
in the medium (Figure 4.6). 
 
 
 
 
 
 
Figure 4.5. Adipocyte conditioned media supports AML blast survival. AML blasts were 
cultured in normal and adipocytes conditioned media for 48 hours and counted by trypan 
blue exclusion. N = 4; p <0.05. 
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Figure 4.6. AML conditioned media stimulate lipolysis in adipocytes. Adipocytes were 
cultured in normal media or in AML conditioned media for 24 hours. Media was then 
assayed for release of glycerol. Data represented as mean of three sample ± standard 
deviation. Kruskal-Wallis test as used to calculate significance between groups. P> 0.05 
 
Taken together, I concluded that AML blasts are constitutively secreting factors that 
stimulate their surrounding cells to secrete factors that positively contribute to AML 
survival. This is indicated by the stimulation of lipolysis by AML-CM. Indeed, in the 
presence of AML blasts in co-culture with adipocytes, the event of lipolysis was increased 
by approximately 4-fold. This was estimated by the concentration of glycerol released in the 
media during the co-culture or after CM treatment of adipocytes; 350 uM and 75 uM 
respectively indicating dynamically occurring lipolysis in the presence of AMLs as opposed 
to their conditioned media which contains a limited amount of lipolysis stimulating factors. 
4.2 Lipolysis is needed for survival of AML blasts 
Acipimox (APX), a nicotinic acid derivative known to impart an anti-lipolytic action on 
adipocytes by inhibiting the release of FFA, has been shown to influence metabolism by 
increasing glucose uptake in a prostate cancer xenograft model by inhibiting the release of 
FFA [246]. This is an important observation as my previous results showed a dependence 
on adipocytes for survival (Chapter 3).  
* 
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To test if the by-product of lipolysis, i.e. FFA is necessary factors for AMLs survival in these 
co-cultures, I sought to inhibit lipolysis of adipocytes prior to co-culturing with AMLs and 
then assay for AML survival in these conditions. To investigate if APX is only effective in 
co-cultures with adipocytes, I pre-treated BMSC and adipocytes with 10 uM APX before 
co-cultures[247]. In all APX experiments, I carried out a drug control which considers the 
toxicity of the drug in mono-culture, so any effect on viability can be distinguished from 
effect of the drug in co-culture simply due to toxicity. All cells were plated at an initial 
seeding density of 5 x 104 and subsequently cultured for 72 hours. Figure 4.7 suggests that 
APX significantly reduces viable cell numbers in co-cultures with adipocytes and has little 
to no effect on co-cultures with BMSC or mono-cultures. This showed that in the presence 
of adipocytes, adipocyte lipolysis was critical in AML survival. 
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Figure 4.7. Lipolysis inhibition effects AML blast survival in an adipocyte co-culture. 
Primary AML blasts in mono-culture or in co-culture with BMSC or adipocytes with or 
without treatment with 10 uM acipimox (APX) for 72 hours. Statistical significant between 
different groups was determined using Mann-Whitney U test. Data represented as mean of 
four samples ± standard deviation. P <0.05 
 
From Figure 3.2, I concluded that freshly isolated AML blasts from AML patient BM were 
rich in lipid content. I then hypothesised that this may be due to AMLs stimulating an 
upregulation of lipolysis in the associated adipocytes. The by-product of lipolysis, FFA, may 
then be transferred to the AMLs and be critical to the survival of the AMLs. Should there be 
an impedance to the acquisition of this by-product, viability of AMLs reduces drastically. 
To test this hypothesis, I first set out to test that FFA released from the adipocytes are in fact 
129 
  
transferred to the AMLs. Figure 2.4 shows a schematic of an experimental setup to 
investigate the movement of FFA to the AMLs from the adipocytes. For this, I incubated a 
monolayer of adipocytes with a FA analogue that is conjugated to a dodeceonic acid 
fluorescent free fatty acid analogue (DAA), which is taken up by lipids. After 3 hours, I 
washed the adipocytes with PBS to ensure removal of any exogenous DAA not taken up by 
the adipocytes. I then co-cultured AMLs at a density of 5 x 104 onto the adipocytes. After 
24 hours, I isolated the AMLs from the co-culture and analysed the mean fluorescence 
intensity of the AMLs to check for transfer of the labelled FFA from the adipocytes. Figure 
4.8 shows the shift in the fluorescence between AMLs on unlabeled adipocytes (black) and 
labelled adipocytes (red). This was done to control for auto-fluorescence of AMLs. The shift 
in fluorescence of AMLs from the unlabeled and labelled adipocytes suggested that the FFA 
from the adipocytes were in fact transported to the AMLs in co-culture. Next, I inhibited 
lipolysis using 10µM APX 3 hours prior to labelling and co-culturing with adipocytes. I also 
labelled BMSCs with DAA to identify any FFA uptake in AMLs from the BMSC component 
of the BM. Figure 4.9 shows the relative fluorescence intensity of the three conditions; 
BMSC co-culture (red), adipocyte co-culture (black) and acipimox-treated adipocyte co-
culture (blue). There was no significant uptake of FFA in AMLs from the BMSC co-culture 
compared to the significant uptake in the adipocyte co-culture.  Importantly, inhibiting 
lipolysis with acipimox in the adipocytes prior to co-culturing with AML significantly 
reduced the fatty acid uptake (FAU) in the AMLs.  
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Figure 4.8. AMLs take up fatty acid released by adipocytes. AML blasts cultured on 
adipocytes with (red) or without (black) pre-loaded FAU dye DAA and fluorescence was 
measured by flow cytometry (C6 BD-Accuri) 
 
 
 
 
 
 
 
 
Figure 4.9. Inhibiting lipolysis reduces FAU in AML blasts. AML blasts cultured on 
adipocytes with and without 10 uM acipomox or BMSC that had been pre-incubated with 
fluorescent DAA for 24 hours (n=4). Blasts were analysed for uptake of the fluorescent DAA 
by flow cytometry (Cube 3 Sysmex-Partec). Data are represented as mean ± standard 
deviation. Red line indicates AML cultured on BMSC; black line indicates AML cultured 
on adipocytes, and blue line indicates AML cultured on adipocytes treated with acipomox. 
*P < .05.  
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4.3 Discussion 
In this chapter, I conclude that adipocytes undergo lipolysis in the presence of AML and this 
effect is not observed in non-malignant co-culture. This stimulation of lipolysis when in 
proximity with tumour cells has also be shown by Nieman et al., where they find a similar 
occurrence in omental fat when cultured with ovarian cancer cells. Selectivity is important 
when identifying novel targets and therefore, it was imperative that I investigate if the same 
lipolytic effect imparted by malignant cells is also induced by normal, non-malignant 
haematopoietic cells.  The difference between levels of glycerol in the media of CD34+ non-
malignant cells when cultured with adipocytes was insignificant compared to mono-cultures 
of the same cells. Also, comparing the concentration of glycerol in the media of CD34+ and 
AMLs with adipocytes (76.9uM vs 232.5uM), there is a prominent difference in their 
concentrations suggesting that AMLs stimulate lipolysis in mechanisms that might relate to 
its existence as a malignancy. These observations are in line with studies that identify 
adipocyte lipolysis as a possible reason for increased cancer cachexia which was shown to 
be more likely a consequence of adipocyte HSL activation and less likely to be due to weight 
loss or other epigenetic factors[248]. 
Interestingly, AML cells cultured with adipocyte-conditioned media show an increase in the 
number of AML cell number. This would suggest that factors secreted by adipocytes, not 
initiated by the presence of AMLs, maintain survival of the blasts. These factors could of 
course still include FFA as even in mono-culture conditions, adipocytes do release FFA and 
glycerol; this is a normal physiological process that occurs to maintain the balance of 
lipogenesis and lipolysis. However, since this supply of FFA is limited, co-cultures with CM 
for longer than 48 hours showed a decline in the number of AML blasts in culture as the 
FFA in the CM is depleted (data not shown).  
Lipolysis of adipocytes is essential for AML survival. Using Acipimox, an anti-lipolytic 
agent, lipolysis was inhibited, which had a direct effect on co-cultured AML cell numbers. 
132 
  
One of the effect of lipolysis on AMLs was shown to be fatty acid uptake. In figure 4.9, there 
is an increase in fluorescence in the AMLs cultured with adipocytes compared to those 
cultured on BMSC. When lipolysis is inhibited in the adipocytes prior to culturing with 
AMLs, there is less FFA available for the AMLs to take up and therefore a decrease in 
fluorescence. This was an important finding as a cause and effect relation was hypothesised 
for the inhibition of lipolysis and the decrease in AML numbers upon inhibition. Three 
things are important to note here; (1) Inhibition of lipolysis had no effect on AMLs cultured 
with BMSC. This meant that when in culture with BMSCs, AML may have a different set 
of signatures for survival on these cells.  (2) This FA uptake dye is an indicator of uptake 
potential and not simply staining of neutral lipids like the BODIPY dye used to visualise and 
quantify lipids within the AMLs or adipocytes. This is because the FA uptake dye consists 
of a fatty acid analogue which is actively taken up by cells that would carry out this process 
if they require FAs whereas, the BODIPY neutral lipid dye is a fluorophore with a structure 
that is intrinsically non-polar and lipophilic and are therefore, not taken up by the cells in 
the same way as the FA analogue. Non-specific fluorescence not attributed to the FA uptake 
has also been accounted for in Figure 4.8. (3) Despite inhibition of lipolysis in the 
adipocytes, AMLs still contain some amounts of FA, more so than AMLs from BMSCs. 
This may be due to the factors other than FA released by adipocytes that may support de 
novo lipid synthesis in the AMLs. This de novo lipid synthesis was studied in the early 50s 
and found levels of generated lipids within the tumour cells comparable to lipids generated 
by liver cells[249]. These generated lipids were used by the tumour cells for their rapid 
proliferation. The same study also revealed that in addition to de novo lipogenesis, tumour 
cells also take up FA from their microenvironment[249, 250]. This increase in lipid content 
within the blasts may be responsible for protection from oxidative damage by reducing lipid 
peroxidation due to increased lipid saturation[104]. 
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Taking the above together, I therefore confirmed that the lipid content in the AMLs are a 
result of FFA uptake from the adipocytes. The adipocytes are also responsible for secreting 
factors that may activate de novo lipid synthesis. Both lipid uptake and lipogenesis within 
the cancer cells have been previously proven in breast cancer to increase protection against 
damage incurred by lipid peroxidation and chemotherapy[251].  
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CHAPTER - 5 
Free fatty acids are transported from adipocytes to AML via transport proteins and 
are essential for blast survival 
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5.1 Adipose-derived FABP4 is upregulated in cultures with AML 
Results from chapters 3 and 4 demonstrate that AML proliferate when in culture with 
adipocytes. I also show that AML induces lipolysis of bone marrow adipocytes and that 
AML blasts take up these lipids. This lead me investigate possible mechanisms by which 
these FA that make up the intracellular lipids of the AML blasts, are transported from 
adipocyte to AML. Previous studies in breast, prostate and oral squamous carcinoma have 
identified a protein, part of the fatty acid binding protein family, as a contributor to cancer 
invasiveness [112, 252-255]. This protein, FABP4 is heavily associated with adipocytes 
(Figure 3.8) and functions as an intercellular transporter of fatty acid. Figure 5.1 shows an 
immuno-histochemistry staining of FABP4 in fat cells isolated from primary BM aspirates 
of leukaemic patients showing FABP4 localised intracellularly surrounding the lipid 
droplets.  The binding of fatty acid to FABP family of proteins allows solubility in cellular 
plasma to enable easy transportation within the cell [256]. Drawing on these previous results, 
my next hypothesis was that upon the stimulation of lipolysis and the release of FFA, 
adipocyte-derived FABP4 may be responsible for shuttling the FFA from the adipocyte to 
the AML blasts. 
I first sought to investigate any transcriptional changes to FABP4 in the presence of AML 
blasts. Figure 5.2a shows a significant transcriptional activation of FABP4 in the adipocytes 
in the presence of AML blasts. I also confirmed that this activation was adipocyte exclusive 
and therefore compared it with possible FABP4 activation in the BMSC co-cultures in 
Figure 5.2b. I also identified protein levels of FABP4 in both adipocytes and BMSCs with 
and without AML blasts co-cultured over a period of 48 hours to 6 days. I observed no 
protein levels of FABP4 in the BMSC, mono-culture or co-culture as shown in Figure 5.3. 
In the adipocytes however, I observed a slight increase of FABP4 in the co-cultured 
adipocytes compared to adipocytes on their own; however, I also observed a decrease of this 
protein concentration by day 6. Additionally, the initial increase in the FABP4 content did 
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not reflect the transcriptional changes observed at an mRNA level. This led me to investigate 
the change in the protein of adipocytes with or without AML blasts in co-culture. I therefore 
repeated the co-culture experiments for a fixed time point, 6 days. I observed a decrease in 
the protein levels of adipocyte FABP4 (Figure 5.4) while the transcriptional level of the 
same was constitutively higher in the co-culture compare to the mono-cultures (Figure 5.2a). 
At this point, the decrease in protein content with the increase in transcription could mean 
one of two things; 1) following translation of FABP4, the protein is shuttled outside the 
adipocytes into the media and further on to the AML blasts where it is picked up and 
transported into the cell or 2) the translation and utilization of FABP4 leading to its ultimate 
denaturing is a high turn-over process which cannot be captured by western blotting. In this 
chapter, I investigate both these possibilities and highlight the role FABP4 plays in both cell 
types. 
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Figure 5.1 FABP4 is expressed in bone marrow adipocytes isolated from AML patients. 
Bone marrow fat from an AML patient isolated and cultured in welled chambers. Immuno-
histochemistry staining was performed using anti-FABP4 in red is a rabbit mAB with 
secondary Alexa Flour 594 goat anti-rabbit IgG, lipids in green using BODIPY® 493/503 
and nuclei in blue with DAPI. This image represents 1 of n=3 AML samples 
  
 
 
 
 
 
 
 
 
 
 
Figure 5.2 FABP4 mRNA is upregulated in adipocytes co-cultured with AMLs. AMLs 
Adipocyte and BMSCs were cultured with or without AMLs for 6 days. AML were washed 
off and RNA was isolated from adipocytes and BMSC. mRNA expression of FABP4 using 
qRT-PCR was examined in both (a) adipocytes and (b) BMSCs. Data represented as mean 
± standard deviation n=6. All data normalised to GAPDH housekeeping gene. Wilcoxon 
signed-rank test was used to assess significance. P>0.5 
 
a 
a b 
* NS 
138 
  
- + + +AML
4h 48h 6d
- + +
AML
6d48h
BMSC
Adi
adipocytes
FABP4
β-actin
1     0.7     1     0.5    
- + - +AML Have another 
mrna for fabp4 
adipocytes for 
6 days
 
 
 
 
 
  
 
 
 
Figure 5.3 FABP4 expression in adipocytes and BMSCs cultured with AML. BMSC and 
adipocytes were cultured with or without AMLs for different time-points. Western blot was 
then carried out to assess FABP4 protein levels in adipocytes at 4h, 48h and 6 days and 
BMSCs at 48h and 6 days. Blots were re-probed with ß-actin to show equal loading and are 
representatives of three individual experiments. 
 
  
 
 
 
 
 
 
Figure 5.4 FABP4 protein expression in adipocytes after 6-day culture with or without 
AMLs. AMLs were taken off and adipocytes where washed and partially trypsinised to 
ensure no AML contamination. Following protein extract and western blotting, membrane 
was probed for FABP4 and then re-probed for ß-actin to show equal loading and are 
representatives of three individual experiments. 
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5.2 Adipocyte FABP4 upregulation is malignancy exclusive. 
So far, I have shown that the adipocyte-derived FABP4 mRNA expression is up-regulated 
in the adipocytes when cultured with AML. No increase in FABP4 expression was observed 
in BMSC under the same conditions. Novel therapies for cancer are reliant on the targeting 
specificities of potential interventions. Therefore, the up-regulation of FABP4 would be of 
expressed interest if these observed effects of co-culturing are specific to a malignancy 
setting. To determine if this is the case, I set up a co-culture assay of adipocytes and non-
malignant CD34+ cells obtained from peripheral blood of normal donors. CD34+ cells were 
isolated using magnetic bead separation protocol and analysed by flow cytometry to acquire 
a percentage of purity. These CD34+ pure populations cultured on the adipocytes did not 
activate any FABP4 transcriptionally in the adipocytes. This assay was repeated on four 
independent samples as shown in Figure 5.5. 
 
 
 
 
 
 
 
 
  
Figure 5.5. FABP4 expression in non-malignant CD34 cells when cultured with adipocytes. 
Non-malignant CD34 cells were cultured alone or with adipocytes for 48 hours. RNA was 
isolated, reverse transcribed and FABP4 mRNA expression was analysed by qRT-PCR. All 
data was normalised to GAPDH housekeeping gene. Data are represented as mean ± 
standard deviation. N=4. Mann-Whitnney U test was used to calculate significance between 
groups 
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5.3 FABP4 is secreted by adipocytes  
Next, I investigated the availability of FABP4 protein by first determining if FABP4 is 
secreted into the co-cultures of AML and adipocytes. To do this, I cultured adipocytes in 
media for 24 hours with or without the AML blasts. I then carried out an enzyme-linked 
immunosorbent assay (ELISA) to quantify the concentration of FABP4 released in the 
media. I observed a significant increase in the concentration of FABP4 in the media of the 
adipose tissue/AML co-culture compared to the monoculture of adipose tissue as shown in 
Figure 5.6. I then moved on to investigate the rate of release of FABP4 by quantifying the 
concentration of FABP4 in the media on adipocyte/AML co-culture at 15, 60 and 120 
minutes. I observed an increase the concentration of FABP4 in the media at 15 minutes 
which is maintained at a relative constant (Figure 5.7). Taking these findings together, I thus 
concluded that FABP4 is an adipokine that is in fact secreted by the adipocytes in co-culture 
with AMLs.  
 
 
 
 
 
 
Figure 5.6 Primary bone marrow adipocytes was isolated and cultured with or without AMLs 
for 24 hours. Media was then taken to assess FABP4 secretion using ELISA. FABP4 is 
secreted from primary adipocytes isolated from AML bone marrow. Significant increase in 
FABP4 secretion from primary adipocytes cultured with primary AML blasts. p <0.05 n=3. 
Mann-Whitnney U test was used to calculate significance between both groups. 
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Figure 5.7 FABP4 secretion was assessed at different time-points in culture. ELISA carried 
out on media from adipocyte/AML co-culture. FABP4 levels detected is secreted 
incrementally in culture with AML blasts but plateau after 60 minutes. P>0.001; Ns 
difference between concentration at 60 minutes and 2 hours. Kruskal-Wallis test as used to 
calculate significance between groups. 
 
 
 
 
 
 
 
 
 
 
 
 
** 
142 
  
5.4 Adipose-derived FABP4 is not transported into the AML blasts. 
I then moved on to investigate the fate of this extracellular adipocyte FABP4. For this, I 
wanted to determine if FABP4 was taken up by the AMLs. I initiated this part of the 
investigation by establishing the basal protein and transcriptional levels of FABP4 in the 
AMLs themselves and subsequently the change in its expression following co-culturing with 
adipocytes for 48 hours. Figure 5.8 shows an increase in mRNA expression of FABP4 in the 
AML blasts following co-culturing adipocytes compared to mono-culture and culture with 
BMSC. For protein content, I did not detect a change in protein content between mono-
cultured and co-cultured AML blasts with adipocytes, as shown in Figure 5.9. Initially, for 
the co-culture experiments, the seeding density I chose was 5x105; however, this density was 
too small to detect FABP4 using western blotting (results not shown). Therefore, I chose a 
seeding density of 1x106 for AML co-cultured with adipocytes to be achieve a detectable 
expression of FABP4 using Western blotting. 
Next I wanted to determine if FABP4 moves out of the adipocytes and into the AML blasts. 
To do this, I added recombinant-His-tagged FABP4 in AML containing media and cultured 
this for 24 hours to determine if the His-tagged-FABP4 would move to the AML. I carried 
out a Western blot for detecting His-tagged-FABP4 using an anti-His-tag antibody and 
FABP4 using a FABP4 antibody. I was unable to detect any His-tagged-FABP4 in the AML 
blasts in media with His-tagged-FABP4. I concluded the FABP4 released by the adipocytes 
may not be taken up by the AML blasts. 
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Figure 5.8 FABP4 expression of AML blasts cultured in isolation or with BMSCs or 
adipocytes for 48 hours. AMLs were then removed and was followed by RNA extraction 
and qRT-PCR for FABP4 mRNA expression analysis. Data are represented as mean ± 
standard deviation. All data was normalised with housekeeping gene, GAPDH. N=6. 
P<0.05. Mann-Whitney U test was used to compare significance between mono-culture 
AML and AML cultured with BMSC or adipocytes. 
 
 
 
Figure 5.9 AMLs were cultured with or without adipocytes for 48 hours and checked for 
intracellular FABP4 expression. Immunoblot of FABP4 protein level in AML after of 
culturing with adipocytes shows no change in protein levels in different conditions. Blots 
were then re-probed with GAPDH acting as loading control. 
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Figure 5.10 AMLs cultured with recombinant His-tagged-FABP4 for 24 hours shows no his-
tagged FABP4 taken up in the AMLs. ß-actin is loading control. N =2 
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5.5 Adipose-derived FABP4 is essential for blast survival 
To investigate the importance of adipocyte-derived FABP4 in regulating the transport of 
FFA to AML, I knocked down FABP4 in the adipocytes. I produced lentiviral particles that 
incorporated plasmid with a short hairpin RNA molecule targeting human FABP4. As a 
control, I produced lentiviral particles that incorporated a plasmid with no short hairpin RNA 
molecule (empty control). At an MOI of 20 (20 infectious lentiviral particles per cell) using 
five different shRNA-targeting FABP4 and the empty vector (shE) as a control I infected 
adipocytes. Figure 5.11 shows the mRNA level the fold change of FABP4 in knockdown 
(KD) compared to shE control and Figure 5.12 shows the protein levels of adipocyte-derived 
FABP4 using the five vectors and controls.  
 
 
 
 
 
 
 
  
 
Figure 5.11 Lentiviral FABP4 knockdown. FABP4 was knocked-down in adipocytes using 
5 lentiviral constructs and an empty control lentivirus was used as control. RNA was isolated 
and mRNA expression of FABP4 was analysed using qRT-PCR after 96 hours. All data was 
normalised to GAPDH. 
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Figure 5.12 Lentiviral FABP4 knockdown. FABP4 was knocked-down in adipocytes using 
5 lentiviral constructs and an empty control lentivirus was used as control. Protein was 
extracted and FABP4 protein expression was analysed using Western blotting after 96 hours. 
GAPDH was used as loading control. 
 
Having determined that sh1 and sh2 target vectors had the best knockdown of FABP4, I then 
investigated the proliferative extent of AML cultured with adipocytes that had FABP4 
knocked down with sh1. I found a significantly reduced number of cells in the co-culture of 
AML with FABP4 KD adipocytes compared to the shE controls after culturing for 48 hours. 
I therefore concluded that FABP4 in the adipocyte is important for AML survival when 
cultured with adipocytes (Figure 5.13).  
Next, I sought to investigate the effect of knocking down adipocyte-derived FABP4 on fatty 
acid uptake. For this, I incubated FABP4-knockdown adipocytes in FBS-free media and FA 
uptake dye for 4 hours. I washed the adipocytes and cultured them with AMLs for 24 hours. 
The AMLs were then run through a flow cytometer to detect fluorescence of FA uptake dye 
that had been taken up from the adipocyte to the AMLs. Figure 5.14 shows a shift in 
fluorescence of FA taken up by AMLs that were cultured on adipocytes with KD FABP4 
compared to shE control, therefore suggesting of FABP4’s role as a FA transporter. 
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Figure 5.13 FABP4 was knocked-down in adipocytes using lentivirus of construct sh1 
FABP4 shRNA or control shRNA. 3 primary AML samples were cultured on adipocytes for 
48 hours and viability was analysed using trypan blue exclusion and flow cytometry. 
Number of AMLs were reduced in cultured with FABP4 knock-down compared to control 
shRNA. (n=3) p<0.05. Wilcoxon signed-rank test was used to calculate significance. 
(CtrshRNA = control vector shE; FABP4shRNA = FABP4 KD) 
 
 
 
 
Figure 5.14 FABP4 was knocked-down in adipocytes using lentivirus of construct sh1. Fatty 
acid uptake was analysed using fatty acid uptake dye (DAA) in 3 primary AML samples 
cultured on adipocytes for 48 hours. Fatty acid uptake was reduced in AMLs cultured with 
FABP4 knock-down adipocytes. Data represents 1 of 3 primary AML samples.  (CtrshRNA 
= control vector shE; FABP4shRNA = FABP4 KD) 
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Next, I wanted to determine if inhibiting FABP4 using a pharmacological inhibitor 
influences AML survival when cultured on adipocytes. I therefore used a FABP4 inhibitor 
(FABi) from BMS (BMS309403) at a concentration of 10uM[257]. Once again, I cultured 
AMLs in isolation with and without FABi and in co-culture with BMSC and adipocytes with 
and without FABi. I did not observe any significant difference in cell numbers between the 
monoculture and BMSC with and without the inhibitor. However, I observed a significant 
difference in the adipocyte culture with and without FABi suggesting in an adipocyte culture 
FABP4 is important in AML survival. However, this may not be the case in BMSCs as 
FABP4 inhibition has no effect on AML survival as shown in Figure 5.15. To test if the drug 
has no effect on normal non-malignant cells and that this process is specific to malignant 
cells, I carried out the same experimental setup on non-malignant CD34+ cell and observed 
no difference in survival between control and drug groups (Figure 5.16).  
Next I wanted to determine the effect of inhibiting FABP4 in vivo. These experiments were 
carried out by Thomas Oellerich and Sebastian Mohr (at Goethe University, Germany). To 
do this a syngeneic in vivo model was used for two mouse AML models. BM cells from 
syngeneic mice were retrovirally transduced with oncogenes Meis1 and HoxA9 for one 
model and MN1 for the second (described in methods). Two experimental arms, control and 
drug treated, were set up per model with 8 animals in each arm of the experiment. For the 
drug treated arm mice were injected with 15mg/kg of FABi per day for 10 days starting on 
day 15[258]. These results showed no significant difference between drug treatment and 
vehicle control treatment (Figure 5.17).  
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Figure 5.15 AMLs were cultured in isolation, with BMSCs or adipocytes with or without 
FABP4 inhibitor at 10uM. FABP4 inhibitor (FABi) effects viability of AML blasts when 
cultured on adipocytes. P<0.05. Wilcoxon signed rank test was used to calculate significance 
between AML and AML with FABi within each group. n=4 
 
 
 
 
 
 
 
Figure 5.16 Non-malignant CD34+ cells were cultured in isolation, with BMSCs or 
adipocytes with or without FABP4 at 10uM. FABP4 inhibitor (FABi) effects viability of 
AML blasts when cultured on adipocytes FABP4 inhibition has no effect on CD34 viability. 
Wilcoxon signed rank test was used to calculate significance between AML and AML with 
FABi within each group. No significance was observed between treated and untreated 
conditions. n=4 
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Figure 5.17 Kaplan-Meier Survival curves of in syngeneic vivo models (Hoxa9/Meis1 and 
MN1 models). Pharmacological inhibition of FABP4 but administration of FABi for 10 days 
at 15mg/kg. Control animal received vehicle control. No significant difference was observed 
between experimental and control arms. N=8 per arm.  
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At this point, I was unsure whether the non-significance between experimental and control 
groups in Figure 5.17 was due to side effects such as toxicity of FABi or that targeting 
FABP4 in-vivo was not a feasible target as the in-vitro data had suggested. To further 
understand if FABP4 is a viable target for AML therapy I decided to investigate the effects 
of FABP4 in the AML blasts. The rationale for investigating FABP4 in AML is that I 
observed mRNA expression of FABP4 is increased in AMLs upon co-culture with 
adipocytes compared to mono-culture (Figure 5.8). To support this in vitro transcriptional 
finding, I sought to determine the same in silico using publicly available mRNA sequencing 
data for a panel of 43 AML patients, which comprised of 22 AML samples obtained from 
the peripheral blood and 21 AML samples obtained from the bone marrow (Gene Expression 
Omnibus Accession ID: GSE49642) and from non-malignant CD34+ cord blood cells 
posing as non-malignant controls (Gene Expression Omnibus Accession ID: GSE48846). I 
found statistical differences between FABP4 expression in peripheral blood AMLs 
compared to bone marrow AML and between non-malignant CD34+ and bone marrow 
AMLs as shown in Figure 5.18. 
To determine the significance of FABP4 in AML, I knocked-down FABP4 in AMLs and 
assessed viability of AMLs with FABP4-KD compared to control shE when cultured on 
adipocytes compared to BMSC co-culture with the same. I observed a reduced viability on 
both BMSCs and adipocytes following the KD of FABP4 in the AMLs shown in Figure 
5.19. With respect to FA uptake, following preloading adipocytes with the FA uptake dye, I 
observed a clear shift in fluorescence in AMLs with FABP4-KD compared to control shE 
shown in Figure 5.20.  
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Figure 5.18 FABP4 gene expression (expressed in log2 RPKM values) obtained from 
GSE49642 and GSE48846 for non-malignant CD34 cells, 22 blood AML, and 21 BM AML 
patient samples. P value obtained by Wilcoxon rank-sum test. Middle band denotes the 
median value with lower and upper bands denoting the first and third quartiles, respectively. 
 
 
 
 
 
 
 
 
Figure 5.19 FABP4 mRNA expression in 4 primary AMLs following lentiviral knockdown. 
Using construct sh1. AML were then cultured on adipocytes or BMSCs for 48 hours and 
viability was analysed using trypan blue exclusion and flow cytometry. AML viability was 
reduced in cultured with FABP4 knock-down AMLs on adipocytes compared to control 
shRNA. (n=4) *p<0.05 **p<0.001. Wilcoxon signed rank test was used to compare AML 
viability between control shRNA and FABP4 shRNA between individual co-cultures. 
(CtrshRNA = control vector shE; FABP4shRNA = FABP4 KD) Data are represented as 
mean ± standard deviation. 
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Figure 5.20 FABP4 knocked-down in 4 primary AMLs using lentivirus of construct sh1. 
Fatty acid uptake was analysed using fatty acid uptake dye (DAA) in AML samples cultured 
on adipocytes for 48 hours. Fatty acid uptake was reduced in AMLs with FABP4 knock-
down. Data represents 1 of 4 primary AML samples.  (CtrshRNA = control vector shE; 
FABP4shRNA = FABP4 KD) 
 
To translate this into an in vivo setting, I used the syngeneic model requiring the use of 
murine AML for transplantation. To do this, I used the Hoxa9/Meis1 expressing AML cell 
line (performed by Thomas Oellerich and Sebastian Mohr). I produced murine FABP4 
targeting lentiviruses (FABP4 shRNA) and transduced murine AML (Hoxa9/Meis1) cells. 
Figure 5.21 shows protein level confirmation of murine FABP4-KD in Hoxa9/Meis1 cells. 
I then assessed viability of FABP4-KD and control shE cells in mono-culture with and 
without cytokine supplemented media required for these cells, or in co-culture with BMSCs 
or adipocytes for 48 hours, as shown in Figure 5.22. The only significant difference in 
viability was observed in FABP4-KD and control shE Hoxa9/Meis1 cells cultured on 
adipocytes. I also investigated the level of fatty acid uptake in these cells and, like human 
AML with FABP4-KD, there was as shift in fluorescence indicating decreased fatty acid 
uptake in the FABP4-KD AMLs (Figure 5.23). 
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Figure 5.21 Western blot confirmation of lentiviral knock-down in murine Hoxa9/Meis1 
expressing cells using FABP4 shRNA and control vector 96 hours following knock-down. 
 
 
 
 
 
 
 
Figure 5.22 Cell count using trypan blue exclusion of Hoxa9/Meis1-expressing cells with 
FABP4-KD (FABP4 shRNA) or control shRNA, incubated either alone, with cytokines, 
with BMSC, or with adipocytes for 48 hours. Hoxa9/Meis1-expressing cells (n=4). Data are 
represented as mean ± standard deviation. P<0.05. Wilcoxon signed rank test was used to 
calculate significance between ctr shRNA and mFABP4 shRNA. 
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Figure 5.23 FABP4 was knocked-down Hoxa9/Meis1 expressing cells using murine FABP4 
targeting lentivirus. Fatty acid uptake was analysed using fatty acid uptake dye (DAA) in 
Hoxa9/Meis1 expressing cells cultured on adipocytes for 48 hours. Fatty acid uptake was 
reduced in Hoxa9/Meis1 expressing cells with FABP4 knock-down. (CtrshRNA = control 
vector shE; mFABP4shRNA = murine FABP4 KD) 
  
Finally, Hoxa9/Meis1 infected with FABP4 shRNA and control vector were injected in to 
the tail vein of C57Bl/6 syngeneic mice (eight animals in each arm). FABP4-KD animals 
showed prolonged survival compared to animals in the shE control group (Figure 5.24). I 
therefore concluded that AML-derived FABP4 is essential for survival due to its function as 
a fatty acid transporter. 
 
 
 
 
 
 
Figure 5.24 Kaplan-Meier Survival curves of syngeneic in vivo models injected with 
Hoxa9/Meis1 with FABP4-KD and control arm. p<0.0001 N=8 per arm.  
 
 
DAA fluorescence 
mFABP4shRNA 
CtrshRNA 
H
o
x
a
9
/M
e
is
1
 
c
e
ll 
c
o
u
n
t 
156 
  
5.6 Discussion 
In this chapter, I identify the significance of adipocyte and AML-derived FABP4 in the 
context of leukaemia. First, I noted the difference between transcriptional FABP4 expression 
in adipocytes cultured with and without AML blasts. I conclude that in a co-culture with 
AMLs, FABP4 is transcriptionally activated in the adipocytes, where no difference is 
observed in BMSCs cultured with AML blasts. This activation in adipocytes is exclusive to 
malignant cells as no difference was observed in FABP4 expression in adipocytes cultured 
with non-malignant CD34+ cells. Interestingly, this transcriptional activation does not 
translate to an increase in FABP4 protein in the adipocytes but, paradoxically, I observed a 
decrease in intracellular protein in co-culture. This inverse relationship between 
transcription and translation led me to hypothesise three things; (1) adipocytes use FABP4 
to chaperone FA extracellularly into the microenvironment (2) adipocyte FABP4 chaperones 
the FA from the adipocytes into the AML cells or (3) excess intracellular FABP4 that is not 
bound to FFA is simply degraded within the adipocytes. For the first hypothesis, I 
investigated the media of mono-culture and co-cultures of primary bone marrow adipose 
tissue and found higher concentrations of FABP4 secreted in co-culture. Whether the origin 
of this FABP4 in the media was the adipocytes or the AMLs was not elucidated as the 
presence of extracellular FABP4 was the proof of concept, i.e. FABP4 is a secreted protein. 
Whether adipocyte-derived FABP4 is secreted and then taken up by associated cells was a 
plausible hypothesis to follow extracellular secretions of FABP4. In prostate cancer studies, 
periprostatic adipose tissue has been shown to fulfil a major role in this cancer 
progression[259]. Secondary sites for prostate cancer metastasis are the lymph nodes and 
bone marrow. It is therefore not unreasonable to assume that in the bone marrow, MAT plays 
a similar role in cancer cell progression and sustenance. FABP4 has also been implicated in 
the progression of prostate cancer, with prostate cancer cells being shown to acquire 
exogenous FABP4. This is then responsible for their invasiveness and activation of the 
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PI3K/Akt pathway responsible for cell survival, proliferation and differentiation 
independent of FA binding. I therefore sought to trace exogenous FABP4 uptake into the 
AMLs and used a recombinant, His-tagged FABP4 at a final concentration of 2µg/mL per 
5x105 AML cells. Following a 4 hour and 24 hours culture, I did not detect any exogenous 
FABP4 however, I was able to detect endogenous FABP4 in the AMLs. This suggested that 
unlike adipocytes, the protein level of FABP4 in AMLs does not decrease but remains 
unchanged. This may be due to the constant turn-over of FABP4 production and utility 
thereby maintaining a constitutive concentration of FABP4 in the AMLs. However, I 
hypothesised this may not be the case for adipocytes as they transport their FABP4 in an 
extracellular-to-membrane transport mechanism, upon where the FA is received at the 
membrane level by other FA transporters and channels on the AML surface membrane and 
is subsequently degraded following the FA transfers. However, a limitation to this use of 
His-tagged proteins is the ability for it to enter into the cells. A study conducted in prostate 
cancer has shown that exogeneous FABP4 bound to a His-tag was detected in DU145 cells 
which is a prostate cancer cell line. However, since my experiments were carried out in 
primary AMLs which are morphologically different from prostate cancer cell lines, I 
concluded that this study did not necessarily reflect real-world biological uptake in primary 
BM-derived AML [255]. Nonetheless, this is an interesting point and would be something 
that future studies should examine. 
Maintenance of the AML blasts seemed to be dependent on both adipocyte-derived and 
AML-derived FABP4. Knock down of FABP4 in the adipocytes sowed a decrease in 
survival of the AML blasts in the co-culture. This decrease in survival may be attributed to 
the fact that there is a decrease in FA chaperones (FABP4) to transport the FA released due 
to lipolysis (Appendix figure E). Having investigated the FA uptake in AMLs that were 
cultured on adipocytes with FABP4-KD, I observed a decrease fluorescence caused by a 
decrease on the fluorescent FA uptake dye.  Pharmacological inhibition of FABP4 in the 
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adipocytes showed a promising decrease in survival of co-cultured AML blasts. 
Interestingly, FABP4 inhibition has no effect on AML survival in cultures with BMSC. This 
suggests a distinct metabolic profile of blasts when in association with the stroma wherein 
AML blasts can switch their metabolism to a non-FA dependent mechanism. This 
phenomenon of metabolic switching was brought to light by Warburg when he suggested 
alterations in cancer cell metabolism were due to malfunctioning mitochondria[260]. 
Although I did not investigate the extent of mitochondrial functioning, I did subject non-
malignant cells to the similar pharmacological inhibition and found it had no effect on the 
survival of these cells. 
Using the syngeneic model described previously, 15mg/kg per day for 10 days was 
administered by oral gavage. No significant difference was observed between any of the two 
experimental or control group. Concentration of drug and administrative procedures were 
done in accordance to published work by Hoo et al., 2013[258]; however, considering the 
different types of mice model and diet, I concluded that insignificant difference between the 
control and FABPi arm may have been due to toxic effects of the drug in the syngeneic AML 
model and therefore co-morbidities inevitably reduced survival masking the biological 
effects of FABP4 inhibition. I therefore decided to investigate the role of FABP4 in the 
AMLs themselves as in co-cultures with adipocytes, their FABP4 transcripts are 
upregulated. First, I looked at transcript levels of FABP4 in a cohort of AML patient samples 
and non-malignant samples. This was a significant finding because this showed FABP4 
transcript levels significantly higher in the bone marrow compartment of AML patients 
compared to the peripheral blood in the leukemic and non-leukaemic setting. FABP4 
upregulation is therefore, a leukaemic bone marrow exclusive event. Knocking down 
FABP4 in primary human AMLs showed a more efficient inhibition in survival of AML 
blasts than pharmacological inhibition, and reduced fatty acid uptake.  
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For in vivo syngeneic transplantation, I used Hoxa9/Meis1 expressing murine AML cells 
and knocked down FABP4. Because these cells are able to proliferate in culture with addition 
of cytokines, it was important to establish how effective FABP4-KD would be in 
monoculture with and without cytokine supplementation. I found FABP4-KD to have no 
effect on survival in monoculture; however, there was a large reduction in survival in these 
cells cultured on adipocytes, once again illustrating the ‘metabolic switch’ phenomenon. I 
also saw a decrease fluorescence in the FABP4-KD cells which is indicative of decreased 
fatty uptake.  Transplantation of these FABP4-KD cells into syngeneic mice significantly 
increased survival in the animals suggesting FABP4 as a potential target for novel 
therapeutic options.  
Taken together, I conclude that FABP4 carrying FFA is transferred outside the adipocytes 
and transported extracellularly, but not into, the AML blasts. However, transport of FFA 
could be a process initiated from the adipocytes and transported extracellularly only up to 
the outer membrane of the AML blasts, where they are then received by AML membrane-
derived FFA transporters, internalised and transported in the AML blasts via AML FABP4. 
In this case, the level of FABP4 in the AMLs is just as important as adipocyte-derived 
FABP4.  
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CHAPTER – 6  
ß – Oxidation is necessary for malignant cell survival 
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6.1 Basal oxygen consumption rate of AML is high 
From my previous results described in the earlier results chapters, I found that (FFA) are 
released by the adipocytes and are then transported to the AML blasts via FABP4. Moreover, 
if the supply of FFA to AML blasts is inhibited and blasts are not subjected to constant 
supply of FA, the lipid stores within AML are depleted. Moreover, blocking this supply of 
FFA also inhibits AML proliferation both in vitro and in vivo. This suggests that the FAs 
within the AML blasts are consumed to supply energy required for energy intensive 
processes such as proliferation.  
To determine if AMLs undergo higher rates of metabolism when cultured on adipocytes 
compared to BMSC or monoculture, I measured the oxygen consumption rate (OCR) of 
AMLs subjected to these conditions using the Seahorse Xfp analyser. The Seahorse can 
determine the intrinsic capacity of a cell to oxidise FA when exogenous sources are limited. 
It also detects simultaneous changes in the rate of respiration when an exogenous source of 
FA is added such a palmitate. This rate of respiration is detected by measuring the changes 
in the concentration of oxygen and therefore addition of FA substrates or oxidation inhibitors 
would result in a change of the respiratory profile. Figure 6.1 shows the OCR of three 
primary AML samples in mono-culture and co-culture with BMSC and adipocytes for 48 
hours. In all three samples, there was a significant increase in OCR in the adipocyte co-
cultures compared to their matched mono-cultures. Co-cultures with BMSC did not impart 
such a significant change in OCR as co-cultures with adipocytes. This may support the 
earlier findings of quiescence in AML blasts in co-cultures with BMSC. 
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Figure 6.1 Primary AML blasts cultured on adipocytes or BMSC for 48 hours and then 
assayed for basal OCR using Seahorse Analyser Xfp showing higher OCR in adipocyte co-
cultures. P<0.05. Kruskal-Wallis test was used to calculate significance between all three 
culture conditions for each AML. Data are represented as mean ± standard deviation. N=3 
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6.2 FA oxidation inhibition decreases OCR in adipocyte-cultured AMLs. 
Having observed a higher OCR in the adipocytes co-culture, I sought to investigate the 
respiration profile of AMLs from the adipocytes co-culture when an exogenous source of 
FA was added to the assay. I also inhibited FA oxidation in the AMLs by the addition of 
etomoxir (ETX) to observe the effects on the respiration profile. Figure 6.2 shows a spike in 
OCR when palmitate is added and an immediate drop in OCR when ETX is added to the 
experimental arm. I then repeated the same on non-malignant CD34+ cells, shown in Figure 
6.3, and observed (1) a lower basal OCR in CD34+ cells compared to AML cells despite 
both being cultured on adipocytes and (2) there was no significant difference in OCR 
between oxidation inhibition using ETX and control in the CD34+ cells. I then looked at 
average OCR between AMLs and CD34+ cell in mono-cultures or in co-culture with 
adipocytes. Each condition was treated with ETX or control shown in Figure 6.4. Here, I 
concluded that FA inhibition only affect OCR in AMLs cultured on adipocytes and has little 
to no effect on non-malignant CD34+ cellc or mono-cultured AMLs. 
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Figure 6.2 Primary AML blasts cultured on adipocytes before measuring OCR (pMoles/min) 
using the Seahorse XFp Analyzer, at baseline and then after injection of palmitate (18 
minutes) and ETX (36 minutes). Circles represent ETX (40 mM) treatment, and squares 
represent no ETX treatment. N=3 Wilcoxon signed rank test was used to compare 
significance between each measurement. P>0.001 
 
 
 
  
  
  
 
 
Figure 6.3 Non-malignant CD34+ cells cultured on adipocytes before measuring OCR 
(pMoles/min) using the Seahorse XFp Analyzer, at baseline and then after injection of 
palmitate (18 minutes) and ETX (36 minutes). Circles represent ETX (40 mM) treatment, 
and squares represent no ETX treatment. N=3 Wilcoxon signed rank test was used to 
compare significance between each measurement. There was no significant difference 
between the groups at varying time points. 
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Figure 6.4 Primary AML blasts or non-malignant CD34+ cells cultured alone or on 
adipocytes. AML blasts and CD34+ cells were then treated with ETX (40 mM), and OCR 
was measured as above. N=4. Significance was assessed between ETX treated and untreated 
groups using Wilcoxon signed rank test.  Data are represented as mean ± standard deviation. 
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6.3 CPT-1A is necessary for ß – oxidation and survival of AML blasts 
From the results above, I found that adipocytes are necessary in enhancing fatty acid 
oxidation in AMLs. Therefore, I decided to investigate, in vitro, the effects of inhibiting fatty 
acid oxidation (ß – oxidation) using ETX on AMLs in monoculture and co-cultures with 
BMSCs and adipocytes. Figure 6.5 shows the viability of AMLs in these conditions 
illustrating the prominent effect ß – oxidation inhibition has on AMLs cultured with 
adipocytes and not the same degree of decreased viability in the other culture conditions. 
Etomoxir is an irreversible inhibitor of CPT-1A which is a mitochondrial enzyme located on 
the outer surface of its membrane. By inhibiting CPT-1A, long-chain fatty acid acyl-CoA is 
inhibited from entering the mitochondria for subsequent biological processes such as ß – 
oxidation. To support the theory of an increased ß – oxidative state in adipocyte co-cultured 
AMLs, I investigated other genes that contribute to the ß – oxidation signature, CPT-2 and 
ACADL. CPT2 is a complementary enzyme to CPT-1A and is located in the inner 
mitochondrial membrane working in concert with CPT-1A to oxidise long-chain fatty acids 
in the mitochondria for internal transport. ACADL (Acyl-CoA Dehydrogenase, Long Chain) 
is a nuclear protein that is translocated to the inner mitochondrial membrane when presented 
with long chain fatty acids and works in conjunction with CPT-1A and CPT2. Following a 
24-hour co-culture of AML blasts with adipocytes, I observed a transcriptional activation of 
CPT-1A and CPT-2 in the AML blasts compared to their mono-cultured counterparts. 
However, this was not the case with ACADL as shown in Figure 6.6. I then knocked down 
CPT-1A in primary AMLs and confirmed knockdown using mRNA transcript analysis by 
RT-PCR and western blotting (Figure 6.7 and 6.8).  I used two primary AML samples with 
CPT-1A KD for in vivo transplantation. Eight animals were used for each primary sample 
with 4 in the control arm and 4 in the CPT-KD arm. Each NSG animal was transplanted with 
2.5 x 105 knockdown AML cells or with control vector. Animals that received CPT-1A-KD 
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cells showed prolonged survival illustrating CPT-1A as a potential therapeutic angle for 
targeted therapy. (Engraftment data is included in Appendix Figure F). 
 
 
Figure 6.5 Primary AML blasts were in monoculture or co-cultured on adipocytes or BMSC 
with and without treatment with ETX for 72 hours. AML blasts were counted using flow 
cytometry and Trypan blue exclusion. N=4. Data are represented as mean ± standard 
deviation. P<0.05. Wilcoxon signed rank test was used to determine significance  
 
 
  
 
 
 
 
Figure 6.6 mRNA expression data of AML in mono-culture and in co-culture with 
adipocytes cultured for 24 hours of CPT1A and CPT2 and ACADL. mRNA expression is 
upregulated in CPT-1A and CPT2 in co-culture but not ACADL. Data is normalised to ß-
actin. Data are represented as mean of ± standard deviation p<0.05. Wilcoxon signed rant 
test was used to assess significance between individual genes in mono and co-cultures. n=4 
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Figure 6.7 CPT-1A was knocked-down in AMLs and an empty control lentivirus was used 
as control. RNA was isolated and mRNA expression of CPT-1A was analysed using qRT-
PCR after 96 hours. All data was normalised to ß-actin. Data are represented as mean ± 
standard deviation. P<0.05. Wilcoxon signed rank test was used to determine significance 
 
 
 
 
 
 
Figure 6.8 CPT-1A was knocked-down in AMLs using an empty control lentivirus was used 
as control. Protein was extracted and CPT-1A protein expression was analysed using 
Western blotting after 96 hours. ß-actin was used as loading control. Figure shows two of 
four primary AML samples. 
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Figure 6.9 Survival of the NSG mice is represented by a Kaplan-Meier plot for mice injected 
with AML CPT1-KD compared with AML control-KD mice. P=0.025. Two primary AML 
samples infected with CPT1A shRNA or control shRNA lentivirus and subsequently 
transplanted into NSG mice. CPT-1A-KD shows prolonged survival compared to control 
KD. 
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6.4 Discussion 
In this chapter, I move forward from the event of fatty acid transport to investigate the fate 
of these molecules and the underlying mechanism in aiding AML blast survival. This 
qualitative analysis of lipid store depletion requires a quantitative measure of respiration 
such as the consumption of oxygen. Oxygen is consumed during respiration and its loss can 
be a measure of metabolic rates[261].   FA oxidation (FAO), from its initiation, consumes 
oxygen – FA undergo oxidative reduction of two successive carbon units[260, 262].  To 
measure this consumption of oxygen in cell types at different conditions, I used the Seahorse 
XF from Agilent. The Seahorse analyser detects the concentration of oxygen and its changes 
by means of a fluorophore that quenches oxygen. A light within the fluorophore chamber 
excites the fluorophore and reads back changes in emission due to changes in oxygen 
concentration.  
The evident process occurring in the blast cultured on adipocytes is FAO (ß – oxidation) 
which is upregulated upon co-culture with adipocytes but is not the case for non-malignant 
CD34 cells. For this analysis, two experimental sets were used, one that received a FAO 
inhibiting drug, etomoxir following addition of FA substrate, palmitate, and another that did 
not receive etomoxir following palmitate. Etomoxir is a member of the oxirane carboxylic 
acid carnitine palmitoyl transferase I family which is converted into CoA esters and 
competitively, irreversibly binds to the active CPT-1 catalytic site. This inhibition of CPT-
1 is known to decrease B oxidation and subsequently FA metabolism arrest[263]. Figure 6.2 
shows the basal oxidation consumption of AML for adipocyte co-culture at ~110 
pMoles/minute. Upon the addition of palmitate, the consumption of oxygen increases as the 
cells begin to metabolise the FA substrate, of which the increased consumption is at a 
constant. Following the second injection (etomoxir or control), the etomoxir arm showed a 
significant decline in oxygen consumption. This inhibition of FAO and its effect on tumour 
cells has been shown in the previous studies in ovarian cancer, and glioblastoma[222, 264]. 
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Interestingly, Samudio et al., have also pharmacologically inhibited of FAO by ETX in 
leukaemia and shown an increase in chemotherapy sensitivity in the leukaemic cells[106]. 
In another study, Samudio et al., show mitochondrial uncoupling due to continued oxygen 
reduction, without ATP synthesis, imparts a Warburg effect in leukaemia/stromal cells co-
culture[265]. They therefore conclude that FAO inhibition in leukaemic cells cultured on 
BMSCs or in isolation reduces proliferation and increases chemosensitivity. My results 
however show that BMSC can support AML blasts maintaining them in a quiescent state. 
When cultured with adipocytes, these cells begin to cycle and progress into a proliferative 
state for which they derive energy from the adipocytes in the form of FAs. This ‘metabolic 
switch’ of cancer cells has been studied and reported as the initial stages of cancer cell 
transition, as they switch their metabolic state to one that favours cancer cell survival[266]. 
It is therefore not unreasonable to suggest the same in the AML blasts that are cultured on 
adipocytes, as they switch their metabolic status to a FAO state to increase energy for their 
proliferation. Because the BMSCs are not an exogenous source of FA, I would not expect to 
see a basal oxygen consumption similar to the rates observed in AMLs cultured on 
adipocytes. This is because FAO is a process that requires oxygen right from the initial stages 
of respiration. This effect is not seen in the non-malignant context as they are not as flexible 
in metabolism as the leukaemic cells. 
The upregulation of FAO associated genes was expected however when I analysed at the 
expression of ACADL, I did not observe the same increase in transcription in co-culture as 
I did with CPT-1A and CPT-2. ACADL being a mitochondrial enzyme associated with FAO, 
is involved in the oxidation of unsaturated FA[267]. Triacylglycerol present in the 
adipocytes are saturated forms of FA and therefore are broken-down independently of 
ACADL. This could explain the non-significant transcriptional upregulation of this gene in 
the AML blasts undergoing FAO of saturated FAs. To investigate this further, I cultured 
primary AML blasts in media supplemented with oleate which is a monounsaturated FA, 
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and compared the cell numbers with those cultured in media supplemented with palmitate 
(which is saturated fatty acid). I detected an increase in cell counts in both conditions, which 
were not significantly different from each other (Appendix Figure D). This suggested that 
AML blasts are capable of oxidising unsaturated as well as saturated FAs. 
Taken together, the FA obtained from the adipocytes are transferred into the AML for 
consumption as an energy source thereby promoting AML survival in vitro and AML 
engraftment and lethality in vivo. 
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CHAPTER – 7 
How do AML and bone marrow adipocytes interact? 
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Having identified a facet of functioning of in the bone marrow microenvironment, I sought 
to delineate the cross-talk between the AMLs and the adipocytes as this could potential hold 
the key of finding the mode of manipulation of the bone marrow by the AMLs making them 
a more favourable host for their survival. In this chapter, I investigated the roles of potential 
targets that may be important players in this leukaemic microenvironment. I used a 
combination of array data, in silico analysis and literature data to inform the rationale for 
experimentation. The data represented in this chapter constitute preliminary findings only 
and additional work will be carried out and detailed in the future work section. 
7.1 Migration and Stromal Derived Factor-1 (SDF-1)/CXCL12 
Having concluded that adipocytes provide various proteins and macromolecules that are 
favourable to the blast survival, I carried out a migration experiment using adipocyte CM to 
observe chemotaxis towards of primary AML cells or away from different culture 
conditions. Figure 7.1a shows a diagrammatic representation of the migration setup where 
migrated primary AML cells in the bottom well were read using Cell-Titre Glo as a measure 
of ATP indicating the viable cells. Exposure to CM may increase ATP production in the 
cells, this is compared relative to the ATP released in the other conditions (SFM and 
Pertussis). The hypothesis here is that this ATP corresponds to viable cell numbers and not 
amount of ATP produced per cell although this was also a consideration.  
Figure 7.1b shows that adipocyte CM enables the most migration compared to serum free 
media (SFM) or in pertussis toxin containing media (10uM/mL). Pertussis toxin is a pan G-
coupled protein receptor inhibitor and is a widely-used migration control[268, 269]. 
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Figure 7.1 (a) Schematic of migration setup. (b) Migration of primary AML cells toward 
SFM (serum free media), CM (adipocyte conditioned media) alone and with pertussis toxin. 
Data are represented as mean ± standard deviation. N=4. Kruskal-Wallis test was used to 
calculate significance between different conditions**p<0.001 
 
From this, I hypothesised AMLs migrate towards a high concentration of adipocyte secreted 
factors that favour AML survival. Whether this migratory effect is amplified in the 
adipocytes, as opposed to adipocyte CM, in the presence of AML has yet to be determined. 
Several studies have shown that within the bone marrow environment, SDF-1 is a major 
contributor toward migration[270, 271]. SDF-1 is a ligand for the chemokine receptor 
CXCR4 and CXCR7. While SDF-1 expression has been reported in many cancers, it 
primarily investigated from the stromal cell angle. I selected SDF-1 as a gene of following 
an investigation of preferentially expressed genes in AML bone marrow-derived samples 
over the peripheral blood-derived samples. I used the DESeq2 method, a tailored method for 
use with RNA sequencing reads, which is count-type as opposed to continuous-type 
data[214]. The same data as Chapter 5 of RPKM data for 43 AML patients, comprising 22 
AML samples obtained from peripheral blood and 21 AML samples obtained from bone 
** 
AML
Adipocyte	CM
AML 
Adipocyte CM 
a 
b 
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marrow aspirate were used (Gene Expression Omnibus Accession ID: GSE49642)[272]. The 
data assayed 21,865 genes in Figure 7.2 showing a volcano plot of these differentially 
expressed genes identifying SDF-1 as the most significantly preferentially expressed in the 
favour of the bone marrow.  
To support this, I investigated the levels of SDF-1 in primary AMLs from patient derived 
xenografts (PDX). Figure 7.3 shows the difference in SDF-1 expression in AMLs derived 
from PDX spleens versus AMLs derived from PDX bone marrow. I used spleen instead of 
peripheral blood from the PDX as bleeding to acquire circulating AMLs from animals would 
not yield efficient RNA for mRNA expression analysis. I therefore considered the spleen as 
a non-bone marrow component. I observed an increase in spleen engraftment in xenograft 
model for AML#4. This may have been due to an increased percentage of engraftment in 
AML#4. This could be assessed by analysing percentage of CD33 and CD45 however 
limited sample quantity limited this analysis. Despite this, a differential expression of SDF-
1a in three out of four primary bone marrow derived-AML samples.  These results 
demonstration that in a PDX model, SDF-1 may be upregulated in the bone marrow-derived 
leukaemic cells themselves.  
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Figure 7.2 Volcano plot of differentially expressed gene in bone marrow and peripheral 
blood (red considered significant). Adjusted p < 0.05 considered significant. SDF-1 p = 
2.63E-9) 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3 SDF-1 mRNA expression in 4 PDX samples from bone marrow and spleen. Bone 
marrow and spleen AMLs were isolated and RNA extracted. SDF-1 mRNA expression was 
then analysed using qRT-PCR. Data is normalised to GAPDH house-keeping gene Samples 
are matched and error bars represent standard deviation between four technical replicates. 
N=4. Wilcoxon signed rank test used to calculate significance p<0.001 between paired 
samples. 
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I also investigated the mRNA expression of primary matched AML samples from bone 
marrow and blood and found that in primary matched peripheral and bone marrow AML 
samples, SDF-1 is preferentially expressed in the bone marrow-derived AMLs as shown in 
Figure 7.4. 
 
 
 
 
 
 
 
 
 
Figure 7.4 SDF-1 mRNA expression in 4 primary matched bone marrow and peripheral 
blood AML samples. AMLs were isolated from primary samples without xenografting and 
RNA extracted. SDF-1 mRNA expression was then analysed using qRT-PCR. Data is 
normalised to GAPDH house-keeping gene. SDF-1 is preferentially expressed in bone 
marrow AML. Error bars represent standard deviation between three technical replicates. 
N=4. Wilcoxon signed rank test was used to calculate significance between different BM 
and PB primary samples p<0.001 
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These results were of particular interest as SDF-1 has long been perceived to be 
predominantly stromal cell derived with their receptors present on tumour cells that facilitate 
migration of tumour to the environment. However, these finding indicate a possible intrinsic 
functioning of SDF-1 in the AML blasts that maybe necessary for other mechanisms 
independent of those required for migration towards stromal cells. To confirm if AML-
derived SDF-1 is necessary for survival, I knocked-down SDF-1 in OCI-AML3 cell lines 
before transplantation into NSG mice. Figure 7.5 shows the Kaplan-Meier survival curves 
of mice transplanted with SDF-1 KD cells and control KD shE. 
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Figure 7.5 (a) mRNA expression of SDF-1 in lentiviral knock-down of SDF-1a in OCI-
AML3 cell line. Wild type (WT), control knock-down (shRNA Ctrl) and SDF-1a knock-
down (shRNA SDF-1a). error bars represent stander deviation between 4 technical 
replicates. (b) Survival of the NSG mice is represented by a Kaplan-Meier plot for mice 
injected with OCI-AML3 cell line with SDF-1-KD compared with AML control-KD mice 
(n=6 each for Control and experimental arm). Mantle-Cox method was used to calculate 
significance between both curves P=0.0210. OCI-AML3 cell line were infected with SDF-1 
shRNA or control shRNA lentivirus and grown on adipocytes and subsequently transplanted 
into NSG mice. SDF-1-KD shows prolonged survival compared to control KD.  
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I therefore hypothesized that SDF-1 is important for survival of leukaemic blast. I then 
moved on to investigate the role of AML derived SDF-1 in the tumour microenvironment 
itself.  
Poznansky et al., have shown that SDF-1 plays a major role in T-cell migration and acts as 
a bi-directional cue that influences the direction of movement of T-cells[273]. Bone marrow 
MSCs have been shown to secrete a multitude of factors that suppress immune responses by 
inhibiting B and T-cell maturation and proliferation[274]. Using the above notion, I decided 
to look at the effect SDF-1 has on T-cells (CD3/8). 
I isolated normal CD3/8 T-cells from peripheral blood using magnetic separation beads 
(Milteny Biotec) and stained them with calcein, a fluorescent dye. I then mixed these with 
primary AMLs at a 1:4 ratio in favour of AML based on percentage proportions reported by 
Berrington et al., 2005 as 20% CD3/CD8 of the bone marrow[275]. I incubated this mixture 
of cells on a porous membrane (5um allowing CD3/8 cells but not AMLs through) atop a 
well containing regular 10% FBS DMEM at 37oC for 4 hours. I then read the bottom well 
for fluorescent, calcein stained CD3/CD8. Figure 7.6 shows the result the incubation of 
AMLs and CD3/8 T-cells. In the presence of AMLs, CD3/CD8 cells migrate away from the 
culture into the lower well. However, I was not able to determine the viability of the CD3/8 
calcien-stained cells that had migrated. This would provide a means to compare correlation 
with calcein staining and death to identify is calcein is released when cells are apoptosing.  
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Figure 7.6 Migration of T-cells away from AMLs (a) Experimental set-up of migration 
experiment T-cell were placed on upper chamber with or without AMLs with porous bottom 
atop a lower chamber with culture media. T-cells were calcein stained prior migration assay 
(b) CD3/8 migrate away from AMLs in co-culture. Data are represented as mean of ± 
standard deviation. N=3 Mann Whitney-U test used to calculate significance between 
different conditions*p<0.05 
 
 
I then used different concentrations of SDF-1 to see the effect it has on CD3/8 migration. 
Figure 7.7 shows the migration of CD3/8 cells that were loaded atop wells that contain two 
different concentrations of recombinant SDF-1. At 100ng/mL, cells migrate towards the well 
containing SDF-1 however, at 1ug/mL cells do not tend to migrate towards this high 
concentration of SDF-1 supporting the study by Poznansky citing varying concentrations of 
SDF-1 impart bi-directional effects on T-cells. 
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Figure 7.7 Bi-directional migration of T-cells by varying concentrations of SDF-1. T-cell 
were placed on upper chamber with porous bottom atop a lower chamber with different 
concentrations of recombinant SDF-1. Data are represented as mean ± of standard 
deviation=3. P<0.05. Kruskal-Wallis test was used to assess significance between the three 
groups. 
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7.2 Does BM adipocyte derived Interleukin-6 (IL-6) play a role in regulating AML 
survival? 
In the previous section, I identified SDF-1a as a potential cytokine differentially expressed 
in the leukaemic bone marrow which may play a role in poor infiltration of CD8 T-cells 
playing an in direct role in tumour immune cell evasion. 
I next investigated other factors that may potentially impact the AML microenvironment. 
IL-6 is a pleiotropic cytokine and is known to play important roles in a range of biological 
activities, including in cancer cells. I initially identified IL-6 following a cytokine screen 
using the human proteome profiler kit from R&D (n=4 primary samples). Figure 7.8 shows 
a representative dot membrane profile of 102 cytokines released in two different conditions, 
adipocytes and an AML/adipocyte co-culture. IL-6 was one of the many cytokines that were 
differentially expressed in the co-culture media. 
 
 
Figure 7.8 Cytokine array of adipocytes and AML/Adipocyte co-culture showing 
differentially expressed cytokines. AML/Adipocytes were cultured for 24 hours before 
media was collected and incubated over-night with cytokine membrane. (a) Quantification 
of pixel intensity relative to control reference points (n=2). (b) Cytokine array of adipocyte 
conditioned media and AML+adipocyte co-culture conditioned media.  
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Because the cytokine array is indiscrete of the origin of the cytokines, I decided to quantify 
the levels of IL-6 secreted in monocultures and co-cultures. Figure 7.9 shows that the levels 
of IL-6 secreted in co-culture of AML and adipocytes is significantly higher than that 
secreted from co-cultures of AMLs and BMSCs or adipocytes and BMSCs in isolation. It 
was interesting to note the low concentrations secreted from AMLs in monoculture. I 
hypothesised that this may be due to the lack of stimulation through a paracrine mechanism 
in the presence of other cell types. I then compared the IL-6 concentration of 7 matched 
AMLs in monoculture and in co-culture with adipocytes (Figure 7.10). 
 
 
 
 
 
 
 
Figure 7.9 ELISA for IL-6 secretion in mono-cultures and co-cultures of AML with BMSC 
or adipocytes. Concentrations of IL-6 secreted by cells in monoculture and co-culture shows 
highest levels of IL-6 secreted in an AML/adipocyte co-culture. Data are represented as 
mean ± standard deviation. N=3. P<0.0001. One-way ANOVA was used to assess 
significance between the groups. 
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Figure 7.10 ELISA for IL-6 secretions in AMLs IL-6 concentration of seven matched AML 
samples in media of monoculture and co-culture with adipocytes. Data are represented as 
mean ± standard deviation. **p<0.001, ***p<0.0001. Wilcoxon signed rank test was used 
to assess significance. 
 
To delineate further which of the two cell types were more likely to be the predominant 
secretor of IL-6, I checked the transcript levels of IL-6 and its receptor IL-6R in the co-
culture compared to its monoculture. Figure 7.11 shows the transcript levels of IL-6 and IL-
6R in adipocytes and adipocytes following co-culture with AMLs. 
 
 
 
 
 
 
Figure 7.11 mRNA expression of IL-6 and IL-6R in adipocytes. Primary AMLs cultured 
with adipocytes for 48 hours. Adipocytes were then isolated from AMLs and RNA extracted 
before mRNA analysis using qRT-PCR of IL-6 (a) and IL-6R (b) in adipocyte cultured with 
AML compared to monoculture using RT-PCR. Data are represented as mean ± standard 
deviation. N =4. P<0.01. Wilcoxon signed rank test was used to determine significance 
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I also investigated the levels of IL-6R mRNA in the AMLs from the co-culture with 
adipocytes, as this would indicate if a predominantly one way paracrine signaling existed. 
However, upon investigation of IL-6 and IL-6R in the AMLs, it was apparent that there were 
higher transcript levels of IL-6 and its receptor on the AMLs which could suggest autocrine 
signaling in response to the IL-6 secreted from the adipocytes (Figure 7.12). 
 
 
 
 
 
 
 
 
Figure 7.12 mRNA expression of IL-6 and IL-6R in AMLs. Primary AMLs cultured with 
adipocytes for 48 hours. AMLs were then isolated from adipocytes and RNA extracted 
before mRNA analysis using qRT-PCR of IL-6 (a) and IL-6R (b) in AMLs cultured with 
adipocytes compared to monoculture using RT-PCR. Data are represented as mean ± 
standard deviation. N =3. P<0.01. Wilcoxon signed rank test was used to determine 
significance 
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Because IL-6 has been shown to play an active role in initiating lipolysis, it was of interest 
to see if this was the case in the leukaemic setting. I used recombinant IL-6 in an adipocyte 
culture and compared the FFA release to a lipolysis control, isoprotenerol, which is a beta-
adrenergic agonist, and an adipocyte/AML co-culture (Figure 7.13). I observed an increase 
in the release of FFA compared to adipocytes on their own.  
 
 
 
 
 
 
Figure 7.13 FFA release from cultures containing adipocytes in monoculture, adipocytes 
stimulated with isoprotenerol, co-culture with AMLs or with 20ng/mLIL-6 for 24 hours. 
Data are represented as mean of ± standard deviation. n=3.  
 
I therefore concluded that IL-6 released from the adipocytes and AML may contribute to 
lipolysis, and subsequently, to AML survival. The data represented here is preliminary and 
further experiments are needed to confirm this data such as quantification of fatty acids 
before and after IL-6 stimulation of lipolysis. Additionally, the possible autocrine function 
of IL-6 in the AMLs conceivably contributes to mechanisms that support their survival, as 
shown in other cancer types[276, 277]. 
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7.3 Fatty acid Translocase (FAT)/ CD36 
CD36 is an integral membrane protein found on the surface of several cell types. Its function 
is to import FA into the cell and it is a member of the B scavenger receptor family of surface 
proteins. Its ligand, thrombospondin, appears to be upregulated in the co-culture media. It 
has also been identified as one of the genes in a FA uptake signature identified in a pan 
cancer investigation of metabolism associated genes in cancers[278]. I therefore investigated 
the mRNA expression of CD36 in AMLs from mono-culture and from co-culture with 
adipocytes and found them to be transcriptionally activated in the co-culture with adipocytes 
(Figure 7.14). 
 
 
 
 
 
 
 
 
 
Figure 7.14 mRNA expression data for AML in mono-culture and in co-culture with 
adipocytes cultured for 24 hours of. mRNA expression of CD36 is upregulated in co-culture. 
Data is normalised to GAPDH house-keeping gene. N=3. Data are represented as mean ± 
standard deviation. P<0.01. Wilcoxon signed rank test was used to determine significance 
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During the time this part of my research was conducted, studies had already identified CD36 
as a driver of tumourgenicity[149, 279]. I sought to identify the level of CD36 in a pan cancer 
dataset. To do this, 8,269 primary samples (representing 26 tumour types), 391 metastatic 
samples (representing 10 tumour types), and 681 samples from adjacent normal tissue 
(representing 20 tumour types) these were obtained from the TCGA (https://tcga-
data.nci.nih.gov). It is important to note the AML data used here is from AML is peripheral 
blood (only peripheral blood available on TCGA). Figure 7.15 shows the expression of 
CD36 in these different samples with AML being among the top 5 and the second highest 
among the primary tumours (despite the top three being normal tissue-matched samples). 
This set a precedence for investigating CD36 in AMLs further.  
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I then knocked-down CD36 in Hoxa9/Meis1 expressing murine AML and analysed mRNA 
of CD36 and protein to ensure knockdown (Figure 7.16). I then cultured CD36-KD murine 
AML on adipocytes that were preloaded DAA for 24 hours and examined the levels of FA 
uptake by these cells shown. I found that AMLs with CD36-KD showed decreased 
fluorescence and therefore decreased FA uptake, as shown in Figure 7.17. 
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Figure 7.16 Knock-down of CD36 in Hoxa9/Meis1 expressing cells. AML blasts were 
infected with CPT1A shRNA or control shRNA lentivirus, and after 96 hours, analysed for 
CPT1A mRNA and protein expression using RT-PCR and western blotting. Blots were re-
probed for a-actin to show equal sample loading. Data are represented as mean ± standard 
deviation. P<0.05. Wilcoxon signed rank test was used to determine significance 
 
 
 
 
 
 
 
 
Figure 7.17 Hoxa9/Meis1 expressing cells were infected with CD36-targeted shRNA or 
control shRNA lentivirus, and after 96 hours, incubated for 24 hours with adipocytes 
preloaded with fluorescent FA DAA. Hoxa9/Meis1-expressing cells were analysed for 
fluorescence using flow cytometry (n = 4). 
 
I then conducted an in vivo investigation of CD36 (in collaboration with Sebastian Mohr) 
Hoxa9/Meis1 infected with CD36 shRNA or control vector were injected in to the tail vein 
of C57Bl/6 syngeneic mice (eight animals in each arm). All though this in vivo experiment 
is still underway at this time, preliminary data shows CD36-KD animals have a prolonged 
survival compared to animals in the shE control group (Figure 7.18).  
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Figure 7.18 Preliminary data - Kaplan-Meier survival curves for syngeneic mice injected 
with Hoxa9/Meis1 CD36-KD cells or Hoxa9/Meis1 AML control-KD cells. 
 
It was then evident that CD36 plays a significant role in AML and would need extensive 
follow-up investigations. However, before further investigations could be carried out, Ye et 
al, 2016 published a comprehensive study on CD36 and its role as a marker of poor prognosis 
and chemotherapy resistance in AML[150]. In this study, Ye et al show that adipose tissue 
act as a reservoir for HSCs and that a subpopulation of leukaemic cells are able to utilise the 
adipose tissue to support their metabolism. They also prove that this same subpopulation is 
CD36+ and is a marked fraction of human blast crisis in CML and AML. 
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7.4 Discussion 
In this chapter, I show preliminary data that highlights three important factors that may 
contribute towards migration, lipolysis and FA uptake respectively, and that are discussed 
in this section. 
Tumour cells are adaptive in that they can evolve functionality to evade apoptosis. They 
have an assembly of mechanisms that occur gradually, starting with initial drivers, 
tumourigenesis and eventually metastasis. During these processes, tumour cells accumulate 
alterations that favour survival and proliferation. They circumvent normal mechanisms of 
cellular destruction, i.e. apoptosis, by adapting strategies that help them evade death. Those 
include amplification of anti-death machinery and switching and modulating favourable 
metabolic changes[280]. In this study I show that AML migrates towards adipocyte CM. 
This media is rich in cytokines released by the adipocytes that favour AML survival.  
Moreover, this migration was inhibited by the G-protein coupled receptor (GCPR) inhibitor 
pertussis toxin, which suggests that the migration is driven through a GPCR mechanism. In 
addition, AML have been shown to migrate towards SDF-1, which is secreted by the 
BMSC[270]. In this study, I did not block adipocyte-induced SDF-1 to determine the exact 
mechanism; however, I did discover that SDF-1 is also highly expressed by the AML and 
this expression is predominantly associated with the bone marrow AML and not peripheral 
blood AML. This is an interesting finding as no other study has shown that SDF-1 is 
preferentially expressed in the bone marrow-derived AMLs. The function of SDF-1 in the 
AMLs has yet to be delineated; however, my in vivo findings, it suggests that SDF-1 is 
important for AML survival. Under normal physiological conditions, SDF-1 rich 
environments are not T-cell infiltrated. In leukaemic conditions, this lack of infiltration may 
be exasperated in favour of an immune evasion of the leukaemic site specific environment. 
An application of this hypothesis can be a manipulation of the concentration of SDF-1 to 
regulate movement of T-cells. I have also shown that SDF-1 imparts concentration-
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dependent effects on migration of T-cells – they tend to move away from higher 
concentrations of SDF-1, a phenomenon known as ‘fugetaxis’[281]. Studies have revealed 
high concentrations of SDF-1 effects T-cell subsets differently. I used CD8 subpopulation 
of T-cells which are cytotoxic and are responsible for destruction of virus-infected cells and 
transplant rejections. Inhibiting the SDF-1 could enhance infiltration into the SDF-1-rich 
environment in the bone marrow, as has been shown by Feig et al., in pancreatic ductal 
adenocarcinoma[282]. In this study, check-point inhibitors, α-PD-L1 (programmed death 
ligand-1) and α-CTLA-4 (cytotoxic T-lymphocyte-associated molecule-4) enhanced T-cell 
activity. CTLA-4 is a negative co-receptor on T-cells while PD-1 is an immune threshold 
regulator that also inhibits T-cell receptor signaling thereby deactivating the T-cell. 
Immunosuppression within the environment was caused by fibroblasts producing SDF-1. 
Administration of CXCR4 inhibitor, AMD3100, and α-PD-L1 greatly reduced the tumour 
cells and increased T-cell infiltration in the animal. In my research, following SDF-1 knock-
down in the AML cell lines OCI-AML3, I found that they affect migration towards the bone 
marrow and engraftment. The fugetaxis of T-cells away from SDF-1 rich environment shows 
SDF-1 has a critical role to play in the immune cell infiltration of tissue sites. 
The NSG model is not the optimal model to study SDF-1 in AML from a T cell point of 
view as NSG models lack a functional immune system. However, this model does provide 
an insight into the ability of SDF-1 to influence the homing and migration of blasts. A better 
in-vivo model would be one that allows an immune-challenge to occur when AMLs are 
transplanted into the animals which would allow an investigation of T-cell infiltration when 
SDF-1 is ablated in the blasts. Alternatively, subcutaneous transplantation of SDF-1-knock-
down tumour cells with supporting cells could also provide some clarity in the role of tumour 
cell-derived SDF-1 in a solid tumour environment. 
Taking these together, I conclude that SDF-1 provides a bi-directional cue in the influence 
of movement of T-cells. This property can be manipulated, which might activate T-cell 
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infiltration into the tumour site. Because SDF-1 is also secreted by the AMLs, I conclude 
that tumour-derived SDF-1 exasperates immunosuppression in the tumour 
microenvironment. However, additional in vivo experiments need to be conducted to verify 
these findings. 
I used a human cytokine screen to detect an increase in IL-6 secretions in AML/adipocyte 
co-cultures. It is important to note that although there are many other differentially secreted 
cytokines, I chose to investigate IL-6 as there has been accumulating evidence of its role in 
lipolysis stimulation[283, 284]. IL-6 is involved in wide range of biological functions 
including immune response, haematopoiesis, platelet production and inflammatory 
response. It activates down-stream JAK-STAT signaling which is a pleiotropic signaling 
cascade that regulates a number of signals. In particular, the JAK-STAT cascade regulates 
lipid metabolism by the activation of enzymes involved in this process[285].  
The upregulation of IL-6 receptor in both cell types (AML and adipocytes) during co-culture 
may indicate a possible autocrine and paracrine response. In multiple myeloma (MM) bone 
marrow, the production of IL-6 and a proliferation-inducing cytokine (APRIL) are key 
requirements for the maintenance of these cells in the bone marrow environment. One study 
has revealed that myeloid precursors are maintained in the MM bone marrow environment 
as they respond to interactions with neighboring MM cells by secreting high levels of IL-6; 
this autocrine response and cascades down into APRIL secretion, ultimately contributing to 
proliferation due to enrichment of both cytokines[286]. This autocrine response in the 
myeloid precursors is possibly a similar mechanism reflected in the AML environment, i.e., 
AMLs respond to factors released from the adipocytes that cause a secretion of IL-6 in the 
AMLs eliciting an autocrine response. From the increase in IL-6R transcription in the 
adipocytes from co-culture, it may be the case that IL-6 secreted from the AMLs may also 
trigger lipolysis in the adipocytes. IL-6, a pleiotropic cytokine, known to play important 
roles in other haematological malignancies such as multiple myeloma, here has shown to be 
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constitutively secreted by the AMLs and induce lipolysis in the adipocytes. These findings 
support various other studies that similarly show IL-6 to be an ancillary lipolysis 
stimulator[283]. There is a potential targetable pocket with IL-6 as anti-IL-6 drugs are 
already undergoing clinical trials in ovarian cancers, prostate cancers and renal cancer[287]. 
Future work into the comprehensive functioning of IL-6 in the tumour microenvironment 
would need to be carried out as these results show a prominent role that IL-6 may play in 
the lipolytic environment of the bone marrow. 
CD36 is a receptor for several ligands including long chain FA. CD36 was identified as part 
of FA uptake signature in >9,000 primary or metastatic tumour samples. FA uptake genes 
were enriched in metastatic tumours where CD36 was among the FA uptake genes shown to 
be enriched in the tumour setting[278]. Following my analysis of a pan-cancer dataset,  I 
found CD36 upregulation to be among the top 5 tissue types, including AML the rational for 
further in vivo experiments. These in vivo data also supported other studies suggesting 
CD36’s role in the tumour setting, including as an important FA uptake protein in liver 
cancer and leukaemias, and also identified in a metastasis-initiating population of tumour 
cells in breast cancer and leukaemias[150, 279, 288]. However, before comprehensive 
analysis could be carried out, Ye, et al confirmed CD36 modulates energy metabolism in 
leukaemic cells and further stratified AMLs on the basis of their CD36 expression showing 
that high CD36 expression, represented a more aggressive subpopulation that is resistant to 
treatment with conventional chemotherapies. It is not unreasonable to anticipate new 
therapies targeting CD36 based in these findings however, there is still future work to be 
carried out which I highlight in the future works section. 
 
 
 
199 
  
CHAPTER – 8 
Final Discussion and Future work 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
200 
  
8.1 Final Discussion 
In this project, I show that AML alters the bone marrow environment in a way favourable to 
leukaemia progression. In addition, the leukaemic blasts also undergo metabolic adaption to 
take advantage of the available source of energy. I have provided evidence in favour of this 
“metabolic symbiosis” by dissecting several aspects of the interactions between the tumour 
and tumour – associated adipocytes. I found that the presence of leukaemic cells cause an 
upregulation of lipolytic pathways and FA-chaperoning protein activity in neighbouring fat 
cells and within themselves. This chaperone, fatty acid binding protein -4 (FABP4), has also 
been identified in prostate cancer, ovarian and breast cancers as a FA transporter that is 
upregulated in the tumour cells[113, 222, 289]. Exposure to lipids stimulates FA uptake 
genes and pro-inflammatory cytokines. 
The implication of my research sheds light on adipose tissue and its potential role in 
influencing the development and progression of cancer.  In the past decade, obesity and 
associated metabolic disorders have been recognized as risk factors for many cancers. The 
International Agency for Research on Cancer have established evidence showing this 
association between obesity and different cancer types such as colon cancer (attributed to 
11% of cases due to obesity), endometrial cancer (attributed to 39% of cases due to obesity) 
and postmenopausal breast cancer (attributed to 9% of cases due to obesity) [290] . Although 
there have not been any genome-wide association studied (GWAS) identifying the genetic 
risk factor specifically correlating obesogenic genes to blood malignancies, a wide range of 
cancers have been linked to an increased dietary intake of fat and subsequent obesity. Body 
fat distribution is a contributing factor to metabolic complications with established fat 
distribution patterns influenced by genetic factors. A GWAS conducted by Sung in 2015 
identified sex-specific loci associated with an increase in abdominal fat in women. 
Interestingly, an earlier study using computed tomography placed visceral fat as a significant 
risk factor for breast cancer. This, along with other studies, strengthens the association 
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between fat and cancer incidence as a genetic risk factor [291]. It is important to note 
however, that the genetic architecture that makes up intricate traits are frequently due to 
multiple, weakly associated loci with joint interactions. These interactions may hold the key 
in providing an insight into genetic susceptibilities to pathway dysregulations and 
subsequent diseases. 
FAs made available by lipolysis within adipocytes are used as a major source of energy not 
only in haematological malignancies such as AML but also other solid tumours such as 
ovarian and prostate cancers[222, 292]. In the event of lipolysis, there is an upregulation of 
FA uptake genes. This would not be unusual in the tumour context, as lipolysis is a 
commonly observed phenomenon and has been shown to be associated with uptake proteins 
and transport proteins[278]. Fatty acid uptake is a malignancy associated phenomenon and 
can be observed in other haematological tumours (Figure C of Appendix) such as Burkit’s 
lymphoma, Mantel Cell Leukaemia, T-cell Acute Lymphoblastic leukaemia, Multiple 
Myeloma (MM) and AML. Additionally, a link between fatty acid uptake and AML 
aggression has been suggest by Yan et al in 2017 where FABP4 and DNMT1 (DNA 
methyltransferase 1) were identified as the regulatory axis of AML progression. DNA 
methylation is attributed to aberrant AML and occurred due to the upregulation of DNMT1. 
The study suggests DNMT1 is regulated by FABP4 in an IL-6 dependent matter and have 
found a positive correlation between DNMT1 and FABP4. The study also further stratified 
patient groups into high and low expressing FABP4 and analysed patient survival. Patients 
expressing high levels of FABP4 had a significantly shorter survival time. Similarly, patients 
expressing high levels of DNMT1 also have significantly shorter survival times compared 
to patients expressing lower levels of DNMT1 [293]. This may indicate FABP4 as a 
prognostic marker and supports the findings of another study identifying FABP3 and FABP4 
as prognostic markers for advanced tumour node metastasis in non-small cell lung cancers 
[294]. More comprehensive and large-scale population studies would need to be carried out 
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to strengthen these findings. Despite this, these findings align with my research in that 
FABP4 is instrumental in enabling tumour cell respiration and subsequent 
proliferation[213]. This proliferation was also observed in MM co-cultures with adipocytes 
(Figure B of Appendix).  
FABP4 functions as a FA shuttling molecule transporting FAs between the cytoplasm and 
nucleus. It is highly expressed in adipocytes at the protein and transcript level however, the 
decreased protein levels in co-culture indicates that the protein is produced and subsequently 
consumed suggesting its participation in the movement of FFAs within the adipocyte. 
Whether it is this adipose-derived FABP4 that enters the AML cells revealed this was not 
the case. In studies of prostate cancer, exogenous FABP4 was shown to have been 
transported into the tumour cells however, this was not observed in our AML studies. This 
suggested unlike in prostate cancer, FABP4 may be involved in extracellular-to-membrane 
transport of FA where the FA is possibly received by plasma membrane FAB proteins or 
other uptake proteins. Interestingly, despite AMLs having upregulation of FABP4 transcript, 
at a protein level there is no change in its expression. Why this is the case is unclear however, 
I speculate that unlike adipocyte FABP4, AML FABP4 does not exit the cell but transports 
intrinsic FA to the mitochondria intracellularly. Therefore, the level of FABP4 may be 
maintained at a constant as the turnover or FABP4 is in balance with its transcription.  
Identifying the overarching role FABP4 plays in cancer progression has yet to be delineated 
as only a handful of studies have investigated the role of FABP4 within the tumour 
environment. A GWAS meta-analysis identified three ovarian cancer susceptibility loci. Of 
these, two loci were associated with all epithelial ovarian cancer (EOC) subtypes while the 
other specific to the serous subtype. Interestingly, region associated with EOC contained 
encoded genes for FABP4, FABP5 and FABP12 among other genes. Moreover, several of 
the identified EOC susceptibility alleles have also been identified in other cancers. For 
example, the EOC susceptibility allele reported by Pharoah 2013 in the GWAS meta-
203 
  
analysis for endometrial cancer has also been reported as associated with prostate cancer risk 
[295]. Variation and multiple loci of genes associated with different cancer types may reveal 
tissue-specific regulation of key genes. Identifying and understanding the mechanism by 
which genetic association differ at the same locus for different phenotypes may provide a 
deeper insight into the aeitiology and development of the cancer to inform therapeutic 
strategies. 
Following on from fatty acid transportation, inhibiting it from moving into the mitochondria 
causes a decrease in energy available to dispense for cellular processes such as proliferation. 
These findings are in line with other studies by Samudio et al., identifying CPT-1A as vital 
enzyme in FAO; however, this study was conducted on AMLs that were cultured with 
BMSCs[106, 265]. Although the concept of CPT-1A inhibition aligned with the findings of 
this previous research, it was in contradiction with the FAO findings in AMLs cultured with 
BMSCs and treated with ETX where I show no difference in FAO rates using ETX. I 
hypothesise that this may be due to the fact that primary cells were used in my research 
whereas cell lines were used in the research by Samudio. Cell lines may not represent 
accurately the metabolic profile of AMLs as they are not dependent on their 
microenvironment. Therefore inhibiting CPT-1A in the cell lines in mono-culture or BMSC 
co-culture may impart a different phenotype to that of primary AMLs. Knowing that a link 
between lipids and cancer metabolism and therefore progression may exist, studies have 
looked at lipid and cholesterol inhibitors, statins, and their potential for reducing cancer 
progression. Statins, commonly used hyperlipidemia medication, inhibit 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA reductase) and therefore inhibit downstream serum 
lipids and cholesterol synthesis. Studies have shown a reduction in cancers such as 
colorectal, breast and liver cancer [296-299]. Statins and other lipid reducing agents may 
represent a new potential therapy to improve outcomes of cancer. However, further studies 
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are needed to scrutinize their role as neoadjuvant therapies (chemotherapies and 
radiosensitizers).  
AMLs migrate towards adipocyte CM, which is rich in cytokines. IL-6 was one of many 
cytokines released in the media of co-cultures, implying a possible role in the maintenance 
of a leukaemic favourable environment[300]. SDF-1, also present in the arrays, has shown 
to be essential in AML survival although the exact functioning of SDF-1 in the AMLs have 
yet to be elucidated. T-cell infiltration in cancer has been associated with enhanced survival 
in colorectal cancers and liver cancers [301, 302]. However, T-cell infiltration is dependent 
on SDF-1 concentration and has been shown to attract T-cells at low concentrations and 
repel them at higher concentrations[303]. Although only a few studies have investigated this 
phenomenon, it is not established in haematological malignancies. Preliminary findings 
from my research show that high concentrations of SDF-1 in the leukaemic 
microenvironment may also be secreted by the AMLs. This is the first recorded result 
showing this preferential expression of SDF-1 in the AMLs from the bone marrow. Based 
on previous studies and preliminary results, I conclude that AML-derived SDF-1 may be 
involved in immune evasion in metastatic sites and may also contribute to BMSC induced 
migration. The secretion of SDF-1 from both BMSCs and AML may influence each other 
in a paracrine and autocrine manner.  
The metabolic and molecular reprogramming of the bone marrow microenvironment has 
been established and the concept can be extended to many cancer types. The role of FABP4, 
although established though this and other research findings, may benefit from translational 
research where patients are stratified based on lipolysis, lipogenesis and FAO signatures 
derived from initial patient screening therefore informing potential prognostic value of using 
FAO and/or lipogenesis inhibitors. To assess genetic predispositions for AML and potential 
treatment strategies, genome wide association studies investigating the genetic associated 
between lipogenic signatures and cancer could help bridge the gap between genetic 
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associations and predicting treatment outcomes. Additionally, a comprehensive 
investigation of the directional migration of immune cell subsets will also contribute to more 
clearly defining the immune profile and possible activation and infiltration of tumour 
infiltrating lymphocytes.  
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Figure 8.1 Model mechanism. Schematic representation of the hypothesised FA transport 
mechanism initiated by the lipolysis of triglycerol and IL-6 and SDF-1 paracrine and 
autocrine signaling. 
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8.2 Future work 
Although the overall aims of this project were achieved, there are a few areas that can be 
developed further in the future. Firstly, the stratification of patients based on their FABP4 
expression would be of particular interest. Because tumour aggressiveness has been 
correlated with FABP4 expression[293], and adipocytes have been shown to protect against 
chemotherapy, this stratification may identify patterns in biomarkers for tumour aggression 
and hold possible prognostic values. To achieve this, GWAS and SNP studies looking into 
specific signatures associated with adiposity of the marrow and their associated risk will add 
to establishing an “at risk” profile for patients. 
We, and several other researches, have shown that adipocytes contribute to chemotherapy 
resistance[150, 304]. Moreover, adipocytes are believed to alter chemotherapy 
pharmacokinetics and may be doing so due to their ability to metabolise 
chemotherapeutics[305]. It would therefore be of interest to investigate the metabolomics 
profile of chemotherapy-treated adipocytes to investigate the extent of chemotherapy 
metabolism and its relation to FA synthesis, uptake and metabolism signatures to extract a 
possible biomarker for chemoresistance. 
Having a clear idea of the functionally relevant pathways in FA transport and uptake, a more 
pertinent question would be through what channel do FA enter and exit cells? Is there more 
than one mechanism by which FAs can enter and exit the cells? Ye et al have shown that 
CD36 is an important FA transporter and segregated leukaemias into two distinct functional 
populations – those with high expression of CD36 and that are resistant to chemotherapy 
and those with low expressing CD36 and that are sensitive to chemotherapy. My preliminary 
in vivo findings show that inhibiting CD36 prolongs survival of the blasts; however, it is not 
unlikely for there to be more than one channel through which FA can be siphoned into the 
AML blasts. Therefore, the exact mechanism of FA entry into the AML blasts must be 
elucidated. 
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Another important future work to be carried out is the in-depth analysis of SDF-1 function 
in AML blasts. The inhibition of the SDF-1 receptor, CXCR4, using AMD3100 and other 
small molecule or peptide inhibitors has shown successful mobilisation of tumour cells from 
the favourable bone marrow microenvironment into the blood, where they are more 
susceptible to chemotherapy due to the absence of protection provided by the 
microenvironment in the bone marrow[306, 307]. Therefore, a possibility of SDF-1 secretion 
from the blasts themselves may have functions where SDF-1/CXCR4 axis initiated by 
stromal cells induces SDF-1 transcription and release from AML, working to keep cytotoxic 
T-cells away and deterring T-cell infiltration into the tumour site. T-cell infiltration of BM 
sites is already at a low due to the secretion of SDF-1 from stroma; however, blast SDF-1 
may be critical during metastasis into sites with no intrinsic SDF-1 secretion and would be 
required for immune cell evasion. The pathways exploited by blasts to subvert the immune 
system still remains an area to be explored as much remains unknown about immune-evasive 
mechanisms harnessed by the blasts.  Therefore, a prominent future work in this area would 
be to identify the mechanism by which this immune evasion is undertaken by malignant cells 
and if efforts, such as SDF-1A inhibition, can circumvent this can influence potential 
therapeutic strategies that aim at synthetically reactivating the immune system to combat a 
cancer invasion. 
Finally, results from this project have hinted at the possibility of microenvironment 
manipulation for more targeted therapies that can be tolerated by the larger population 
suffering from this disease: the older population. I would therefore like to investigate 
combinations of immune cell permissive and anti-FA transport and synthesis approaches as 
a novel therapeutic strategy. 
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Supplementary Figures and Tables 
 
 
 
 
 
 
 
Figure A Flow cytometry analysis of AML after separation from adipocytes. AML cells 
were grown on adipocytes for 24 hours and then separated and analysed for CD45 and 
CD105 expression. 
 
 
 
 
 
 
 
 
Figure B Proliferation of MM on adipocytes – BrdU assay. MM cells were plated on 
adipocytes for 6 days and then stained with BrdU. Flow cytometry plot shows shift in 
fluorescence on day 6. N=2 
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Figure C. Fatty acids in a panel of haematological malignancies. Tumour cell were cultured 
for 48 hours and fatty acid content was analysed over this period using neutral lipid BODIPY 
dye. Freshly isolated tumour cells (day 0) contain lipids, which are lost by day 2.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure D. AMLs cultured with or without saturated or unsaturated fatty acids. AMLs 
cultured in media supplemented with palmitate-BSA conjugate or oleate-BSA conjugate at 
200μM and 100μM for 2 days shows no difference in cell numbers between fatty acids. Fatty 
acid-free BSA was used as control. N=4 
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Figure E. FABP4 KD in adipocytes reduces FFA release in the media. FABP4 is knocked-
down in the adipocytes followed by co-culturing with AMLs. Control for lentivirus shE 
shows high concentrations of FFA release when cultured with AMLs. N=3 
 
 
 
 
 
 
 
 
 
 
 
 
Figure F. Engraftment for CPT-1A in vivo KD. Human CD33 and CD45 antibodies were 
used to analysed engraftment of AMLs in the bone marrow and spleen of animal. Two 
primary samples were used in 8 animals (4 experimental arm and 4 control) 
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Figure G. mRNA expression of UCP1 and UCP2 in adipocytes derived from BMSC 
differentiation. mRNA expression (fold change over BMSC) shows that adipocytes have 
upregulated UCP2 expression and UCP1 expression. All data is normalized to GAPDH and 
all BMSC and adipocyte samples are match. 
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Table A. Differential expression analysis of raw RNA sequencing reads using DESeq2 
method. Top 200 significant genes with p-value < 0.05 following adjustment 
  Gene FoldChange stat padj 
1 CXCL12 2.641509303 6.158132381 2.12E-05 
2 ADAMTS2 2.63948746 5.953310457 1.19E-05 
3 SPARCL1 2.175482299 5.385238982 0.000194907 
4 C7 2.09614128 4.707747605 0.001333735 
5 OSMR 2.090915459 4.903575083 0.000894801 
6 FAM178B 2.073774429 4.754394376 0.001323021 
7 PPP1R9A -2.04762397 -4.64396904 0.001674095 
8 TPSAB1 -2.02762954 -4.77231296 0.001279923 
9 VCAM1 1.984447378 4.452774181 0.002772852 
10 NETO1 -1.98067679 -4.44797173 0.002772852 
11 PKLR 1.972031042 4.794802816 0.001253364 
12 ANGPTL2 1.914539428 4.422275839 0.002946866 
13 TF 1.896652041 5.800109009 3.57E-05 
14 CCDC80 1.87674232 4.546798809 0.002147368 
15 A2M 1.863646167 4.965189156 0.000787119 
16 KCNH8 -1.86264488 -5.26874466 0.000277536 
17 ATP1B2 1.810194006 4.164306924 0.00448467 
18 ACHE 1.801105869 4.338766855 0.003470166 
19 TERT 1.800238869 4.420555162 0.002946866 
20 RIC3 -1.79456789 -5.23050691 0.000303606 
21 APOE 1.778212092 4.967318482 0.000787119 
22 PDCD1 -1.77411774 -4.95309134 0.000787119 
23 TMEM56 1.770516323 4.323022482 0.00353702 
24 EBF3 1.765014675 4.784389103 0.001260117 
25 CDH1 1.727534786 4.13052744 0.004875223 
26 CENPA 1.721967586 5.175200555 0.000334545 
27 LBP 1.706906747 3.835725907 0.008760326 
28 MFAP4 1.700771794 4.474596375 0.002578016 
29 CCL18 1.698972636 3.844832163 0.008630778 
30 ACOX2 1.696646873 4.337917936 0.003470166 
31 OLFML3 1.691412274 3.92745006 0.007639174 
32 CTSE 1.672742444 4.511215871 0.002315298 
33 PLK1 1.670220177 4.985807557 0.000787119 
34 CACNA1H -1.66468814 -3.92156265 0.00772855 
35 PEG10 -1.6613635 -4.43565711 0.002853315 
36 C1QB 1.641703281 3.843999722 0.008630778 
37 HAS1 -1.63945975 -3.77114325 0.00967117 
38 LOC285954 -1.6394454 -4.29045867 0.003695017 
39 LAMA4 1.633400641 3.66478578 0.012125238 
40 LIMCH1 1.621148783 3.949865843 0.007348512 
41 BCL6B -1.61450383 -3.7988172 0.009252189 
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42 RGS1 -1.61254003 -4.25182178 0.004163709 
43 ACSL6 1.603567906 4.060251984 0.005741709 
44 C1orf106 1.602177509 3.687694707 0.011394855 
45 ARHGEF37 1.598471132 4.554829437 0.002147368 
46 CLGN 1.597888152 4.383885574 0.003089206 
47 LOC100101938 -1.58398193 -3.61668154 0.012971425 
48 ALDH1L2 1.583892512 4.220743944 0.004347063 
49 USP2 1.577861946 4.189076828 0.004438628 
50 SDC1 1.566307026 4.084802078 0.005281964 
51 SOX6 1.563604748 4.089021539 0.005281964 
52 CLEC4G 1.550197763 3.484423061 0.016961303 
53 SETBP1 -1.54294468 -4.1309267 0.004875223 
54 PDGFRA 1.537310605 3.859085355 0.008630778 
55 GHR 1.522632205 3.491386263 0.016739529 
56 C1QC 1.520750855 3.475554143 0.017273765 
57 S1PR1 -1.51713447 -4.39314804 0.003009764 
58 KRT72 -1.51300521 -3.83021128 0.008761643 
59 ENPEP 1.508619388 3.453094321 0.018016075 
60 RET 1.500119419 3.950934191 0.007348512 
61 SELE 1.499945215 3.367843237 0.021483561 
62 ZBTB20 -1.4852489 -5.57588164 9.95E-05 
63 DIRAS1 -1.48171023 -3.85946727 0.008630778 
64 LAMA3 -1.47947121 -3.84481983 0.008630778 
65 CDHR4 -1.47888023 -4.23331827 0.004278226 
66 HES1 -1.47292967 -3.54307945 0.014901156 
67 EGR3 -1.47165392 -3.67140881 0.011923651 
68 BLK -1.46908742 -5.18498342 0.000334545 
69 HSPB6 1.465167082 3.560425943 0.014472607 
70 HIST1H2BF -1.46464844 -3.86220013 0.008630778 
71 WWTR1 1.448244418 3.542233093 0.014914286 
72 AMPD1 1.44526748 3.301777269 0.024074431 
73 TJP1 1.444386797 3.251038219 0.026781093 
74 HSPA1B -1.44375472 -4.06211509 0.005737641 
75 ATF3 -1.44281531 -4.22855593 0.004320124 
76 RPL39L 1.441597844 3.638858094 0.012683964 
77 PAX5 -1.44102784 -4.58935551 0.002053367 
78 CDC20 1.439962791 4.162785843 0.00448467 
79 MPPED2 1.435516682 3.22066069 0.028012228 
80 CTGF 1.435336175 3.233743223 0.027315428 
81 PLBD1 1.430600725 3.313589385 0.023594486 
82 GNG12 1.426284412 3.19985882 0.029089894 
83 ANTXR1 1.424607326 3.716918633 0.010829738 
84 SLC6A9 1.423151456 4.168265887 0.00448467 
85 COL8A2 1.415256429 3.637667972 0.012705725 
86 C17orf66 -1.41375288 -4.10234332 0.005206267 
216 
  
87 COL1A1 1.40891375 3.268509282 0.025697661 
88 TSPYL2 -1.40771465 -4.55227639 0.002147368 
89 UBE2C 1.402484007 3.906896204 0.007958008 
90 CYGB 1.398991838 3.459786137 0.01785379 
91 UNC5C -1.39716225 -3.53945284 0.014969788 
92 GSTM5 1.393846854 3.127598536 0.033086588 
93 FBLIM1 1.3929618 3.20084673 0.029068294 
94 EGR4 -1.39126705 -3.30409016 0.023953183 
95 IGFBP4 1.388977723 3.691956697 0.01134989 
96 KIF20A 1.383990077 3.94091556 0.007458014 
97 CNKSR3 -1.38239962 -3.75673281 0.00993775 
98 SLC22A3 1.381798123 3.102650176 0.034562479 
99 GATM 1.381004461 3.551443947 0.014809162 
100 TOP2A 1.376919708 3.866040258 0.008630778 
101 IGFBP3 1.376038095 3.256976814 0.026340918 
102 COL16A1 1.371303146 3.470348937 0.017455673 
103 ICAM5 -1.37129245 -3.57125399 0.014320907 
104 PLA2G16 1.370030603 3.400799209 0.020414391 
105 VSTM2L 1.366020728 3.618109911 0.012971425 
106 DLGAP5 1.365552282 3.92208878 0.00772855 
107 CCNB1 1.365287252 5.31634154 0.000244479 
108 CADPS2 1.363176547 3.070976041 0.036602439 
109 SLC4A1 1.356065358 3.218396673 0.028092809 
110 NGFR 1.354757355 3.81581937 0.008991674 
111 DEPDC1 1.354217871 4.143465661 0.004766935 
112 MS4A1 -1.34936651 -4.36145602 0.0032129 
113 SLCO2A1 1.345031584 3.156498652 0.031437233 
114 PPL -1.34340176 -4.12155419 0.005027203 
115 SLC38A11 -1.33633382 -3.06519996 0.036953958 
116 CHL1 1.332384153 2.999188312 0.04066537 
117 HIST1H2BG -1.33086803 -3.49258204 0.016735537 
118 FJX1 1.328863455 3.119087234 0.033666447 
119 EVC 1.328626401 3.014441618 0.040207404 
120 SCGB3A1 1.327606661 3.526761763 0.015349418 
121 PTH1R 1.32696186 3.22524967 0.027803391 
122 THBD -1.32639071 -3.62877276 0.012857684 
123 ICOSLG -1.32294369 -4.04202357 0.005808372 
124 COL19A1 -1.32234516 -3.8202482 0.008945539 
125 MKI67 1.319646396 3.808180021 0.009087761 
126 GAL 1.318141694 3.077297085 0.03609621 
127 KRT73 -1.31684743 -3.99191603 0.006747861 
128 HIST1H2BJ -1.31463273 -4.00795263 0.006461131 
129 SLC35F3 1.31306961 2.956853057 0.043459125 
130 TMEM176B 1.312103561 3.236180711 0.027193527 
131 SLC1A2 -1.31017461 -4.28206346 0.003788681 
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132 TPSB2 -1.30689133 -3.03352562 0.039142535 
133 TMEM98 1.303799165 2.931068081 0.045691873 
134 EHD2 -1.30267329 -3.24830999 0.026816968 
135 PVRL4 1.301228184 3.090798799 0.035186903 
136 PCDH1 1.300398274 3.433327949 0.018923564 
137 CCNF 1.298678883 4.931934755 0.000822537 
138 CDK1 1.297295281 3.931418281 0.007625634 
139 XYLB 1.296597478 4.730795993 0.001333735 
140 APOC1 1.292777213 2.962894944 0.043170225 
141 EPR1 1.292358619 3.906758564 0.007958008 
142 LOC100128081 1.292325597 2.933265556 0.045445752 
143 BNC2 -1.29097879 -3.78821151 0.009325685 
144 C14orf182 -1.29034833 -4.55145954 0.002147368 
145 DNASE1L3 1.289244176 2.891363812 0.048666302 
146 PBK 1.282349666 3.313924735 0.023594486 
147 SRPX 1.279954665 3.153494786 0.031563484 
148 IFI44L -1.27898198 -3.14878273 0.031756612 
149 MIAT -1.27805869 -4.32529542 0.00353702 
150 MGP 1.27278228 3.088097436 0.035461528 
151 ABCA9 -1.26868176 -3.55476483 0.014664558 
152 HPDL 1.268591119 4.796290079 0.001253364 
153 HMMR 1.267290962 3.88916785 0.008253366 
154 GTSE1 1.267259012 3.996534674 0.006660031 
155 SLC4A4 1.266110271 3.2681161 0.025697661 
156 PRTN3 1.265833885 3.160055856 0.031259756 
157 AMOTL2 1.264568148 2.97173588 0.042657923 
158 PIF1 1.264470756 3.839734189 0.008656004 
159 N4BP3 -1.264198 -3.33488493 0.022836923 
160 ALOX15B 1.263603371 2.976492794 0.042343861 
161 TNC 1.261437626 3.747464336 0.010051678 
162 RBP4 1.25760964 2.910940854 0.047392772 
163 BIRC5 1.256465582 3.781762507 0.009446889 
164 CCNB2 1.252192703 3.797099574 0.009271586 
165 CCNA2 1.24767397 4.041438187 0.005808372 
166 DEPDC1B 1.247593155 4.477158182 0.002578016 
167 COL4A3 -1.2460695 -4.20286642 0.004347063 
168 VAT1L 1.245726739 2.80659903 0.056792379 
169 DTX1 -1.24510731 -3.74126063 0.010240902 
170 YAP1 1.243815772 2.821450331 0.055293419 
171 SDC3 1.242585018 3.064941547 0.036953958 
172 FHDC1 1.240639807 3.507400111 0.016146452 
173 SFRP1 1.240435254 2.837949854 0.053806111 
174 KDR 1.237636519 2.783525684 0.058812714 
175 CDKN3 1.231509611 3.904065697 0.008004996 
176 ABCC3 1.22582287 3.190762187 0.029557213 
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177 FCRL1 -1.22458365 -3.96713634 0.007257974 
178 PODN 1.220993237 2.96989363 0.042657923 
179 HPGD -1.22069671 -3.1026444 0.034562479 
180 F2RL1 -1.21817501 -2.97148543 0.042657923 
181 FSTL1 1.217513792 3.030054119 0.039375672 
182 FAM72A 1.21034986 3.753144115 0.010009665 
183 F2RL2 -1.20904217 -3.66313116 0.012156497 
184 STX1A -1.20684621 -3.30888073 0.023843741 
185 EFHA2 -1.20616213 -3.00378985 0.040478083 
186 CLEC17A -1.20608018 -3.18491673 0.029777063 
187 LOC340357 -1.20488528 -2.70301631 0.067363643 
188 HIST1H2AD -1.20348399 -3.33305771 0.02294481 
189 ECM2 1.203340506 3.110523895 0.034225856 
190 FBXW4P1 -1.20242184 -3.96250715 0.007265648 
191 DLGAP2 -1.19895388 -2.69284968 0.068439284 
192 GALNT14 1.19878575 2.98069728 0.041960728 
193 PRKG2 -1.19876756 -2.8617183 0.051324199 
194 LOC100132891 -1.19874575 -3.17062723 0.030691317 
195 CDCA8 1.197572137 4.200351953 0.004351224 
196 ARID5B -1.1968156 -4.52341242 0.002315298 
197 TRPV6 1.196008103 3.4982984 0.016489285 
198 psiTPTE22 1.195314624 2.768985248 0.060200357 
199 C14orf181 -1.19477864 -3.54798674 0.014809162 
200 GALNTL2 1.194696405 2.709685444 0.066662439 
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Table B. List of primers and their sequences 
Gene Forward sequence (5'-3') Reverse sequence (3'-5') Species 
ACADL AGTGTAGCTTACGACTGTG  CATAAGCTTTTGCAATTGGG Human 
ACOX1 GCTAGGTTCCTGATGAAAAG TTTATATGCTTCGGTTAGGC Human 
ADIPQ GGTCTTATTGGTCCTAAGGG  GTAGAAGATCTTGGTAAAGCG Human 
B-Actin ACCACAGTCCATGCCATCAC TCCACCACCCTGTTGCTGTA Human 
C/EBPA AGCCTTGTTTGTACTGTATG  AAAATGGTGGTTTAGCAGAG Human 
CD36 AGCTTTCCAATGATTAGACG  GTTTCTACAAGCTCTGGTTC  Human 
CD36 CATTTGCAGGTCTATCTACG CAATGTCTAGCACACCATAAG  Mouse 
CPT-1A TGGATCTGCTGTATATCCTTC  AATTGGTTTGATTTCCTCCC  Human 
CPT-1A GGGAGGAATACATCTACCTG  GAAGACGAATAGGTTTGAGTTC  Mouse 
CPT-2 AGCTGCTAAGGAAAAGTTTG  TTCTTCAGGAATTCTTTGCC Human 
CXCR4 TCAGTGGCTGACCTCCTCTT CTTGGCCTTTGACTGTTGGT Human 
FABP4 CCACCATAAAGAGAAAACGAG  AGTTGCTTGCTAAATCATGG Human 
FABP4 GTAAATGGGGATTTGGTCAC  TATGATGCTCTTCACCTTCC  Mouse 
GAPDH CTTTTGCGTCGCCAG  TTGATGGCAACAATATCCAC  Human 
HSL GAAGGACAGGACAGTGAG  GGAAGTGCACTATCAGGG Human 
IL-6 GACAACTTTGGCATTGTGG ATGCAGGGATGATGTTCTG Human 
IL-6R CTGGAAACTATTCATGCTACC  GACTGTTCTGAAACTTCCTC  Human 
Leptin TCAATGACATTTCACACACG  TCCATCTTGGATAAGGTCAG Human 
MGLL GTTCTTGCCAATCCTGAATC  TGTCGACCTCTGTCTTATTC  Human 
Perilipin CCAGACAAGGAAGAGTCAG GTGTATCGAGAGAGGGTG  Human 
SDF-1 CTTTAGCTTCGGGTCAATGC CCAAACTGTGCCCTTCAGAT  Human 
UCP1 CAGCACCTAGTTTAGGAAG  CTGTACGCATTATAAGTCCC Human 
UCP2 AGTTTTTCTCCATCTCCTGG  CTTTCTCCTTGGATCTGTAAC Human 
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Table C. List of shRNA and sequences 
shRN
A 
Clone/cat # Sequence 
shE MISSION pLKO.1 
-puro  
Em 
pty Vector Control 
No shRNA insert 
FABP
4 
NM_001442.2-
562s21c1/TRCN0000
419901 
CCGGGATTTAGCAAGCAACTAATTTCTCGAGAAATTAGTTGCTTGC
TAAATCTTTTTTG 
 NM_001442.2-
412s21c1/TRCN0000
414857 
CCGGTGGTGGTGGAATGCGTCATGACTCGAGTCATGACGCATTCC
ACCACCATTTTTTG 
 NM_001442.2-
501s21c1/TRCN0000
418254 
CCGGGCATTGAACTCTACAACATTCCTCGAGGAATGTTGTAGAGTT
CAATGCTTTTTTG 
 NM_001442.1-
413s1c1/TRCN00000
59618 
CCGGCGTCACTTCCACGAGAGTTTACTCGAGTAAACTCTCGTGGA
AGTGACGTTTTTG 
 NM_001442.1-
424s1c1/TRCN00000
59619 
CCGGCGAGAGTTTATGAGAGAGCATCTCGAGATGCTCTCTCATAA
ACTCTCGTTTTTG 
CD36 NM_000072.2-
1781s1c1/TRCN0000
056998 
CCGGGAAGTTACATATTAGGCCATACTCGAGTATGGCCTAATATGT
AACTTCTTTTTG 
CPT-
1A 
NM_001876.1-
147s1c1/TRCN00000
36279 
CCGGGCCATGAAGCTCTTAGACAAACTCGAGTTTGTCTAAGAGCTT
CATGGCTTTTTG 
mCPT
-1A 
NM_013495.1-
294s1c1/TRCN00001
10599 
CCGGGCAAAGATCAATCGGACCCTACTCGAGTAGGGTCCGATTGA
TCTTTGCTTTTTG 
SDF-1 NM_000609.4-
247s21c1/TRCN0000
282367 
CCGGCAAACTGTGCCCTTCAGATTGCTCGAGCAATCTGAAGGGCA
CAGTTTGTTTTTG 
mFAB
P4 
NM_024406.2-
180s21c1/TRCN0000
105185 
CCGGCCCAACATGATCATCAGCGTACTCGAGTACGCTGATGATCA
TGTTGGGTTTTTG 
mCD3
6 
NM_007643.2-
2861s1c1/TRCN0000
066518 
CCGGCCAGGGTAAGACACAGTGATACTCGAGTATCACTGTGTCTT
ACCCTGGTTTTTG 
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Table D. List of primary antibodies 
Anti Clone/Cat. # Conjugate Host Reactivity 
used 
Source Application 
CD105 REA794/130-112-166 APC - Human Milteny Biotec FC 
CD33 AC104.3E3/130-091-
731 
APC - Mouse Milteny Biotec FC 
CD34 ICO-115/CAY10208 FITC Mouse Human Cambridge 
bioscience 
ICC/FC 
CD34 AC136/130-113-176 APC - Human Milteny Biotec FC 
CD36 JC63.1/CAY1000989
3 
- Mouse Human, 
Mouse 
Cambridge 
bioscience 
WB/ICC 
CD36 REA760/130-110-876 FITC - Human Milteny Biotec FC 
CD45 30F11/130-102-778 FITC - Mouse Milteny Biotec FC 
CD45 REA747/130-110-770 PE - Human Milteny Biotec FC 
CD73 AD2/130-097-945 APC - Human Milteny Biotec FC 
CD90 REA897/130-114-859 FITC - Human Milteny Biotec ICC/FC 
FABP4 #3544 - Rabbit Human Cell Signaling 
Technology 
WB/ICC 
GAPDH #5174 - Rabbit Human Milteny Biotec WB 
Hit-Tag #2365 - Rabbit His-tag 
epitope 
Cell Signaling 
Technology 
WB 
HSL #4107 - Rabbit Human Cell Signaling 
Technology 
WB/ICC 
IgG 
Isotype 
control 
IS5-21F5/130-092-
212 
PE - Human, 
Mouse 
Milteny Biotec FC 
IgG 
Isotype 
control 
IS5-21F5/130-092-
213 
FITC - Human, 
Mouse 
Milteny Biotec FC 
IgG 
Isotype 
control 
IS5-21F5/130-094-
968 
PercP - Human, 
Mouse 
Milteny Biotec FC 
IgG 
Isotype 
control 
IS5-21F5/130-092-
214 
APC - Human, 
Mouse 
Milteny Biotec FC 
Perilipin #9349 - Rabbit Human Cell Signaling 
Technology 
WB 
pHSL #4126 - Rabbit Human Cell Signaling 
Technology 
WB 
β-Actin #3700 - Mouse Human Milteny Biotec WB 
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Table E. List of secondary antibodies 
Anti Clone/Cat. # Conjugate Host Source Application 
Rabbit 7074 HRP Goat Dako WB 
Rabbit A-21222 Alexa-488 Goat Invitrogen WB 
Mouse 43R-
ID041hrp 
HRP Donkey Dako WB 
Rabbit A-21223 Alexa-594 Goat Invitrogen ICC 
Mouse A-11001 Alexa-488 Goat Invitrogen ICC 
Mouse A-11005 Alexa-594 Goat Invitrogen ICC 
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